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Abstract 
 
HIV-1 infection detrimentally affects CD4 T lymphocytes as well as the blood plasmacytoid (pDC) and 
myeloid dendritic cell (mDC) compartment. DCs act as innate sensors and as initiators and directors of 
antigen-specific immune responses. Whereas, mDCs have the unique ability to prime naïve T-lymphocytes 
and activate adaptive immune responses, pDCs are primary producers of type 1 interferons (IFNs), playing a 
pivotal role in anti-viral immunity. In the current study both pDCs and mDCs from chronically HIV-1 infected 
South African individuals (on or naïve for ARV therapy) as well as with and without concurrent TB disease, 
were compared to matched uninfected controls. Similar to CD4 T lymphocytes, bothpDCs and mDCs, were 
significantly depleted during HIV-1 infection, (reduction of pDC, mDC and CD4 T lymphocyte was 63% (p 
0.001), 80% (p  0.001) and 31% (p  0.01), respectively).In parallel, significantly higher levels of 
generalised immune activation and exhaustion (CD38+CD8+, PD-1+CD8+ and CD38+PD-1+CD8+ T 
lymphocytes) were observed.  ARV treatment ( 1 year) did not result in DC number recovery despite a 
significant increase of CD4 T lymphocytes numbers (CD4 T lymphocyte number gain of 89% (p  0.01), it fell 
short of full recovery).TB co-infection did not exacerbate number loss. Phenotypic characterisation of  DC 
populations in circulation during HIV-1 infection may indicate the underlying reasons for the loss from 
circulation. Phenotypic profiling by multiparameter flow cytometry included: markers of activation (CD86, 
CD80 and CD62L), maturation (CD83), apoptosis (TNF-R2, FAS, FASL and TRAIL R1-R4) and chemotaxis 
(CCR5, CCR7, CCR9 and CXCR6). HIV-infection was associated with a significantly higher percentage of 
CD86+mDCs which may be indicative of early maturation or transition to secondary lymphoid tissue.  The 
frequency of the CD86+mDCs subset normalised upon ARV therapy. Also, HIV-1 infection influenced the 
distribution of TNF-R2+pDCs and TNF-R2+mDCs. Increased TNF-R2 expression in both subsets, may attest 
to enhanced survival function. Functionally, DCs of HIV-1 infected individuals were reactive to TLR-L 
stimulation and in some cases showed enhanced responses compared to uninfected individuals. A 
significantly higher frequency of TNF-R2+pDCs, IFN-+pDCs, and TNF+mDCs was observed in whole blood 
TLR cultures of HIV-1 infected individuals (TNF-R2+pDCs: LPS (p = 0.002) and R848 (p = 0.01), IFN-

+pDCs: R848 (p = 0.04), TNF+mDCs: LPS (p = 0.003))s.In addition, whole blood TLR cultures of the ARV 
treated study group generally showed normalisation of the responses, however; in certain cases ARV 
therapy reduced responsiveness to levels significantly lower than the control study group (i.e.TNF-R2+pDCs 
and TNF-R2+mDCs in CpG ODN stimulation). In contrast, a significantly lower frequency of IL12p40+mDCs 
was observed during HIV-1 infection (p = 0.02). TLR-L cultures of the ARV treated study groups showed 
normalisation of IL12p40+mDCsfrequency. Notably, treatment with the immunomodulating peptide VIP 
induced a decline in IL12p40+mDCs to levels lower than the control study group.The frequency of 
TNF+pDCs in TLR-L whole blood cultures was similar between the healthy, untreated and treated HIV-1 
infected study groups, however, significantly reduced frequencies were observed in these study groups upon 
VIP treatment. These data indicate unique phenotypic and functional changes in DC subsets in chronic HIV-
1 infection which may provide potential targets for immunotherapeutic intervention. 
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Opsomming 
 
Die CD4 T limfosiet asook die plasmasitoede (pDSe) en myeloede dendritiese selle (mDSe) word nadelig 
geraak deur `n MIV-1 infeksie. Dendrietiese selle tree op as aangebore sensors en as inisieerders en 
reguleerders van antigeen-spesifieke immuun reaksies. mDSe het `n besonderse funksie om naïewe T 
limfosiete teinisieer en so die verworwe immune reaksies te aktiveer. pDSe is primêre produseerders van 
tipe 1 Interferon wat `n rol speel in anti-virale immuniteit. In die studie is beide die pDSe en mDSe van Suid-
Afrikaners met chroniese MIV-1 infeksie (ARV en nie ARV gebruikers) met of sonder TB siekte vergelyk met 
ooreenstemmende MIV-1 negative kontroles. Soortgelyk aan CD4 T limfosiete, was beide die pDSe en 
mDSe beduidend verminder tydens `n MIV-1 infeksie (die verlaging in pDSe, mDSe en CD4 T limfosiete was 
onderskeidelik 63% (p 0.001), 80% (p  0.001) en 31% (p  0.01). Terselfdertyd is `n verhoogde vlak van 
algemene immuun aktivering en uitputting (CD38+CD8+, PD-1+CD8+T en CD38+PD-1+CD8+ T limfosiete) 
waargeneem. ARV behandeling ( 1 jaar) het nie gelei tot die herstel in DSe getalle alhoewel die studie `n 
beduidende vermeerdering in CD4 T limfosiete waargeneem het (CD4 T limfosiet vermeerdering van 89% (p 
 0.01), die verhogingwas nie voldoende nie). TB mede-infeksie het nie die vermindering van DSe vererger 
nie. Fenotipiese karakterising van die DS populasie in sirkulasie tydens MIV-1 infeksie mag die 
onderliggende rede vir die verlaging aandui. Fenotipiese profilering deur multi-parametriese vloeisitrometrie 
het ingesluit merkers van aktivering (CD86, CD80 en CD60L), maturasie (CD83), seldood (TNF-R2, FAS, 
FASL en TRAIL R1-R4) en chemotaksiese (CCR5, CCR7, CCR9 en CXCR6). MIV-1 infeksie was 
geassosieer met beduidende hoër persentasie van CD86+mDSe wat moontlik vroeë maturasie  of transisie 
na die sekondêre limfoïedeweefsel aandui. Die frekwensie van die CD86+mDSe subpopulasie normaliseer 
tydens ARV terapie. MIV-1 infeksie het ook `n invloed op die distribusie van TNF-R2+pDSe en TNF-
R2+mDSe gehad. Verhoogde TNF-R2 uitdrukking in beide DS populasies mag moontlik getuig van `n 
verhoogde oorlewings funksie.Op `n funksionele vlak het DSe van MIV-1 geinfekteerde individue reaksie tot 
TLR-L stimulasie getoon en in sommige gevalle was die reaksie hoër as in MIV-1 negatiewe individue. `n 
Beduidende hoër frekwensie van TNF-R2+pDSe, IFN-+pDSe, TNF+mDSe was waargeneem in heel bloed 
TLR-L kulture van MIV-1 geinfekteerde individue (TNF-R2+pDSe: LPS (p = 0.002) and R848 (p = 0.01), IFN-
+pDSe: R848 (p = 0.04), TNF+mDSe: LPS (p = 0.003)) terwyl die heel bloed kulture van die ARV studie 
groep in die algemeen normalisering getoon het. In sekere gevalle het ARV terapie reaksies verlaag tot 
vlakke beduidend laer as die van die kontrole studie groep (i.e.TNF-R2+pDSe and TNF-R2+mDSe met CpG 
ODN stimulasie). In kontras, `n beduidende laer frekwensie van IL12p40+mDSe is opgemerk gedurende 
MIV-1 infeksie (p = 0.02). TLR-L kulture van die ARV studie groep het normalisering van die IL12p40+mDSe 
frekwensie getoon. Behandeling met die immunomodulerende VIP peptied het `n verlaging in IL12p40+mDSe 
vlakke geinduseer wat laer was as die van die kontrole groep. Normalisering van die IL12p40+mDSe vlakke 
is waargeeem in die TLR-L kulture van die ARV studie groep. Die frekwensie van TNF+pDSe in TLR-L heel 
bloed kulture was soortgelyk tussen die MIV-1 negatiewe, onbehandelde and behandelde MIV-1 
geinfekteerde studie groepe. `n Beduidende verlaagde frekwensie was waargeneem in hierdie studie groepe 
tydens VIP behandeling. Hierdie data wys op unieke fenotipiese en funksionele veranderinge in die DS 
populasies tydens chroniese MIV-1 infeksie wat`n moontlik potensiele teiken vir immunoterapeutiese 
intervensie kan wees. 
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Chapter 1 
 
Introduction 
The year 2015 commemorates 32 years since the first published report on the Acquired Immunodeficiency 
Syndrome (AIDS), a fatal disease caused by the type-1 Human Immunodeficiency Virus (HIV-1). During 
these three decades, research has immensely advanced our understanding of HIV-1 pathogenesis. 
However, despite better understanding of disease processes, scientists have not yet been able to develop 
treatment to completely clear (i.e. cure) or a vaccine to prevent HIV infection. To date, the HIV/AIDS disease 
has claimed many lives and also disseminated rapidly throughout the world. The global burden of people 
living with HIV has reached pandemic proportions with an estimated 36.9 million people currently infected. 
Most concerning is the fact that South Africa is marked as the country with the highest number of HIV-1 
infected people in the world.  
 
HIV/AIDS disease is characterised by the gradual deterioration of the immune system and if left untreated, 
infection ultimately leads to death. Impairment of the immune system is driven by the infectious agent (HIV), 
which is transmitted via contact with contaminated body fluids (either during sexual intercourse, blood 
transfusion, trans-placental passage or shared use of syringes/needles during intravenous drug abuse). An 
important feature of this disease is its high morbidity and mortality rate, mostly brought on by an enhanced 
susceptibility of HIV infected patients to opportunistic infections due to a compromised immune system. In 
South Africa, particularly, Tuberculosis (TB) is one of the leading causes of death in HIV-infected individuals.  
 
Treatment options are limited to the chronic use of antiretrovirals (ARVs). Although effective in controlling 
viral load (in most cases), it has been reported that ARVs only contribute to partial immune reconstitution. 
This partial recovery is most evident in the T lymphocyte (primarily CD4+) compartment (Almeida M, et al. 
2006; Finke JS, et al. 2004). In addition, the chronic use of ARVs has been associated with an increased risk 
for the development of cardiovascular diseases and several metabolic syndromes in HIV infected patients 
(van Wijk JPH and Cabezas MC, 2012; Kotler DP, 2008; Friis-Møller N, et al. 2007). Also, drug resistance is 
another well described problem (most possibly stemming from long term non-compliance) impacting on the 
use of ARVs (Gupta RK, et al 2012; van Zyl GU, et al. 2011). These findings suggest that while a cure 
remains the ultimate goal, advances in current treatment is also a necessity to lessen the burden of side 
effects associated with ongoing ARV therapy.  
 
In recent years the paradigm “persistent immune activation, driving immune exhaustion” has become a 
central concept in HIV pathogenesis. A well-described outcome of this phenomenon is the progressive and 
systemic loss of CD4 T lymphocytes in untreated patients. Cellular deprivation during HIV-1 infection is, 
however, not limited to the CD4 T lymphocyte compartment. A simultaneous decline in precursor 
plasmacytoid dendritic cells (pDC) and myeloid DCs (mDC) (also termed conventional DC or cDC) from 
peripheral blood has been reported by many researchers (Mojumdar K, et al. 2010; Sabado RL et al. 2010; 
Lichtner M, et al. 2008; Finke JS, et al. 2004; Donaghy H, et al. 2001; Soumelis V, et al. 2001). In view of the 
central role that these cells play in the surveillance, recognition and elimination of antigens from the 
microenvironment, it is believed that depletion of these cells from circulation may contribute to major immune 
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dysfunction during HIV-1 infection. Driven by an interest to know more about the impact of HIV-1 infection on 
DCs, the current study aimed to characterise the residual DC pool in circulation during HIV-1 infection. 
 
Characteristically, DCs are scarcely distributed in peripheral blood, representing less than 1% of total blood 
mononuclear cells. However, despite their low frequency they have unique properties (functionally and 
morphologically) that make them essential role players in effective host immunity. On a functional level, DCs 
have been referred to as linking innate and adaptive immunity (McKenna K, et al. 2005). This is based on the 
fact that DCs are acknowledged as the primary cell type that recognises and internalises antigen in the 
periphery, then enters the lymphatic system to transport processed antigen to secondary lymphoid tissue 
where it primes naïve T-lymphocytes for the initiation of adaptive immune responses. Recognition of 
antigens is primarily the task of the immature peripheral tissue-resident mDCs and is performed via 
evolutionary conserved receptors. These include Toll like receptors (TLR) expressed on the cell surface as 
well as intracellulary within the endosome. Specifically, the processed antigens are presented by the 
lymphoid tissue-associated mature mDCs to the naïve T lymphocytes in secondary lymphoid tissue. In 
contrast to mDCs, pDCs are primary producers of type 1 interferons (IFNs), playing a pivotal role in anti-viral 
immunity. Both immature and mature pDCs primarily populate lymphoid tissues. Furthermore, DCs have 
unique morphological features, displaying branch-like cellular extensions, aiding in optimally executing the 
important functions of pathogen surveillance, recognition and capture.  
 
Examination of DCs function in vitro is challenging due to the naturally low frequency of these cells in 
peripheral blood. Previously, studies have relied on culturing monocyte-derived DCs (mo-DCs) to 
experimentally investigate DCs at a functional level. However, this is a laborious and time-consuming 
technique of questionable significance and it has been debated whether this method generates responses 
resembling reactions in vivo. Fortunately, advances in modern technology and identification of specific 
markers allows for the rapid profiling, isolation and manipulation of DCs using freshly isolated whole blood. In 
the current study DC subsets were collectively distinguished, using flow cytometric applications, within the 
heterogeneous cell population of whole blood by mutual positive expression of the Human Leucocyte 
Antigen – antigen D Related (HLA-DR) and low/absent expression of lymphoid markers (CD3, CD14, CD16, 
CD19, CD 20 and CD56 – collectively referred to as Lineage 1 (LIN1)). Separately defining the pDC and 
mDC subsets was performed via the differential expression of CD11c and CD123 markers (pDCs: 
CD123+CD11c-; mDC: CD123DIMCD11c+).  
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1.1 Hypothesis and study design 
Little has been reported on the effect of HIV-1 infection on DCs in South Africa (a country in which the 
heterosexual subtype C HIV-1 epidemic predominates). Also, the effect of a TB co-infection (the 
predominant factor causing HIV-1 related deaths in South Africa) and ARV treatment on blood DCs has also 
been scantily addressed. Accordingly, the present cross-sectional study focused on investigating changes 
exerted on blood pDCs and mDCs via HIV-1 infection, HIV-1/TB co-infection (i.e. active TB disease) and 
ARV therapy.  
 
Altered peripheral blood DC numbers during chronic HIV-1 infection is a well-described phenomenon. It is 
also well-documented that, in addition to detectable levels of HIV antigens, significantly elevated levels of 
inflammatory components are present in the plasma/serum of HIV-1 infected patients. Accordingly, the 
current study hypothesised that the decline of pDCs and mDCs is the net effect of persistent exposure 
and/or response to a combination of HIV-1 and host factors (HHF). These may include 1) viral elements that 
may induce a direct cytopathic effect, 2) excessive/persistent production of host inflammatory mediators 
and/or 3) gut “leakage” components in circulation. It is unclear; however, by which mechanism DCs wane 
from peripheral blood, whether this phenomenon is permanent (apoptosis) or temporary (enhanced 
migratory response to HIV-1 associated inflammatory signals) and, in particular, if number loss is also linked 
to DC dysfunction (e.g. altered cytokine production). The current study proposed the investigation of the 
residual pool of HHF exposed DCs from HIV-1 infected individuals in current circulation, suggesting these 
cells to provide “clues” to the cause of the decline of blood DCs and provide information on their functional 
abilities. 
 
The current study was performed in three parts. The first part (Chapter 3) aimed to determine the frequency 
distribution of 1) pDC, mDC, CD4 T lymphocyte (the primary diagnostic laboratory marker used to monitor 
disease progression) and CD8 T lymphocyte absolute numbers and 2) CD4 T lymphocyte to CD8 T 
lymphocyte absolute number ratio (also referred to as CD4:CD8 ratio) in uninfected vs. chronically HIV-1 
infected, HIV-1/TB co-infected and ARV-treated HIV-1 infected individuals. Also, the relationship between 
DC and CD4 T lymphocyte absolute numbers as well as CD8 T lymphocyte counts and HIV-1 viral load 
within each applicable study group was investigated. Following this it was proposed, in reference to the study 
hypothesis, that an increase in/alteration of specific physiological mechanisms of cellular waning will result in 
the net effect of low DC numbers during HIV-1 infection. The study refers to mechanisms suchs as apoptotic 
cell death, cell activation and/or export/tissue homing (either due to antigen capture and consequent 
mobilisation to lymph nodes to present antigen to naïve T lymphocytes (lymphoid directed) or chemotactic 
movement in response to inflammatory signals generated at sites of infections (tissue directed e.g. gut 
associated)). Therefore, the second part of the study (Chapter 4) profiled pDCs and mDCs in the 
peripheral blood of uninfected vs. chronically HIV-1 infected, HIV-1/TB co-infected and ARV-treated 
individuals using 15 phenotypic markers related to A) activation (CD86, CD80 and CD62L) and DC 
maturation (CD83), B) apoptosis (both as inducers: FAS Ligand (FASL/CD178) and susceptibility: FAS 
(CD95), Tumor Necrosis Factor Receptor (TNF-R)-2, TNF- related apoptosis inducing ligand receptor 
(TRAIL-R) 1 and 2 as well as resistance or avoidance: TRAIL-R3 and -R4) and C) homing (CCR9 - putative 
gastrointestinal tract (GIT) homing receptor, CXCR6 - putative pulmonary tissue homing receptor, CCR5 and 
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CCR7 -  both lymph node homing receptors). We proposed that modification in the expression of these 
phenotypic markers may direct the fate of DCs during HIV-1 infection. The third part of the study (Chapter 
5) aimed to 1) define whether the functional abilities of the DCs were altered during HIV-1 infection and if so 
2) determine the alleviation potential of ARV therapy. The current study hypothesised that persistent 
exposure of circulatory pDCs and mDCs to potentially harmful HHF substances affects their functional 
abilities. Impaired function of DCs during HIV-1 infection has been reported, in particular, the impaired ability 
of pDCs and mDCs of HIV-1 infected individuals to respond to Toll-like receptor stimulation in vitro, attributed 
to persistent activation, exhaustion and/or general impairment of DCs. However, few studies have addressed 
the impact of ARV therapy on the functional responses of DCs from HIV-1 infected patients. In this part of 
the study, TLR responses of DCs in uninfected controls were compared to that of the residual DC pool of 
HIV infected and ARV treated patients. The response upon in vitro whole blood TLR stimulation of pDCs and 
mDCs were measured by the expression of markers of apoptosis (FAS, TRAIL-R1, TRAIL-R2, TNF-R2) and 
migration (CCR5, CCR7, CCR9) and production of intracellular cytokines (IFN-(2b), IL12p40, TNF-). As a 
sub-project, the following was also investigated 1) the expression of novel immunemodulatory receptors for 
the neuropeptide: vasoactive intestinal peptide (VIP), namely VPAC1 and VPAC2, in fresh and cultured 
whole blood and 2) the immunemodulatory properties of VIP upon in vitro whole blood TLR activation of 
pDCs and mDCs. This sub-study was part of a bigger project aimed at limiting immune activation as a 
potential treatment option for chronic HIV-1 infection. Various factors (e.g. competent viral reservoirs, host 
genomic integration) make the development of treatments that aim at the complete elimination of HIV a 
challenging task. Proposing the development of treatment targeting persistent immune activation with 
consequent alleviation of immune exhaustion is the first of its kind. The development of treatment that can 
modulate or “dampen” immune activation via the use of a natural peptide (with the prospects of limited side 
effects) might possibly increase the life expectancy of HIV-infected patients. The final part of the study 
(Chapter 6) aimed to investigate the relationship of the DC subsets positively expressing phenotypic markers 
of activation, apoptosis and migration (characterised in Chapter 4) to markers of immune activation and 
exhaustion commonly associated with HIV-1 infection. The latter factors were profiled via the expression of 
CD38 and the Programmed death – 1 (PD-1) receptor on CD8 T lymphocytes, respectively. In this chapter 
the immune activation and exhaustion profile of the control, untreated and treated HIV-1 and HIV-1/TB co-
infected study groups was firstly examined. This entailed determining the 1) frequency distribution of the 
CD8+CD38+ and CD8+PD-1+ subsets as well as the CD38+PD-1+ dual expressing CD8 T lymphocyte subsets 
in peripheral blood and 2) relationship of the CD8 T lymphocyte subsets to CD4 T lymphocyte counts and 
viral load (as applicable). Following this, the DC relationship to the CD8 T lymphocyte subsets for each study 
group was examined.  
 
In an attempt to streamline the reporting of information, each chapter commences with a brief literature 
review, specific study aim and objectives on the related topic. Chapter 2 serves as an introductory overview 
and survey of the literature on HIV and DCs, particularly their role in HIV pathogenesis. 
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Chapter 2 
 
Literature Review 
 
2.1 The HIV-1 pandemic 
Since, the first published report on HIV/AIDS, a mere 32 years ago, the disease rapidly transformed into a 
worldwide pandemic. This is evident from the 2015 HIV global statistics report on people living with HIV, 
showing that the total number of HIV-infected adults (15 years and older) and children (0-14 years) amounts 
to 36.9 million individuals globally (The Joint United Nations Program on HIV/AIDS (UNAIDS) global statistics 
fact sheet, 2015). Furthermore, approximately 70% of the global HIV-infected population resides in Sub-
Saharan Africa, marking South Africa part of a region with the highest number of HIV infections in the world.  
 
The worldwide attempt to resolve the problem of HIV/AIDS should not solely focus on finding a cure or a 
vaccine but should also undertake the challenge of preventing the spread of the disease. Successful 
eradication of HIV/AIDS would be dependent on a significant decrease in mortality numbers and also, in 
particular, the rate of new infections. Although, a decline of 35.5% in new infections was apparent in 
comparing data collected from the 2000 to the 2014 survey, new infections during 2014 were estimated at 2 
million individuals (UNAIDS 2015 Global statistics facts sheet). It was/has been proposed that lack of 
adherence to ARV therapy, society’s misinterpretation of the disease and continued high risk sexual 
behaviour are some factors still playing a significant role in the current spread of the virus. In South Africa, 
particularly, a major complicating factor in the HIV epidemic is sexual violence against women (Jewkes RK, 
et al. 2010.) 
 
Currently, no cure or vaccine is available for HIV/AIDS treatment is restricted to the chronic use of ARVs. It 
has proven to be effective in controlling viral replication by decreasing the plasma viral load to undetectable 
levels (in most cases) and also contributed to a reduction in morbidity and mortality associated with the 
disease (WHO guidelines 2015; Palella FJ Jr, et al. 1998). However, there are other factors that mark ARVs 
as suboptimal in treating an HIV infection. One important finding is that it contributes minimally in a) reducing 
generalised immune activation, a hallmark of an HIV infection (Boasso and Shearer GM. 2008; Silvestri G 
and Feinberg MB. 2003) and b) immune reconstitution (Almeida M, et al. 2006; Guadalupe M, et al. 2003). 
Furthermore, long term ARVs have also been implicated in causing cardiovascular disease, several 
metabolic syndromes and hypertriglyceridemia in HIV infected patients (van Wijk JPH and Cabezas MC, 
2012; Kotler DP, 2008; Friis-Møller N, et al. 2007). Drug resistance is another well described problem 
impacting on the use of ARVs (Gupta RK, et al, 2012; van Zyl GU, et al. 2011). 
 
Although an immense volume of published data on the pathogenesis of HIV infection exists, we still do not 
clearly understand the disease process. Also, in the absence of individuals who have spontaneously 
recovered, the natural correlates of protection remain unknown. These factors are the main reasons for the 
lack of available treatment targeting the complete eradication of the virus. In view of this, perhaps a cure for 
the HIV/AIDS disease entails a radically different approach than the current vaccine/treatment approaches. 
Nonetheless, it is imperative that scientists persevere in defining host responses to obtain better insight into 
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HIV pathogenesis. Unravelling the disease process might aid in reaching the ultimate goal of developing a 
remedy that would alleviate the detrimental effects that HIV infection inflicts on mankind. 
 
2.2 Society’s misconceptions on HIV infection 
The HIV/AIDS problem is a multi-faceted challenge for all health sectors worldwide. Not only is finding a cure 
or an effective vaccine for the disease crucial, also society’s misconceptions regarding the origin of the 
disease should be addressed as it might play a role in high rate of new infections recorded yearly. In 
particular, certain groups believe that its ontogeny is politically driven. In a study conducted by Ross and 
colleagues in 2006, it was found that most of the sample subjects, which included both genders of four 
different racial groups (African American, Latino, non-Hispanic whites, Asian) living in Houston, Texas, 
believed that HIV’s development was part of a genocidal conspiracy by the federal government. This view 
was seemingly associated with reduced condom use in especially African American men. As hypothesised 
by Bogart LM and Thorburn S (2005), this action might be based on mistrust and suspicious belief in 
government. These men believed that those allegedly “responsible” for HIV’s creation are now suddenly 
proclaiming the use of condoms to prevent HIV infection. The opinion of black inhabitants from San 
Bernardino, California, was that the HIV was “man-made”, targeting the extermination of this ethnic group 
specifically (Klonoff EA and Landrine H, 1999). 
 
Other studies have reported on the myth that condoms cause HIV/AIDS. Some people in rural Northern 
Namibia believe that the virus is contained in the lubricant. As expected, this view was also associated with 
reduced condom use (Mufune P, 2005). Similarly, the view of a group of Zimbabwean individuals transpired 
to “virus-containing condoms produced by racist Whites/Americans” (Rödlach A, 2006). Locally, in addition to 
genocidal beliefs, a cultural practice such as witchcraft is contemplated by young black South Africans as 
cause of the HIV/AIDS disease. They also believed that HIV can be cured simply by consuming fresh fruits 
and vegetables. Also, these views were associated with lack of condom use during intercourse (Bogart LM, 
et al. 2011). These misconceptions undoubtedly result in continuous sexual risk behavior within a 
community, having a profound effect on the global spread of the disease. Addressing misconceptions 
regarding the HIV/AIDS disease is as important as finding a cure and/or effective treatment for eradicating 
and preventing the spread of the HIV. 
 
2.3 So from where did the HIV actually originate? 
Zoonotic transmission is accepted as the main introductory path into the human population. Phylogenetic 
analyses have shown that the virus was introduced into the human species via transmission from African 
primates including Sooty Mangabeys (Cercocebus atys), African Green monkeys (Chlorocebus sabaeus), 
Mandrills (Mandrillus sphinx) as well as chimpanzees (Pan troglodytes). Notably, these animals are regarded 
as natural hosts of SIV (simian immunodeficiency virus) - HIV’s counterpart -as it, in contrast to HIV infection 
in humans, does not cause a life-threatening pathogenic effect. SIV refers to simian “immunodeficiency” 
virus but unlike its name, given in reference to the primary discovered HIV, the natural host rarely progress to 
the associated disease. Primate non-natural hosts to SIV infection include Rhesus Macaque monkeys 
(Macaca mulatta). The sooty mangabey SIV specific strain is related to the HIV-2 subtype (Hirsch VM, et al. 
1989) whereas the origin of HIV-1 subtype have been traced to a SIV specific strain that naturally infect 
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chimpanzees (Gao F, et al. 1999). Recently, it was reported that zoonotic transmission could also have 
occurred via the western lowland gorillas (Gorilla gorilla gorilla) from west-central Africa (D’arc M, et al. 
2015). 
 
The mechanism of zoonotic transfer of the virus to humans has been linked to bushmeat trading, which 
refers to the hunting and sale of wild animals including above-mentioned non-human primates. Cross-
species transmission may have occurred upon contact with meat of SIV-infected animals during handling 
and/or butchery (Hahn BH, 2005). Apetrei C, et al. (2005) conducted a study on Sooty Mangabey bushmeat 
sold at markets of rural Sierra Leone in West Africa. They obtained twelve subjects and found that seven of 
these were positive for the SIV. In fact, they characterised seven new sooty mangabey SIV specific strains. 
Also, SIV infected bushmeat has been reported in a study conducted in Cameroon, and most alarming is that 
researchers also detected SIV infection in monkeys owned as pets (Ndembi N, et al. 2009; Peeters M, et al. 
2002).  
 
In addition to possibly contracting SIV (genus: lentivirus) infection from bushmeat hunting and consumption, 
there is also the risk of becoming infected with other viruses. In two separate studies conducted in 
Cameroon, serological and molecular testing of blood samples from human volunteers who have had 
exposure to blood and other body fluids of non-human primates during bushmeat practices, tested positive 
for simian foamy virus (SFV) infection (genus: retroviruses)  (Calattini S, et al, 2007; Wolfe ND, et al. 2004). 
SFV has also been detected in employees working at the zoo and research institutions in Northern America 
(injury and non-injury related), with no evidence of horizontal transmission when tests were extended to 
include spouses (Calattini S, et al. 2007; Switzer WM, et al. 2004). Similar results were observed in wives 
and children of men exposed to non-human primates in the natural setting (Betsem E, et al. 2011). Notably, 
SFV infection does not manifest with clear disease symptoms in both humans and non-human primates even 
after years of infection (Boneva RS, et al. 2007; Switzer WM, et al. 2005), whereas in vitro assays have 
shown this virus to exert a cytopathic effect. It is presumed that certain host factors are suppressing disease 
progression during SFV infection (Murray SM, et al. 2006; Meiering CD and Linial ML, 2001). Interestingly, 
higher SFV messenger ribonucleic acid (mRNA) levels have been observed in the small intestine of SIV 
infected than in uninfected Rhesus Macaques monkeys. This finding seems to indicate the reduced level of 
immune control in an immune-compromised system (Murray SM, et al. 2006). 
 
2.4 SIV and HIV:  cousin viruses with opposing pathogenic effect in the natural and non-natural 
host 
The underlying mechanism preventing transition to AIDS in the natural host have not been elucidated. It is 
believed that upon accurately identifying the immune correlates of protection that prevents pathogenic SIV 
infection in the natural host, it might aid in clarifying the reason(s) for the opposing effect of SIV/HIV infection 
in the non-natural host. This may also pave the way for the development of effective treatment or a cure for 
HIV infection. Nevertheless, researchers have acquired much knowledge on HIV pathogenesis from studies 
of SIV infection in the natural and non-natural host. In HIV/SIV infection of the non-natural host, disease 
progression is characterised by a) loss of peripheral and mucosal CD4 T lymphocytes, b) chronic immune 
activation and inflammatory responses and c) microbial leakage from the lumen of the GIT into circulation. In 
contrast, SIV infection of the natural host shows a) CD4 T lymphocytes maintained at levels similar to that of 
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the uninfected natural host, b) limited immune activation and c) no microbial translocation (as reviewed by 
Paiardini M, et al. 2009). Added to these key features is the finding of disrupted fibroblastic reticular cell 
network (FRC) (important for the livelihood of the naïve T lymphocytes) during HIV/SIV infection of the non-
natural host, which remains intact during SIV infection of the natural host (Zeng M, et al. 2012). Figure 2.1 
depicts, in relation to viral load, HIV-associated changes of specific host immune parameters (CD4 from 
peripheral blood, CD4 from mucosa-associated lymphoid tissue and immune activation) involved in the 
development of AIDS from primary infection in the non-natural vs. natural host (Figure 2.1a and 2.1b, 
respectively). In acute infection the profile of these parameters in HIV/SIV infection of the non-natural host 
seem similar to that of SIV infection in the natural host with a peak increase in viral load accompanied by an 
increase in immune activation and parallel decline of Peripheral blood and mucosa-associated lymphoid 
tissue CD4. However, during chronic infection these parameters profile differently in the non-natural vs. 
natural host. In chronic SIV infection of the natural host immune control is evident, displaying recovery in 
peripheral blood and mucosa-associated lymphoid tissue CD4 (recovery in African green monkeys more 
significant than in sooty mangabeys) and a decline in viral load (although the latter is not completely cleared 
from the host) and immune activation. In the early phase of chronic infection of the non-natural host, a slight 
decline in immune activation levels and increase of peripheral blood CD4 was observed. However, this 
changes as the disease progresses as evidenced by declining numbers of the mucosa-associated lymphoid 
tissue CD4 and a steady viral load. The status of these parameters persists with transition to AIDS/death, 
except for viral load that increases in the non-natural host. In contrast, in the natural host these parameters 
are maintained and the host, rarely, develops AIDS (as reviewed by Paiardini M, et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  Kinetics on the changes of specific host immune parameters, in relation to viral load, 
during HIV/SIV infection of the natural and non-natural host. 
The line graph compares viral load to specific host immune parameters (CD4 from peripheral blood, CD4 in 
mucosa-associated lymphoid tissue and immune activation) to illustrate the changes of these parameters 
between HIV/SIV infection of the non-natural hosts: human and rhesus macaque monkeys (A) and SIV 
infection of the natural hosts: sooty mangabeys and african green monkeys (B) (as reviewed by Paiardini M, 
et al. 2009).  
Death 
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2.5 Biological characteristics of the HIV 
The HIV is taxonomically within the Lentivirus group (lentus-, Latin for "slow") and is a member of the 
Retroviridae family. Two types of HIVs have been identified namely HIV-1 (previously termed Lymphotropic 
Adeno Virus or Human T-lymphotropic virus Type III) and HIV-2 (Wain-Hobson S, et al. 1985). The latter 
type is a less virulent form of the virus and is primarily localised to West Africa. Morphologically, the HIV 
virion has a spherical structure and measures approximately 120 nm in diameter. The inner core or capsid of 
the virus is enclosed by a coat of viral encoded proteins (p24) containing the genome (9.2kb) of the virus 
which consists of two identical positive sense, single-stranded RNA strands as well as the enzymes: reverse 
transcriptase, protease and integrase. These essential components are protected from the external 
environment by a phospholipid bilayer membrane envelope derived from the infected host cell. The envelope 
membrane contains approximately 70 copies of a trans-membrane trimeric complex consisting of 
glycoproteins gp41, which anchors the outer external unit, gp120, in the envelope membrane itself (Figure 
2.2) (Abbas AK, et al. 2012). 
Figure 2.2:  An illustration of the HIV virion 
The figure shows the constituents of the internal core and envelope membrane of the HIV virion (Abbas AK, 
et al. 2012) 
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2.6 Replication in the host cell: HIV viral entry, integration and budding of new virions 
The gp120/gp41 complex plays a distinct role in the attachment and consequent entry of the virus into the 
host cell. The gp120 subunit binds to the CD4 receptor and chemokine co-receptors (the most important co-
receptors are CCR5 and CXCR4, however, others have also been defined which include CCR2, CCR3, 
CCR4, CCR2b, CCR8 and CXCR6) promoting the insertion of the fusion peptide gp41 into the cell 
membrane of the host. This allows for the viral envelope membrane to merge with the membrane of the 
target cell (Figure 2.3). Fusion results in the subsequent release and disassembly of the HIV capsid into the 
target cell and activation of the core enzymes: reverse transcriptase and integrase. The reverse 
transcriptase enzyme transcribes the viral single stranded RNA (ssRNA) into double stranded 
complimentaryDNA in the cytoplasm which is transported to the nucleus where the integrase enzyme 
promotes integration of viral DNA, i.e. provirus, into the host cell genome (Figure 2.4). The integrated 
provirus either remains in a dormant phase or produces new virions under appropriate conditions (Abbas AK, 
et al. 2012). 
 
Host and other physiological factors (e.g. cytokines, stimuli) that normally induce the activation of T 
lymphocytes are major role players in the initiation of HIV replication. Activation of T lymphocytes results in 
the up-regulation of host transcriptional factors, especially, Nuclear Factor kappa Beta (NF-B). The Long 
Terminal Repeat (LTR) endpoints of the HIV genome contain binding sites for NF-B and subsequent 
interaction triggers the transcription of HIV integrated proviral genes and production of multiple new RNA 
copies. Proteins are translated from full length mRNA transcripts which are appropriately spliced to produce 
regulatory (Tat, Rev, Nef, Vif, Vpr, Vpu) and structural proteins (Pol, Gag, Env). Fully spliced mRNA 
transcripts of the regulatory proteins and at a later stage incompletely spliced structural proteins are 
transported from the nucleus to the cytoplasm of the host cell. Further processing includes the generation of 
the enzymes: reverse transcriptase, protease and integrase from the Pol precursor protein; p24 (capsid), p17 
(matrix surrounding capsid) and p15 (nucleocapsid) polypeptides from the Gag precursor protein and gp120 
and gp41 proteins from the Env precursor protein. In the final phase of virion formation, the full length RNA 
transcripts of the proviral genome together with the Gag and Pol proteins are packaged within the 
nucleoprotein capsid and this buds from the surface of the host together with the membrane-associated Env 
proteins (Figures 2.4 and 2.5) (Abbas AK, et al. 2012)  
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Figure 2.3: HIV membrane fusion with the viral host membrane 
Viral entry entails binding of the gp120/gp41 complex to the CD4 and chemokine receptors (CCR5/CXCR4) 
of the host cell and the consequent fusion of the viral and host membrane (Abbas AK, et al. 2012) 
 
 
Figure 2.4: HIV viral entry, genomic integration and budding from host cell. 
The HIV enters the cell via membrane fusion and enzymatic activity allows for the integration of proviral DNA 
into the host genome. Host cell activation results in the up-regulation of proviral genes and the subsequent 
formation and release of new virions (Abbas AK, et al. 2012) 
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2.7 Clinical hallmarks of HIV infection: loss of CD4 T lymphocyt
The progressive loss of CD4 T lymphocytes from various compartments of the human body 
hallmarks of HIV infection, which persists to some extent even after ARV suppression of viral replication. In 
addition, the numbers of blood pDCs and mDCs (as well as other cell types) are also detrimentally affected. 
(Sabado RL, et al. 2010;Hosmalin, A 
et al. 2001). It is proposed that DC loss may impact on the uniq
responses. Specifically, DCs are central to the initiation of effective immunity (mDC stimulation of naïve T 
lymphocytes) and in mounting of effective innate antiviral defenses (pDC production of interferon
reviewed by Banchereau J, et al. 2000). 
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2.8 Discovery of DCs - the ‘one of a kind’ blood cell 
The 2011 Nobel Prize winner Ralph M. Steinman and his colleague Zanvil A. Cohn from the Rockefeller 
University, New York were the first to report on a novel adherent cell type, they termed dendritic cell. 
According to their original published work (1973), while investigating cells of mouse spleen that adhere to 
plastic and glass they noticed a large stellate cell with distinctive morphological features different from other 
adherent cells such as mononuclear phagocytes (macrophages), and to a lesser extent granulocytes and 
lymphocytes. To date, two major types of DCs have been described, mDCs and pDCs, both naturally present 
in very low numbers in peripheral blood. mDC constitute less than 1% of peripheral blood mononuclear cells 
(Upham J, et al. 2000) and pDCs have been quantified at levels to half that of mDCs (as reviewed by Reizis, 
et al. 2011). These cells are described as “one of a kind” as no other blood cell has the same morphological 
and mobility characteristics (Banchereau J and Steinman RM, et al. 1998). During certain stages of 
maturation they develop branch-like structures, key to the amplification of their specific function in the 
immune response (Figure 2.6 A and B). Cella M, et al. (1999) has reported on the different level of branch 
formation observed between pDCs and mDCs. In culturing these cells with Granulocyte-macrophage colony-
stimulating factor (GM-CSF) and Interleukin (IL)-4 (or solely culturing pDCs with IL-3) the formation of 
branch-like structures in pDCs was minimal compared to the abundance observed in mDCs (Figure 2.6 C 
and D). Also, in vitro culturing revealed that pDCs had a more dispersed and mDCs a more clustered 
distribution pattern (Figure 2.6 E and F). 
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Figure 2.6:  Microscopic images of DCs 
Graph A represents a phase-contrast micrograph of a single DC isolated from the spleen of mouse. This is 
the first image of a DCs published by the cofounders Steinman RM and Cohn ZA in 1973. Graph B represent 
a 3-D micrograph of a single DC, clearly showing the dendrite-like structures unique to this cell type 
(Behnsen J, et al. 2007). pDCs and mDCs differ morphologically. Micrograph C and D represents May-
Grünwald Giemsa staining of DCs, showing the high and low levels of dendrite-like structures of mDCs and 
pDCs, respectively (Cella M, et al. 1999).Micrograph E shows the multiple formations of mDC aggregates in 
comparison to the less clustered and more dispersed appearance of pDCs as presented in micrograph F 
(Cella M, et al. 1999). 
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2.9 Origin of DCs 
DCs, like all other blood cell types, originate from a pluripotent CD34 expressing hematopoietic stem cell 
(HSC) in the bone marrow. During the process of haematopoiesis, the CD34+HSC differentiates into myeloid 
and lymphoid progenitors, giving rise to the myeloid and lymphoid lineages of blood cells, respectively. The 
myeloid lineage of cells refers to the development of thrombocytes, erythrocytes, mast cells, basophils, 
eosinophils and monocytes/macrophages whereas the lymphoid lineage of blood cells refers to development 
of the lymphocytes viz. Natural Killer cells, T and B lymphocytes. mDCs derive from the myeloid lineage but 
it is still unclear from which of the two described lineages pDCs originate. The controversy regarding the line 
of descent of pDCs lead to these cells being given various titles and before the accepted term of 
“plasmacytoid” DCs they were also referred to as “plasmacytoid monocytes” or “plasmacytoid T cells”. They 
were given the general term plasmacytoid due to their morphology resembling that of a plasma cells 
(antibody producing B cells), but as they lack B cell markers and were abundant in the T cell zone of human 
lymphoid tissue they were then designated as plasmacytoid T cells. However, in the late 1980s, studies 
showed that these cells lacked most lymphocytic markers (although expressing low levels of CD4) but 
expressed markers associated with monocytes (CD31, CD36, CD68), hence, their name changed to 
plasmacytoid monocytes (as reviewed by Galibert L, et al. 2001). Being referred to as a DC, came from a 
study by Grouard G, et al. (1997) who observed the formation of DC specific branch-like structures (and 
rescue from apoptosis) upon in vitro culturing of these “plasmacytoid T cells” with IL-3 and CD40L. 
 
Research on the origin of pDCs has been controversial as some studies seem to assign pDC development 
to the lymphoid lineage and others to the myeloid lineage. One study investigated pDCs origin via ectopic 
expression of two specific genes (Id2 and Id3 - Inhibitor of DNA binding proteins), reported to be involved in 
hindering lymphoid T and B cell development, in CD34+CD38- progenitor cells. The authors found that 
enforced expression of Id2 and Id3 genes inhibited development of precursor pDCs, but had no effect on the 
development of the myeloid lineage derived mDC precursors, hence promoting lymphoid lineage of origin 
(Spits H, et al. 2000). In contrast, a myeloid lineage of origin was proposed by Olweus J and colleagues 
(1997) based on 1) pDC’s expression of a marker restricted to CD34+ cells of the myeloid lineage, namely 
GM-CSF receptor (GM-CSFR) and 2) the parallel expression of CD123 (IL-3) receptor) by pDCs and CD34+ 
myeloid cells. Stemming from experiments showing that within a subset of cultured CD34 progenitor cells up-
regulation of CD123 coincided with a down-regulation of GM-CSFR during in vitro culturing, the authors 
suggest that CD34+GM-CSFR+CD123+ cells defined a pDC precursor of myeloid lineage. However, recent 
molecular studies might have shed some light on the controversy regarding the origin of pDCs and proposed 
the development of these cells from a lymphoid rather than a myeloid progenitor. This was assumed on the 
basis that the same transcription factor (E protein transcription factor E2-2) involved in T lymphocyte 
development also controls pDC gene transcription (Reizis B, 2010). 
 
2.10 DC: Markers of identification, subtypes and their respective locations 
The conventional method for detecting pDCs and mDCs from the heterogeneous cell population in blood or 
lymphoid tissue requires the use of a combination of markers. The expression pattern of these markers 
profile pDCs and mDCs as follows: 1) differential expression of CD11c (X subunit of the integrin CR4) and 
CD123 markers - pDCs: CD11c- CD123+, mDC: CD11c+CD123DIM and  2) mutual positive expression of 
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HLA-DR and dim expression of lymphocytic lineage markers: collectively refer to as LIN1 which includes 
CD3 (expressed by T lymphocytes), CD14 (expressed by monocytes, macrophages, neutrophils and 
eosinophils), CD16 (expressed by NK cells, macrophages, monocytes and neutrophils), CD19 and CD20 (B 
lymphocyte marker) and CD56 (expressed on activated and resting NK cells). This method of detection was 
used in this study although single marker detection of pDCs and mDCs can also be performed via the blood 
DC antigen (BDCA) markers: BDCA-1 (also referred to as CD1c), BDCA-2 (CD303), BDCA-3 (CD141) and 
BDCA-4 (CD304) (Dzionek A, et al. 2000). BDCA-1 detects the LIN1-HLA-DR+CD11c+CD123DIM subset or 
mDCs. A smaller mDC subset defined as LIN1-HLA-DR+CD11c+CD123- express BDCA-3 and differs from 
the BDCA-1 subset by the expression of CLEC9A, a C-type lectin with immunoreceptor tyrosine-based 
activation motif (ITAM)-like motifs. Dual expression of BDCA-2 and BDCA-4 identifies the LIN-HLA-
DR+CD11c-CD123+ subset or pDCs. To date, two pDC subsets have been identified namely, CD2HIGH and 
CD2LOW, and these showed, via Mixed Leukocyte Reaction (MLR), to play a role in the stimulation of 
allogeneic T lymphocytes. The latter subtype, however, shows a weaker T cell stimulation ability (Ueno H, et 
al. 2010; Dzionek A, et al. 2000).  
 
DCs in different stages of development are found in different compartments of the body also having different 
function. Precursor mDC circulate in blood while immature (immDC) and mature mDC (mmDC) phenotypes 
are found in peripheral tissue and secondary lymphoid tissue, respectively. immDCs from skin, also known 
as the Langerhans cells, contains Birbeck granules and expresses CD1a and CD207 (langerin). They are 
found predominantly in the epidermis, while the dermis hosts a DC population with a CD1a+CD14+ 
phenotype (dermal DCs). In contrast to mDCs, pDCs are not peripheral tissue resident cells - both the 
immature and mature pDC phenotypes are found in secondary lymphoid tissue, while precursor pDC 
circulate in the blood (Gessani S and Filippo B, 2007) 
 
2.11 In vitro research: the mo-DC model vs. blood DCs 
The naturally scarce distribution of DCs together with the (prior) limited availability of DC-specific research 
tools made exploring these subsets complex. Previously, to overcome this obstacle the mo-DC model was 
used. Briefly, this entailed in vitro culturing of purified peripheral blood CD14+ monocytes with various 
supplementary agents which included GM-CSF, IL-4 and Tumor Necrosis Factor (TNF)- for seven days 
(Van Brussel I, et al. 2012). However, it has been debated whether mo-DCs are a true representation of the 
CD11c blood DC counterpart as these cells differ morphologically and functionally. Osugi Y, et al. (2002) 
reported that freshly isolated CD11c DCs were smaller than mo-DCs, also the nucleus of the CD11c DC had 
lobule-like features, while that of the mo-DCs was large, rounded and located eccentrically. Furthermore, the 
expression of the Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-
SIGN/CD209), a DC specific marker playing a role as HIV attachment receptor, was found expressed by mo-
DCs but not blood CD11c DCs. Nonetheless, similar expression of HLA-DR, CD40, CD86 and CD83 has 
been detected in both phenotypes. On a functional level, higher proliferation responses of T lymphocyte 
were observed with mo-DCs than blood CD11c DCs in allostimulatory MLRs. However, the latter induced 
higher antigen specific T lymphocyte proliferation responses and, in particular, induced higher IFN- 
production than mo-DCs (Osugi Y, et al. 2002). Advances in modern technology have mostly eliminated the 
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need to use laborious and time-consuming preparations of mo-DCs, allowing for the direct analyses of DCs 
in whole blood or in vitro. 
 
2.12 The imperative role of DCs in the initiation of primary adaptive immune responses 
Primary adaptive immune responses are essential for the elimination of harmful pathogens and fundamental 
to the activation and priming of effector cells is a series of events primarily performed by DCs, in particular, 
mDCs. These include recognition and capture of pathogens at peripheral sites of preferential pathogen entry 
(gastrointestinal-, respiratory- and genital tracts), processing of antigen in a “readable” format, delivery and 
presentation to the naïve CD4 and CD8 T lymphocytes in secondary lymphoid tissue. Specifically, 
recognition, internalisation and processing are performed by the immDCs that circulate in peripheral tissue. 
Upon differentiation into the mature phenotype, mmDCs migrate to secondary lymphoid tissue and present 
processed peptide antigen via the MHC molecule to naïve T lymphocytes (as reviewed by Banchereau J, et 
al. 2000). Also, essential to this interaction is communication between the co-stimulatory/activation ligands 
CD86 and CD80 expressed on mmDCs and the CD28 receptor expressed on CD4 and CD8 T lymphocytes. 
Conventionally, the outcome of these events is 1) the activation and clonal expansion of antigen-specific T 
lymphocytes, 2) antigen clearance and 3) establishment of antigen-specific central and effector memory T 
cells. The latter cells are situated primarily in lymphoid and peripheral non-lymphoid tissue and mount a rapid 
and vigorous immune response upon re-entry of the pathogen. 
 
2.13 “Tools” for the recognition of pathogens 
Initiation of immune responses is greatly dependent on the ability of the immune system to distinguish 
between self and non-self antigens. This recognition process is central to the innate immune system, the first 
line of defense against antigen, involving among other innate immune cells also pDCs and mDCs. 
Recognition of microbial pathogens within the host’s microenvironment is an important “cognitive” function 
and is performed via molecular structures referred to as pattern recognition receptors (PRRs). These 
receptors are found in different locations of the cell and accordingly differ in antigen specificity (Refer to 
Figure 2.7). The best described class of PRRs is the TLRs. Toll refers to the gene which was first identified 
to be involved in the development of the dorsal-ventral axis of the Drosophila Melanogaster fruit fly during 
embryogenesis. The anti-fungal properties of the receptor were only later discovered (Lemaitre B, et al. 
1996). In general 10-15 TLRs, labeled as TLR 1, TLR 2 etc., have been identified in mammalian species (as 
reviewed by Iwasaki A and Medzhitov R, 2004). In humans 10 TLRs have been described (Barreiro LB, et al. 
2009). PRRs function by recognizing evolutionary conserved pathogen-associated molecular patterns 
(PAMPs). PAMPs can be divided in two groups: microbe specific and microbe non - specific. The microbe 
specific PAMPs are molecular structures unique to microbes and not characteristic of the host. These 
microbe-specific PAMPs are recognised by TLRs located on the surface of cells. Examples include PAMPs 
of mostly a structural nature such as the lipopolysaccharide (LPS) and lipoteichoic acid, the major structural 
components of the cell wall of gram-negative and gram-positive bacteria, respectively (Abbas AK, et al. 
2012). The latter PAMPs are recognised by TLR 4 (Beutler B, 2000) and TLR 2 (Schwandner R, et al.1999), 
respectively. The protein flagellin, the major constitute of the structural component of bacteria involved in the 
motility, namely the flagellum, is recognised by TLR5 (Hayashi F, et al. 2001).  
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The microbe non-specific PAMPs refer to the recognition of molecular structures generally found in both 
the host and microbe species and includes various types of nucleic acids. Differentiation between self and 
non - self is in this case location-specific and not entirely performed on the basis of molecular structure. 
Microbial nucleic acids are captured and trapped in endosomes, a compartment within eukaryotic cells that 
does not normally internalise nucleic acids of the host. Examples of microbe non-specific PAMPs include 
unmethylated CpG DNA sequences of bacterial origin that is recognised by TLR9 and ssRNA and double 
stranded RNA (dsRNA) of viral origin recognised by TLR7 and TLR8, respectively. TLR 7, 8 and 9 is 
expressed on the endosome (Abbas AK, et al. 2012). 
 
TLRs are membrane constituents of both pDCs and mDCs, specifically, pDCs express TLR’s 1, 6, 7 and 9 
and mDCs express TLR 1 - 6 and 8 (Liu K-J, 2006; Gorden KB, et al. 2005; Iwasaki A and Medzhitov R, 
2004;Kadowaki, et al. 2001). TLRs are also found expressed on macrophages, neutrophils and epithelial 
cells. Other members of the PRRs include NOD-like and RIG-like receptors which are expressed in the 
cytoplasm and sense bacterial cell wall peptidoglycans and viral nucleic acid (ssRNA and dsRNA), 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7:  Cell surface and Intra-vesicular TLRs 
TLR 1, 2, 4, 5 and 6 are located on the cell surface and senses PAMPs of a structural nature in the external 
milieu while TLRs 3, 7, 8 and 9 are located intra-vesicularly and senses PAMPs of genomic origin. (Abbas 
AK, et al. 2012) 
 
Interaction between PAMPs and the PRRs, such as TLRs, initiates signal transduction pathways culminating 
in transcription factor activation and production of pro-inflammatory mediators (e.g. cytokines and 
chemokines) which initiate cell responses that promote the elimination of pathogens and enforce healing. 
Specifically, these inflammatory mediators function as activators of intracellular cell signaling (initiated upon 
binding to its cognate cell surface receptor) which subsequently leads to the activation of additional genes 
and the production of other cytokines and proteins involved in inflammation (e.g. IL-6), inhibition of viral 
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replication (IFN), proliferation (IL-2), apoptosis (FASL), etc. However, crucial to the activation of the immune 
system is subsequent “deactivation” upon clearance of the pathogen as components produced during 
inflammation, although beneficial in eliminating pathogens, are harmful in excessive quantities and can 
cause pathological damage. In HIV infection the inability of immune activity status to return to a basal state 
(homeostasis) is a well-described and problematic f
 
2.14 The transmission role of DCs in HIV pathogenesis
DCs are problematic in HIV pathogenesis in that they paradoxically both function in initiating effective 
immunity, and also play a central role in disseminating of
to lymph nodes via the lymphatics and then expose the virus to its primary target cells (activated CD4 T 
cells).It is also proposed that these cells are the first to make contact with the virus. In h
transmission of HIV, which is mainly via sexual intercourse (vaginal or anal) with semen being the main 
transmitting source from male to female/male, the deposition of semen from HIV
infectious virus either as free virus, spermatozoa
in the epithelial layer at the vaginal mucosal surfaces and/or trauma to the single cell epithelium of the rectal 
mucosa lining provide easy entry to HIV. However, an intact epithelial lining effectively hinders 
transmigration of HIV virions and viral entry via transcytosis has proven insufficient in cellular transmigration 
during HIV infection (Bobardt MD, et al.
involve DCs, believed to be facilitated by the branch
cross the mucosal epithelial surface and enter the lumen of the vagina/rectum, it
virions can latch on and be transported across. Refer to Figure 2.8 for a
process. 
Figure 2.8:  The proposed role of 
vagina into circulation.
Semen deposited during intercourse can cross the mucosa epithelial 
the DC projections that extend into the lumen of the vagina (Lederman MM, et al. 2006). 
 
 
eature.  
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Attachment receptors expressed on DCs and involved in facilitating transport of HIV virions across the 
vaginal epithelial barrier have been linked to Syndecan-3. The latter is a DC-specific heparin sulfate 
proteoglycan, found abundantly expressed on the projections of cervical DCs. Its interaction with the HIV has 
been linked to the gp120 envelope glycoprotein. Another DC specific receptor, well described in literature to 
play a role in HIV binding and dissemination, is DC-SIGN. DC-SIGN is a C-type lectin receptor which 
localises mostly at the center rather than the dendrite compartment of the cells. Interestingly, dual blocking of 
these HIV attachment receptors completely abolished viral capture and transmission, while blocking of 
Syndecan-3 alone elicited only partial blocking (de Witte L, et al. 2007). Notably, heparin sulfate expression 
on spermatozoa has been implicated in facilitating virus binding and transport of HIV into the lumen of the 
vagina. Other well-described HIV attachment receptors, namely, CD4, chemokine receptors and mannose, 
seemed not to play a role. Accordingly, it was determined that spermatozoa lack CD4 expression and that 
binding of HIV to spermatozoa was preserved despite blocking/cleaving of mannose receptors (Ceballos A, 
et al. (2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
21
2.15 References 
 
Books 
Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 7th ed. USA: Elsevier Saunders. 2012. 
P55-88. 
 
Gessani S and Filippo B.The biology of dendritic cells and HIV infection. US: Springer; 2007. p406-433. 
 
Hosmalin A, Lichtner M, Louis S. Clinical analysis of dendritic cell subsets The Dendritogram. In: Ewbank J, 
Vivier E, editors. Methods in Molecular BiologyTM 415. New Jersey: Humana Press Inc; 2008.p.273-290.  
 
Rödlach A. Witches, Westerners, and HIV: AIDS and cultures of blame in Africa Walnut Creek, California: 
Left Coast Press; 2006. p1-247. 
 
Journals 
Almeida, M., Cordero, M., Almeida, J., and Orfao, A. (2006).Persistent abnormalities in peripheral blood 
dendritic cells and monocytes from HIV-1 positive patients after 1 year of antiretroviral therapy. J. Acquir. 
Immune Defic.Syndr.41, 405–415. 
Apetrei, C., Metzger, M.J., Richardson, D., Ling, B., Telfer, P.T., Reed, P., Robertson, D.L., and Marx, P.A. 
(2005). Detection and partial characterization of Simian Immunodeficiency Virus SIVsm strains from bush 
meat samples from rural Sierra Leone. J. Virol. 79, 2631–2636. 
Banchereau, J., and Steinman, R.M. (1998).Dendritic cells and the control of immunity. Nature 392, 245–
252. 
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y., Pulendran, B., and Palucka, K. 
(2000). Immunobiology of dendritic cells.Annu. Rev. Immunol. 18, 767–811. 
Barreiro, L.B., Ben-Ali, M., Quach, H., Laval, G., Patin, E., Pickrell, J.K., Bouchier, C., Tichit, M., Neyrolles, 
O., Gicquel, B., et al. (2009).Evolutionary dynamics of human Toll-like receptors and their different 
contributions to host defense. PLoS Genet. 5, 1–18. 
Behnsen, J., Narang, P., Hasenberg, M., Gunzer, F., Bilitewski, U., Klippel, N., Rohde, M., Brock, M., 
Brakhage, A.A., and Gunzer, M. (2007). Environmental dimensionality controls the interaction of phagocytes 
with the pathogenic fungi Aspergillus fumigatus and Candida albicans. PLoS Pathog. 3, 138–151. 
Betsem, E., Rua, R., Tortevoye, P., Froment, A., and Gessain, A. (2011).Frequent and recent human 
acquisition of simian foamy viruses through apes’ bites in central Africa. PLoS Pathog. 7, 1–15. 
Beutler, B. (2000). TLR4: central component of the sole mammalian LPS sensor. Curr.Opin.Immunol.12, 20–
26. 
Boasso, A., and Shearer, G.M. (2008).Chronic innate immune activation as a cause of HIV-1 
immunopathogenesis.Clin.Immunol.126, 235–242. 
Bobardt, M.D., Chatterji, U., Selvarajah, S., Van der Schueren, B., David, G., Kahn, B., and Gallay, P.A. 
(2007). Cell-free Human Immunodeficiency Virus type 1 transcytosis through primary genital epithelial cells. 
J. Virol. 81, 395–405. 
Bogart, L.M., and Thorburn, S. (2005). Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among 
African Americans? J. Acquir. Immune Defic.Syndr.38, 213–218. 
Bogart, L.M., Skinner, D., Weinhardt, L.S., Glasman, L., Sitzler, C., Toefy, Y., and Kalichman, S.C. (2011). 
HIV misconceptions associated with condom use among black South Africans: an exploratory study. African 
J. AIDS Res. 10, 181–187. 
Stellenbosch University  https://scholar.sun.ac.za
  
 
22
Boneva, R.S., Switzer, W.M., Spira, T.J., Bhullar, V.B., Shanmugam, V., Cong, M.-E., Lam, L., Heneine, W., 
Folks, T.M., and Chapman, L.E. (2007). Clinical and virological characterization of persistent human infection 
with Simian Foamy Viruses.AIDS Res. Hum. Retroviruses 23, 1330–1337. 
Brown, K.N., Trichel, A., and Barratt-boyes, S.M. (2007).Parallel loss of myeloid and plasmacytoid dendritic 
cells from blood and lymphoid tissue in simian AIDS. J. Immunol. 6958–6967. 
Calattini, S., Betsem, E.B.A., Froment, A., Mauclère, P., Tortevoye, P., Schmitt, C., Njouom, R., Saib, A., and 
Gessain, A. (2007).Simian Foamy Virus Transmission from Apes to Humans, Rural Cameroon.Emerg. Infect. 
Dis. 13, 1314–1320. 
Ceballos, A., Lenicov, F.R., Sabatté, J., Rodrígues, C.R., Cabrini, M., Jancic, C., Raiden, S., Donaldson, M., 
Agustín, R., Pasqualini Jr, R.A., et al. (2009). Spermatozoa capture HIV-1 through heparan sulfate and 
efficiently transmit the virus to dendritic cells. J. Exp. Med. 206, 2717–2733. 
Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., and Colonna, M. (1999). 
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. 
Nat. Med. 5, 919–923. 
D’arc, M., Ayouba, A., Esteban, A., Learn, G.H., Boué, V., Liegeois, F., Etienne, L., Tagg, N., Leendertz, 
F.H., Boesch, C., et al. (2015). Origin of the HIV-1 group O epidemic in Western Lowland gorillas.Proc. Natl. 
Acad. Sci. 112, E1343–E1352. 
de Witte, L., Bobardt, M., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and Gallay, P. (2007). 
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl. Acad. Sci. U. S. A. 104, 
19464–19469. 
Donaghy, H., Pozniak, A., Gazzard, B., Qazi, N., Gilmour, J., Gotch, F., and Patterson, S. (2001). Loss of 
blood CD11c+ myeloid and CD11c- plasmacytoid dendritic cells in patients with HIV-1 infection correlates 
with HIV-1 RNA virus load. Blood 98, 2574–2576. 
Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D.W., and Schmitz, J. (2000). 
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral 
blood. J. Immunol. 165, 6037–6046. 
Finke, J.S., Shodell, M., Shah, K., Siegal, F.P., and Steinman, R.M. (2004). Dendritic cell numbers in the 
blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J. Clin. Immunol.24, 647–
652. 
Friis-Møller, N., Reiss, P., Sabin, C.A., Weber, R., Monforte, A. d’Arminio, El-Sadr, W., Thiébaut, R., De Wit, 
S., Kirk, O., Fontas, E., et al. (2007). Class of antiretroviral drugs and the risk of myocardial infarction. N. 
Engl. J. Med. 356, 1723–1735. 
Galibert, L., Maliszewski, C.R., and Vandenabeele, S. (2001). Plasmacytoid monocytes/T cells: a dendritic 
cell lineage? Semin.Imunol.13, 283–289. 
Gao, F., Bailes, E., Robertson, D.L., Chen, Y., Rodenburg, C.M., Michael, S.F., Cummins, L.B., Arthur, L.O., 
Peeters, M., Shaw, G.M., et al. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. 
Nature 397, 436–441. 
Gorden, K.B., Gorski, K.S., Gibson, S.J., Kedl, R.M., Kieper, W.C., Qiu, X., Tomai, M.A., Alkan, S.S., and 
Vasilakos, J.P. (2005). Synthetic TLR agonists reveal functional differences between human TLR7 and 
TLR8. J. Immunol. 174, 1259–1268. 
Grouard, G., Rissoan, M., Filgueira, L., Durand, I., Banchereau, J., and Liu, Y. (1997). The enigmatic 
plasmacytoid T cells develop into dendritic cells with Interleukin (IL)-3 and CD40-Ligand. J. Exp. Med. 185, 
1101–1111. 
Stellenbosch University  https://scholar.sun.ac.za
  
 
23
Guadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., Mcneil, A., and Dandekar, S. (2003). 
Severe CD4+ T-cell depletion in gut lymphoid tissue during primary Human Immunodeficiency Virus type 1 
infection and substantial delay in restoration following Highly Active Antiretroviral Therapy. J. Virol. 77, 
11708–11717. 
Gupta, R.K., Jordan, M.R., Sultan, B.J., Hill, A., Davis, D.H.J., Gregson, J., Sawyer, A.W., Hamers, R.L., 
Ndembi, N., Pillay, D., et al. (2012). Global trends in antiretroviral resistance in treatment-naive individuals 
with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and 
meta-regression analysis. Lancet 380, 1250–1258. 
Hahn, B.H. (2005). Tracing the Origin of the AIDS Pandemic.PRN Noteb.10, 4–8. 
Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., Eng, J.K., Akira, S., Underhill, 
D.M., and Aderem, A. (2001). The innate immune response to bacterial flagellin is mediated by Toll-like 
receptor 5. Nature 410, 1099–1103. 
Hirsch, V., Olmsted, R., Murphey-Corb, M., Purcell, R., and Johnson, P. (1989). An African primate lentivirus 
(SIVsm) closely related to HIV-2. Nature 339, 389–392. 
Iwasaki, A., and Medzhitov, R. (2004).Toll-like receptor control of the adaptive immune responses. Nat. 
Immunol. 5, 987–995. 
Jewkes, R.K., Dunkle, K., Nduna, M., and Shai, N. (2010). Intimate partner violence, relationship power 
inequity, and incidence of HIV infection in young women in South Africa: A cohort study. Lancet 376, 41–48. 
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R.A., Bazan, F., and Liu, Y.J. (2001). 
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different 
microbial antigens. J. Exp. Med. 194, 863–869. 
Klonoff, E.A., and Landrine, H. (1999). Do Blacks believe that HIV/AIDS is a government conspiracy against 
them? Prev. Med. 28, 451–457. 
Kotler, D.P. (2008). HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in 
HIV-infected patients. J. Acquir. Immune Defic.Syndr.49, S79–S85. 
Lederman, M.M., Offord, R.E., and Hartley, O. (2006).Microbicides and other topical strategies to prevent 
vaginal transmission of HIV. Nat. Rev. Immunol. 6, 371–382. 
Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M., and Hoffmann, J. A.(1996). The dorsoventral 
regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. 
Cell 86, 973–983. 
Lichtner, M., Rossi, R., Rizza, M.C., Mengoni, F., Sauzullo, I., Massetti, A.P., Luzi, G., Hosmalin, A., 
Mastroianni, C.M., and Vullo, V. (2008). Plasmacytoid dendritic cells count in antiretroviral-treated patients is 
predictive of HIV load control independent of CD4+ T-cell count. Curr. HIV Res. 6, 19–27. 
Liu, K.-J.(2006). Dendritic cell, Toll-like receptor and the immune system. J. Cancer Mol. 2, 213–215. 
McKenna, K., Beignon, A.-S., and Bhardwaj, N. (2005). Plasmacytoid dendritic cells: Linking innate and 
adaptive immunity. J. Virol. 79, 17–27. 
Meiering, C.D., and Linial, M.L. (2001).Historical perspective of Foamy virus epidemiology and 
infection.Clin.Microbiol. Rev. 14, 165–176. 
Mojumdar, K., Vajpayee, M., Chauhan, N.K., Mendiratta, S., and Wig, N. (2010). Defects in blood dendritic 
cell subsets in HIV-1 subtype C infected Indians. Indian J. Med. Res. 132, 318–327. 
Stellenbosch University  https://scholar.sun.ac.za
  
 
24
Mufune, P. (2005). Myths about condoms and HIV/AIDS in rural northern Namibia. Int. Soc. Sci. J. 57, 675–
686. 
Murray, S.M., Picker, L.J., Axthelm, M.K., and Linial, M.L. (2006). Expanded tissue targets for foamy virus 
replication with Simian Immunodeficiency Virus-induced immunosuppression. J. Virol. 80, 663–670. 
Ndembi, N., Kaptue, L., and Ido, E. (2009). Exposure to SIVmnd-2 in Southern Cameroon: Public health 
implications. AIDS Rev. 11, 135–139. 
Olweus, J., BitMansour, A., Warnke, R., Thompson, P.A., Carballido, J., Picker, L.J., and Lund-Johansen, F. 
(1997). Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl. Acad. Sci. U. S. 
A. 94, 12551–12556. 
Osugi, Y., Vuckovic, S., and Hart, D.N.J. (2002). Myeloid blood CD11c(+) dendritic cells and monocyte-
derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 100, 2858–2866. 
Paiardini, M., Pandrea, I., Apetrei, C., and Silvestri, G. (2009). Lessons learned from the natural hosts of 
HIV-related viruses. Annu. Rev. Med. 60, 485–495. 
Palella, F.J. Jr., Delaney, K., Moorman, A., Loveless, M.., Fuhrer, J., Satten, G., Aschman, D., and 
Holmberg, S. (1998). Declining morbidity and mortality among patients with advanced Human 
Immunodeficiency Virus infection. N. Engl. J. Med. 338, 853–860. 
Peeters, M., Courgnaud, V., Abela, B., Auzel, P., Pourrut, X., Bibollet-Ruche, F., Loul, S., Liegeois, F., Butel, 
C., Koulagna, D., et al. (2002).Risk to human health from a plethora of Simian Immunodeficiency Viruses in 
primate bushmeat.Emerg. Infect. Dis. 8, 451–457. 
Reizis, B. (2010). Regulation of plasmacytoid dendritic cell development.Curr.Opin.Immunol.22, 206–211. 
Reizis, B., Bunin, A., Ghosh, H.S., Lewis, K.L., and Sisirak, V. (2011). Plasmacytoid dendritic cells: recent 
progress and open questions. Annu. Rev. Immunol. 29, 163–183. 
Ross, M.W., Essien, E.J., and Torres, I. (2006).Conspiracy beliefs about the origin of HIV/AIDS in four racial 
ethnic groups. J. Acquir. Immune Defic.Syndr.41, 342–344. 
Sabado, R.L., O’Brien, M., Subedi, A., Qin, L., Hu, N., Taylor, E., Dibben, O., Stacey, A., Fellay, J., Shianna, 
K. V, et al. (2010).Evidence of dysregulation of dendritic cells in primary HIV infection.Blood 116, 3839–
3852. 
Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C.J. (1999). Peptidoglycan- and 
lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem. 274, 17406–17409. 
Silvestri, G., and Feinberg, M.B. (2003).Turnover of lymphocytes and conceptual paradigms in HIV infection. 
J. Clin. Invest. 112, 821–824. 
Soumelis, V., Scott, I., Gheyas, F., Bouhour, D., Cozon, G., Cotte, L., Huang, L., Levy, J.A., and Liu, Y.-
J.(2001). Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. 
Blood 98, 906–912. 
Spits, H., Couwenberg, F., Bakker, A.Q., Weijer, K., and Uittenbogaart, C.H. (2000). Id2 and Id3 inhibit 
development of CD34(+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a 
lymphoid origin of pre-DC2. J. Exp. Med. 192, 1775–1783. 
Steinman, R.M., and Cohn, Z.A. (1973).Identification of a novel cell type in peripheral lymphoid organs of 
mice. J. Exp. Med. 137, 1142–1162. 
Stellenbosch University  https://scholar.sun.ac.za
  
 
25
Switzer, W.M., Bhullar, V., Shanmugam, V., Cong, M., Parekh, B., Lerche, N.W., Yee, Joann, L., Ely, J.J., 
Boneva, R., Chapman, L.E., et al. (2004). Frequent Simian Foamy Virus infection in persons occupationally 
exposed to nonhuman primates. J. Virol. 78, 2780–2789. 
Switzer, W.M., Salemi, M., Shanmugam, V., Gao, F., Cong, M., Kuiken, C., Bhullar, V., Beer, B.E., Vallet, D., 
Gautier-hion, A., et al. (2005). Ancient co-speciation of simian foamy viruses and primates. Nature 434, 376–
380. 
The Joint United Nations Program on HIV/AIDS (UNAIDS) (2015). Global statistics facts sheet.Geneva, 
Switzerland.1–8. 
Ueno, H., Schmitt, N., Klechevsky, E., Pedroza-Gonzales, A., Matsui, T., Zurawski, G., Oh, S., Fay, J., 
Pascual, V., Banchereau, J., et al. (2010). Harnessing human dendritic cell subsets for medicine.Immunol. 
Rev. 234, 199–212. 
Upham, J.W., Lundahl, J., Liang, H., Denburg, J.A., O’Byrne, P.M., and Snider, D.P. (2000).Simplified 
quantitation of myeloid dendritic cells in peripheral blood using flow cytometry. Cytometry 40, 50–59. 
Van Brussel, I., Berneman, Z.N., and Cools, N. (2012). Optimizing dendritic cell-based immunotherapy: 
tackling the complexity of different arms of the immune system. Mediators Inflamm.1–14. 
Van Wijk, J.P.H., and Cabezas, M.C. (2012). Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular 
disease in HIV-Infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int. J. Vasc. 
Med. 1–13. 
Van Zyl, G.U., Merwe, L. Van Der, Claassen, M., Zeier, M., and Preiser, W. (2011). Antiretroviral resistance 
patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the 
Western Cape, South Africa. J. Med. Virol. 83, 1764–1769. 
Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S., Alizon, M. (1985).Nucleotide sequence of the AIDS virus, 
LAV. Cell 40, 9-17. 
World Health Organisation (WHO) (2015).Guideline on when to start antiretroviral therapy and on pre-
exposure prophylaxis for HIV.1–76. 
Wolfe, N.D., Switzer, W.M., Carr, J.K., Bhullar, V.B., Shanmugam, V., Tamoufe, U., Prosser, A.T., Torimiro, 
J.N., Wright, A., Mpoudi-Ngole, E., et al. (2004). Naturally acquired simian retrovirus infections in central 
African hunters. Lancet 363, 932–937. 
Zeng, M., Paiardini, M., Engram, J.C., Beilman, G.J., Chipman, J.G., Schacker, T.W., Silvestri, G., and 
Haase, A.T. (2012). Critical role of CD4 T cells in maintaining lymphoid tissue structure for immune cell 
homeostasis and reconstitution. Blood 120, 1856–1867. 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
26
Chapter 3 
 
Impact of HIV-1 infection on absolute pDC and mDC numbers in peripheral whole blood:  relationship 
to standard clinical markers of disease progression 
 
3.1  Introduction 
The systemic loss of CD4 T lymphocytes is a distinctive characteristic of an HIV-1 infection. In clinical 
practice in South Africa, enumeration of absolute number of CD4 T lymphocytes in peripheral blood is used 
as the primary immunological marker to assess HIV-1 disease progression and eligibility for ARV treatment. 
Recently, the value of the CD4:CD8 ratio as an important marker to evaluate immunological status during 
long term ARV therapy has been reviewed (Lu W, et al. 2015). The current CD4 T lymphocyte threshold for 
initiation of ARV therapy in South Africa is 500 cells/µl, which has been newly implemented since January 
2015 (Green A and Skosana I, 2014; Department of Health, South Africa, 2014).Previously, a threshold CD4 
T lymphocyte count of 350 cells/µl provided admissibility to ARV therapy. This scale raise was 
recommended by the WHO and reported in their revised guidelines of 2013. It was based on studies 
showing that earlier initiation of ARV therapy, in particular, improved the clinical outcome of HIV-1 infected 
individuals and reduced the risk of HIV transmission to the HIV negative partner in discordant infected 
couples. Notably, WHO has recently (September 2015) released revised guidelines recommending the 
administration of ARV therapy to HIV-infected individuals regardless of their CD4 count. 
 
Similar to the loss of CD4 T lymphocytes, a decline in pDC and mDC numbers in peripheral blood during 
acute and chronic HIV-1 infection has been reported (Mojumdar K, et al. 2010; Sabado RL et al. 2010; 
Lichtner M, et al. 2008; Finke JS, et al. 2004; Donaghy H, et al. 2001; Soumelis V, et al. 2001). DC depletion 
has also been observed in peripheral blood of SIV infected macaque monkeys (Macaca mulatta) 
(Wijewardana V, et al. 2010; Malleret B, et al. 2008; Brown KN, et al. 2007; Reeves RK and Futz PN, et al. 
2007). In one particular SIV study the loss of blood pDCs during infection was mirrored by the loss of these 
cells from axillary lymph nodes (Brown KN, et al. 2009). This finding contradicted the hypothesis that DC loss 
from peripheral blood is due to increased migration to and accumulation in lymph nodes. Brown KN, et al. 
(2009) initially proposed that the systemic decline of pDCs might be due to arrested development of these 
cells in the bone marrow but no association was found. However, apoptosis was seemingly involved as 
higher expression of Annexin V and 7-AAD (markers for early and late stage apoptosis, respectively) was 
observed in lymph node pDCs. Also, up-regulation of the FAS receptor was detected (other cell death 
associated markers, TRAIL-R2, FASL and TNF-related apoptosis inducing ligand (TRAIL), showed no 
change in expression). These findings might explain why Brown KN et al. in a previous study (2007) 
observed a significantly higher degree of spontaneous apoptosis by lymph node harvested pDCs and mDCs 
of SIV infected macaque monkeys compared to their uninfected counterparts in 24h cultures. Wijewardana 
V, et al. (2013) also confirmed the role of apoptosis in the loss of mDCs during SIV infection and illuminated 
the role of these cells in contributing to immune activation during HIV-1 infection. In contrast to the findings in 
SIV infected macaque monkeys, DC number loss in peripheral blood of chronically HIV-1 infected humans 
were analogous to DC number increase in lymph nodes (Dillon SM, et al. 2008). This finding was supported 
by a study conducted by Dave B and colleagues (2012) who also reasoned that the contrasting reports 
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regarding DC numbers in the lymph nodes versus peripheral blood of the non-natural human and monkey 
hosts during HIV/SIV infection may be due to the extraction of DCs at inconsistent time points during 
infection. 
 
Main research focus 
The loss of DCs from peripheral blood during HIV-1 infection has been reported, however, little is 
known regarding the distribution of pDCs and mDCs in peripheral blood of chronically HIV-1 infected 
patients from South Africa. Also, not much has been reported on the impact of active TB co-infection 
(the major death-causing co-infection among HIV-1-infected South African) and combination ARV 
treatment (the standard treatment approach) on DC numbers. 
 
The study aim 
The aim of the present study was to gain an understanding of the whole blood distribution of 
absolute pDC and mDC numbers of South African HIV-1 mono, HIV-1/TB co-infected and ARV treated 
individuals compared to uninfected matched controls. 
 
The objectives of the study were 
- to describe the absolute number distribution of pDCs and mDCs as well CD4 and CD8 T 
lymphocytes in peripheral blood during HIV-1 infection 
- to determine the impact of a TB co-infection and ARV treatment on the pDC and mDCs number as 
well as CD4 and CD8 T lymphocyte numbers in peripheral blood 
- to evaluate the CD4:CD8 ratio between the control study group and HIV-1 related study groups 
- to determine whether pDC and mDC numbers correlates with CD4 and CD8 T lymphocytes as well 
as viral load 
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3.2  Outline of the study 
Refer to sections 3.3.1 - 3.3.8 for a detailed description on the collection and processing of samples and data 
 
SAMPLE COLLECTION 
Patient recruitment, blood collection by venesection 
at various clinics in the Western Cape, South Africa 
 
STUDY GROUPS 
5 Study groups: Control, ARV-HIV-1, ARV-HIV-1/TB, ARV+HIV-1 and  ARV+HIV-1/TB 
 
WHOLE BLOOD (EDTA) PLASMA (EDTA) 
50µl 100µl 100µl 1ml 
    
4-COLOUR FLOW CYTOMETRIC QUANTIFICATION OF 
REAL TIME PCR 
QUANTIFICATION 
OF  
CD4 and CD8 T cells 
 
ASSAY: Staining with  BD 
MultiTEST™ mAbs:           
CD3 FITC, CD8 PE, CD45 
PerCP, CD4 APC in BD 
TruCOUNTTM tube 
pDCs 
 
ASSAY: Staining with 
mAbs:  HLA-DR APC, CD45 
PerCP, LIN1 FITC, CD123 
PE in BD TruCOUNTTM tube 
mDCs 
 
ASSAY: Staining with 
mAbs: HLA-DR APC, 
CD45 PerCP, LIN1 FITC, 
CD11c PE in BD 
TruCOUNTTM tube 
Viral load  
 
ASSAY: ABBOTT 
Real Time HIV-1 
PCR assay 
(ABBOTTm 
2000rt)/ 
bioMérieux 
NucliSens EasyQ® 
HIV-1, v1.2 test 
    
DATA COLLECTED 
CD4 and CD8 T cells 
- cells/µl 
- % of CD45+CD3+ cells 
pDCs 
- cells/ml 
- % of HLA-DR_LIN1DIM 
events 
mDCs  
- cells/ml 
- % of HLA-DR_LIN1DIM 
events  
Viral load 
- RNA copies/ml 
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3.3  Materials and Methods 
 
3.3.1 Study groups and clinical data 
A total of five study groups were included in this first part of the study which included the Control (n=24), 
ARV-HIV-1 (n=21), ARV-HIV-1/TB (n=20), ARV+HIV-1 (n=22) and ARV+HIV-1/TB (n=17) study groups. The 
selection criteria for participant enrolment for each study group is summarised in Table 3.1. Participants were 
enrolled from February to October 2009 and were of black African or mixed race origin. The enrolled 
individuals were also of similar socio-economic status. The majority of patients on ARV therapy (61%) were 
following the Stavudine, Lamivudine and Efavirenz (EFV) regimen, 20% were using the Stavudine, 
Lamivudine and Nevirapine (NVP) regimen, 5% were on the Prevention of Mother-to-Child Transmission 
(PMTCT) regimen and 2-4% was using one of five different ARV regimens. At the time of enrolment, HIV-
1/TB co-infected patients were primarily using either Pyridoxine and/or Rifafour (combination of four agents 
Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) drugs. Participants of each study group were recruited 
from the following state clinics in a peri-urban area of Cape Town, South Africa, which included Stellenbosch 
(47% of total recruits), Idasvalley (12%), Kuils River (2%), Tygerberg (13%), Eerste River (23%) as well as 
the Carl Bremer Hospital in Parow (2%).  
 
Informed consent was obtained from all the study participants. The study was reviewed and approved by the 
Health Research Ethics committee (HREC) of the Faculty of Medicine and Health Sciences of Stellenbosch 
University and was assigned the Ethics reference number N08/02/057. Demographic and clinical data of the 
study participants are shown in Table 3.2. 
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Table 3.1: Description of study groups for the whole blood analysis of pDCs and mDCs 
Study groups Description of study group 
Control 
At the time of blood collection participants had  
a) a negative HIV-1 serologya test result, 
b) showed no clinical symptoms of other infections. 
ARV- 
HIV-1 
HIV-1 diagnoses of participants of this study group were confirmed with a 
positive HIV-1 serologya test. At the time of blood collection, enlistees 
a) were not receiving ARV therapy,  
b) had no clinical symptoms of a current TB co-infection. 
HIV-1/TBb 
HIV-1 diagnoses of participants of this study group were confirmed with a 
positive HIV-1 serologya test. Diagnosis of active TB co-infection (cough, 
night sweats, weight loss) was confirmed with sputum culture and/or chest 
X-ray evidence. At the time of blood collection, enlistees were 
a) not on ARV treatment, 
b) using anti-TBc medication. 
 
ARV+ 
 
HIV-1 
HIV-1 diagnoses of participants of this study group were confirmed with a 
positive HIV-1 serologya test. At the time of blood collection, enlistees 
a) were receiving ARVc treatment, 
b) showed no clinical symptoms of a current TB co-infection. 
HIV-1/TBb 
At the time of diagnoses, HIV-1 infection was confirmed by an HIV-1 
serology testa and active TB infection was confirmed with sputum 
culture/chest X rays. At the time of blood collection the enlistees were  
a) on ARVc treatment, 
b) using anti-TBc medication. 
aCombination antibody and antigen 
bTB co-infection being either a primary/secondary infection or reactivation 
cSpecific time on treatment was not a defining criteria for this study 
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Table 3.2: Demographic and clinical data of participants in the study groups analysed for the 
whole blood enumeration of pDCs and mDCs 
 Study groups 
 Control 
ARV- ARV+ 
HIV-1 HIV-1/TB HIV-1 HIV-1/TB 
Total (n) 24 21 20 22 17 
Male: Female 
Nr 
% 
 
11:13 
46:54 
 
11:10 
52:48 
 
14:6 
70:30 
 
9:13 
41:59 
 
9:8 
53:47 
Agea 
Median 
Range 
 
35 
18 - 62 
 
37 
21 - 53 
 
37 
24 - 53 
 
34 
19 - 53 
 
35 
24 - 53 
Time on ARV therapyb 
Median 
Range 
N/A N/A N/A 
 
9 
<1 - 43 
 
15 
<1 - 44 
Time on anti-TB therapyb 
Median  
Range 
N/A N/A 
 
1 
<1 - 5 
N/A 
 
3 
<1 - 8  
aAge median and range expressed in years 
bTime on treatment median and range expressed in months 
 
 
3.3.2  General specimen processing 
Each of the participants enrolled in the study was allocated a patient number and all laboratory procedures 
were performed in reference to this number. Whole blood from participants was obtained aseptically by 
venisection into 5 ml Ethylene diamine tetra acetic acid (EDTA) vacutainer tubes (Becton, Dickinson and 
Company (BD) Biosciences, San Jose, CA) of which 500µl was aliquoted into screw cap tubes for the whole 
blood CD4 and CD8 T lymphocyte count assay. A volume of 200µl of the remainder blood volume was 
collected for the whole blood procedure used to determine the absolute number of pDCs and mDCs. The 
remaining blood volume was used for plasma collection to determine the viral load (refer to section 3.3.7) 
and/or storage at -80°C.Processing of samples was at all times performed in a biosafety cabinet (NUAIRE 
biological class II safety cabinet). 
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3.3.3 Monoclonal antibodies (mAbs) used for the detection of pDCs and mDCs in peripheral whole 
blood 
In identifying the general DC population in whole blood, the following mouse anti-human monoclonal 
antibodies, all obtained from BD Biosciences (San Jose, CA), were used: HLA-DR APC, CD45 PerCP, 
CD123 PE, CD11c PE and LIN 1. The latter contains a combination of 6 mAb clones against several 
leukocyte subsets all conjugated to the same fluorochrome, namely FITC. It is also labeled as the “dump 
channel” as it is used to identify the majority of “unwanted” cells. The mAb clones of the LIN1 cocktail 
includes CD3 (expressed on all T lymphocytes), CD16 (expressed on resting NK cells, and certain 
macrophages, monocytes and neutrophils), CD19 and CD20 (expressed on B lymphocytes), CD14 
(expressed on monocytes, macrophages, neutrophils and eosinophils) and CD56 (expressed on activated 
and resting NK cells). For the purpose of the study the target markers HLA-DR, LIN1, CD123 and CD11c 
were collectively given the term, DCID (DC identification) markers. Refer to Table 3.3 for mAb clone and 
isotype information. 
 
Table 3.3:  Clone, isotype and reactivity information on the mAbs used to detect pDCs and mDCs 
mAb Clone Isotype Reactivity 
LIN1 FITC:CD3 
CD16 
CD19 
CD20 
CD14 
CD56 
SK7 
3G8 
SJ25C1 
L27 
MP9 
NCAM16.2 
Mouse IgG1,  
Mouse IgG1,  
Mouse IgG1,  
Mouse IgG1,  
Mouse IgG2b,  
Mouse IgG2b,  
Human 
CD45 PerCP 2D1 Mouse IgG1,  Human 
HLA-DR APC L243 Mouse IgG2a,  Human 
CD123 PE 9F5 Mouse IgG1,  Human 
CD11c PE S-HCL-3 Mouse IgG2b,  Human 
 
3.3.4 Whole blood staining procedure for the detection of pDCs and mDCs 
The whole blood staining procedure to detect and enumerate the pDC and mDC population was performed 
in BD TruCOUNTTM tubes (BD Biosciences, San Jose, CA) usually used for absolute CD4 and CD8 count 
procedures. The BD TruCOUNTTM tube contains a lyophilised pellet with fluorescent beads situated beneath 
a stainless steel retainer at the base of the tube. Once the specimen and the mixture of fluorochrome-
conjugated antibodies have been added, the bead pellet dissolves, resulting in the release of a fixed number 
of beads. The absolute number of cells is then determined by comparing bead events to cellular events.  
 
Two sets of cocktails were separately prepared in Eppendorf tubes (Hamburg, Germany) labeled as cocktail 
1 (pDC) and 2 (mDC). Both of these contained the mAbs HLA-DR Allophycocyanin (APC), CD45 Peridinin 
Chlorophyll Protein (PerCP) and LIN1 Fluorescein isothiocyanate (FITC), while the CD123 Phycoerythrin 
(PE) and CD11c PE mAbs was added to cocktail 1 and cocktail 2, respectively. All antibodies were used 
according to the manufacturers’ recommendations (during the course of the study titration of mAbs was 
introduced which aids in determining the optimal volume to use in an assay as the manufacturer 
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recommended volume may be an overestimate. mAb titrations were applied to the assays performed in 
chapters 4 and 5). Whole blood (100 µl), followed by cocktail 1, was carefully and without touching the bead 
pellet, aspirated above the metal retainer of a BD TruCOUNTTM tube (BD Biosciences, San Jose, CA). The 
sample was gently vortexed and incubated for 15 min in the dark at room temperature. Afterwards, the red 
blood cells were lysed and leukocytes fixed with 900 µl of 1x BD FACS Lysing solution (BD Biosciences, San 
Jose, CA) for 10 min at room temperature. The same staining procedure was followed for cocktail 2. 
Experimental staining controls such as Fluorescence Minus One (FMO), which aids in defining true positive 
events from a complex marker staining profile (cases where positive and negative marker expression cannot 
be clearly defined), was not required as the populations of interest were clearly identifiable upon analyses 
post staining. The samples were immediately acquired on a BD FACSCaliburTM 4-colour flow cytometer (BD 
Biosciences, San Jose, CA). Approximately 100 000 total events were acquired with a specific threshold set 
on the FL3 (PerCP) detector to exclude negative events and debris. Refer to Appendix A for the 
configuration of the BD FACSCalibur™ 4-colour flow cytometer (BD Biosciences, San Jose, CA) utilised in 
this part of the study. 
 
3.3.5  Flow cytometric analyses: Gating strategy to identify DC subset and bead events 
The identification of beads, pDC and mDC events was performed via a specific gating strategy designed 
using the BD CellQuestTM Pro software (BD Biosciences, San Jose, CA). The graphical representation of 
events as seen in Figures 3.1 and 3.2 was generated using the BD FACSDiva™ software v6.1.3 (BD 
Biosciences, San Jose, CA) utilised for its automated hierarchical gating function which is not a defined 
option of the BD CellQuestTM Pro software. Bead events were identified and gated from a PE Fluorescence 
(FL) 2 vs. FITC FL1 density plot in which all events were displayed (Figure 3.1). In identification of the blood 
DCs, firstly, a polygon gate, designated as population (P)1, was drawn to include the monocyte and 
lymphocyte population in a Side Scatter (SSC) vs. CD45 density plot (Figure 3.2: A1 (pDCs), B1 (mDCs)). 
This broad gate was drawn to ensure maximum collection of the DC population which granular properties 
places it in the region between that of the monocyte and lymphocyte events on a SSC scale. The P1 
population was then displayed in a HLA-DR vs. LIN1 density plot and a P2 gate collected LIN1DIM as well as 
both HLA-DR+ and HLA-DR- events (referred to as  HLA-DR_LIN1DIM events) (Figure 3.2: A2 (pDCs), B2 
(mDCs)) (markers with either “+”, “DIM” or “-”superscriptrefers to their expression as bright positive, 
intermediate intensity or extremely low/absent, respectively). In effect, DCs are characteristically positive for 
HLA-DR expression and the reason for the broad P2 gate was to ensure that DCs with a lower range of 
HLA-DR expression was also included during gating of events. Events in the P2 gate was displayed in HLA-
DR vs.CD123 density plot and the pDC population identified as HLA-DR+CD123+ and collected in a P3 gate. 
Similarly, mDC events were identified as HLA-DR+CD11c+ upon analysis of P2 events in a HLA-DR 
vs.CD11c density plot and collected in a P4 gate (Figure 3.2: A3 (pDCs) and B3 (mDCs)). The absolute 
count, cells/µl, of pDCs and mDCs was determined using the following mathematical formula:  
 
	
		
	
	
		

	
	
		
	

		
 

 
 
Stellenbosch University  https://scholar.sun.ac.za
  
Both the absolute number and percentage of gated events, as per standard flow cytometric analysis, for the 
pDCs and mDCs were determined. Percentage o
within the CD45+HLA-DR_LIN1DIM events and fraction of CD4 and CD8 T lymphocytes within the CD45
population. 
Figure 3.1:  Collecting bead events to determine absolute cell counts
Bead events (green-coloured events) required to determine absolute pDC and mDC events in cells/µl were 
collected from a PE (FL2) vs. FITC (FL1) density plot displaying all events
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Figure 3.2:  Gating strategy to identify
A broad gate (P1) was used to select the lymphocyte and monocyte events in a SSC vs. CD45 density plot 
(A1: pDCs, B1: mDCs).The broad gate ens
mDCs (blue-coloured events) located, based on their unique granular properties, between the lymphocyte 
and monocyte events on a SSC scale. P1 events were displayed in a HLA
polygon gate collected the HLA-DR_LIN1
HLA-DR vs. CD123 (A3: pDCs) and CD11c (B3: mDCs) density plot to collect the pDC (P3) and mDC (P4) 
events, respectively. 
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3.3.6  Procedure for determining CD4 and CD8 T lymphocyte counts from whole blood 
The absolute numbers of CD4 and CD8 T lymphocytes were determined by staining 50µl whole blood with 
the BD MultiTEST™ CD3 FITC, CD8 PE, CD45 PerCP, CD4 APC mAb cocktail in BD TruCOUNT™ tubes 
according to the manufacturer’s recommendations (BD Biosciences, San Jose, CA). Red blood cells were 
then lysed for 10 minutes (min) with 450µl of BD FACS lysing solution (BD Biosciences, San Jose, CA). The 
sample was immediately acquired using a BD FACSCalibur™ 4 colour flow cytometer (BD Biosciences, San 
Jose, CA) and analyzed using the BD MultiSET™ V1.1.2 software (BD Biosciences, San Jose, CA) which 
automatically determines the absolute number of CD4 and CD8 T lymphocyte in the sample. In addition, the 
software also defines the CD4:CD8 ratio as well as CD4 and CD8 T lymphocytes as a percentage of the 
CD45+CD3+ population. Routine quality control included daily preparation of a standardised blood sample of 
LymphoSure (Synexa Life Sciences, South Africa) and quarterly use of an external control (National External 
Quality Assessment Service (NEQAS)) from the NHLS. The CD4 and CD8 T lymphocyte count assay 
performed has been accredited by the South African National Accreditation System (SANAS). 
 
3.3.7   Assay for viral load quantification 
Viral load testing is performed as a routine assay by the SANAS accredited diagnostic laboratories of the 
Division of Medical Virology, Stellenbosch University and National Health Laboratory Services (NHLS).  
Plasma samples from HIV-1 infected patients were prepared by centrifuging whole blood, obtained in EDTA 
vacutainer tubes (BD Biosciences, San Jose, CA), for 10 min at 800 x g (Hettich Rotanta 460R benchtop 
centrifuge, Massachussets, USA). A volume of 1ml plasma was collected for viral load testing and the 
remaining plasma stored in labeled cryovials at -80°C. Multiple platforms were involved in detecting the viral 
load during the study. Initially, the bioMérieux NucliSens EasyQ® HIV-1 v1.2 test, which expressed the viral 
load as IU/ml (IU-international units), was used and later the updated v2.0 version, which expressed the viral 
load as RNA copies/ml.  Conversion of 1 copy = 1 IU was confirmed by the supplier’s memorandum (Scott 
LE, et al. 2009). Limit of detection (LOD) for this assay using 1 ml plasma input was estimated at 25 RNA 
copies/ml. This viral load detection system was later replaced by the ABBOTT Real Time HIV-1 PCR assay 
(ABBOTT m2000rt) which also expressed the viral load as RNA copies/ml. TheLOD for this assay using 1ml 
plasma input was estimated at 40 RNA copies/ml.  
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3.3.8 Statistical analyses 
Comparative analyses of the absolute number of CD4 and CD8 T lymphocytes, pDCs and mDCs were 
performed as follows:  
- to assess HIV-1 infection (mono and TB dual infection), the ARV-HIV-1 and ARV-HIV-1/TB study 
groups were compared to the control study group. The one-way ANOVA non-parametric Kruskal-Wallis test 
with pairwise comparison to the control group using the Dunns multiple comparison post-test was applied;  
- to assess probable immune reconstitution during HIV-1 infection (mono and TB dual infection): the 
ARV+HIV-1 and ARV+HIV-1/TB study groups were compared to the control study group. The one-way 
ANOVA non-parametric Kruskal-Wallis test with pairwise comparison to the control group using the Dunns 
multiple comparison post-test was applied; 
- to assess the impact of ARV treatment: the ARV+HIV-1 and ARV+HIV-1/TB study groups were compared 
to the ARV-HIV-1 and ARV-HIV-1/TB study groups, respectively. The non-parametric two tailed Mann-
Whitney t test was applied; 
- to assess the impact of TB co-infection: the ARV-HIV-1/TB study group was compared to the ARV-HIV-1 
study group. The non-parametric two tailed Mann-Whitney t test was applied. 
 
Similar data analyses were performed with data representing CD4 and CD8 T lymphocytes as a percentage 
of CD45+CD3+ cells and pDCs and mDCs as a percentage of CD45+HLA-DR_LIN1DIMevents. This was 
performed to determine whether the frequency distribution as determined by absolute count is comparable to 
percentage data. 
 
Correlation analyses were performed as follows: 
- to assess disease severity and progression: the relationship of pDC and mDC counts to CD4 and CD8 
T lymphocyte counts was determined for the control, combined ARV-HIV-1 study group (ARV-HIV-1 and 
ARV-HIV-1/TB study groups) and combined ARV+HIV-1 study group (ARV+HIV-1 and ARV+HIV-1/TB study 
groups). Also, the relationship of DCs to viral load was determined for the combined ARV-HIV-1 study 
groups. Correlation measurements were performed using the non-parametric Spearman test in which the 
correlation coefficient (r) was used to determine the type of relationship (direct, indirect or none) and t-
statistics (p) the significance thereof.  
 
These tests were performed using the Graphpad Prism version 5.00 software (San Diego, California, USA). 
Refer to Table 3. 4 for the summary of the method used to report significant and non-significant data as well 
as the corresponding p value range. 
 
Table 3.4: Summary of the method used to report significant and non-significant data as well as 
the corresponding p value range 
The software used to determine statistical significance report p value from the ANOVA test as indicated in 
the table below while the t-test reports exact numbers. 
Method Definition p value 
*** Extremely significant  0.001 
** Very significant  0.01  
* Significant  0.05 
ns Not significant >0.05 
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3.4 Results and Discussion 
 
3.4.1  Frequency distribution of CD4 and CD8 T lymphocytes, pDCs and mDCs in the peripheral 
blood of the control and HIV-1 related study groups 
Number of pDCs, mDCs and CD4 T lymphocytes in peripheral blood is similar between HIV-1 untreated and 
HIV-1/TB co-infected patients, but reduced in comparison with uninfected patients  
Similar to the reports of others, we found a significant decline in CD4 T lymphocyte, pDC and mDC numbers 
in peripheral blood during chronic HIV-1 infection. Compared to the control study group, the ARV-HIV-1 study 
group showed a reduction (determined as the percentage change in absolute number from the reference 
study group) of 80% (p  0.001), 63% (p 0.001) and 31% (p  0.01) in the median CD4 T lymphocyte, pDC 
and mDC numbers, respectively. A similar profile was observed with the ARV+HIV-1 study group with a 
reduction of 80% (p  0.001), 66% (p  0.001) and 35% (p  0.01) in the median CD4 T lymphocyte, pDC 
and mDC numbers when compared to the control study group, respectively.(Refer to Table 3.5; Figure 3.3 A, 
C and D, respectively). The blood cell number data of the ARV-HIV-1 and ARV-HIV-1/TB study groups was 
comparable even though the study participants of the latter group were on TB treatment at the time of blood 
collection. Notably, the TB participants enrolled were within the first term of anti-TB treatment with a strong 
likelihood of a TB infection persisting (median time on anti-TB therapy: 1 month (Table 3.2)). Hence, the data 
suggested that a TB dual infection does not significantly exacerbate cell number loss during HIV-1 infection. 
 
The literature also reports on the loss of blood DCs during HIV-1 infection. Both pDC and mDC median 
numbers during HIV-1 infection, as determined by Barron MA, et al. (2003), were found to circulate at a 
reduced rate of 50% compared to the control. According to numbers defined by Donaghy H, et al. (2001), the 
median number loss of pDCs and mDCs was estimated at 67% and 82%, respectively. Similarly, the median 
pDC and mDC numbers reported by Mojumdar K, et al. (2010) showed a decline of 69% and 79%, 
respectively. The level of signature CD4 T lymphocyte decline during HIV-1 infection as reported by Messele 
T, et al. (1999) accounted for a median loss of 43%. The reported data of Moir S, et al. (2010) revealed a 
47% and 71% decline in median CD4 T lymphocytes during acute and chronic HIV-1 infection, respectively. 
The median CD4 T lymphocyte numbers as reported by Rodriques DSS, et al. (2003) converted to a loss of 
greater than 80% in both the HIV-1 and HIV-1/TB co-infected study groups investigated. As with the current 
study, the authors did not observe a statistical difference between these study groups. In contrast, another 
study observed that the level of decline in CD4 T lymphocytes between the HIV-1 and HIV-1/TB study group 
was significant. However, the HIV-1/TB cohort of this study comprised of a very small number of participants 
(n=6) which may have affected the statistical estimates (Pitabut N, et al. 2013). 
 
Notably, a decline in the number of pDCs and mDCs in peripheral blood has also been observed in other 
viral infections such as Hepatitis C (Longman RS, et al. 2005; Kanto T, et al. 2004) and dengue virus (De 
Carvalho Bittencourt M, et al. 2012) as well as parasitic associated infections such as Malaria (Pinzon-
Charry A, et al. 2013). This may be suggestive of DC decline not being HIV-1 specific but rather a normal 
consequence of infection.  
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Number of CD8 T lymphocytes in peripheral blood is similar between HIV-1 untreated and HIV-1/TB co-
infected patients, but significantly higher in comparison with uninfected patients  
Parallel to the number loss of CD4 T lymphocytes, pDCs and mDCs during HIV-1 infection, significantly 
higher CD8 T lymphocyte numbers were observed in the ARV-HIV-1 and ARV-HIV-1/TB study groups. 
Notably, the absolute CD8 T lymphocyte numbers in peripheral blood during HIV-1 infection was not as 
severely altered as the CD4 T lymphocyte numbers. Compared to the control, a significant 46% (p  0.05) 
and 40% (p  0.01) higher median CD8 T lymphocyte number was observed in the ARV-HIV-1 and the ARV-
HIV-1/TB study group, respectively (Table 3.5; Figure 3.3 B). Higher numbers of CD8 T lymphocytes during 
HIV-1 infection have also been reported by others. The absolute numbers as reported by Messele T, et al. 
(1999) showed a 57% increase in the CD8 T lymphocyte subset whereas the data of Moir S, et al. (2010) 
showed a 64% increase in both early and chronic HIV-1 infection. As with CD4 T lymphocytes, pDCs and 
mDCs, a significant change in CD8 T lymphocyte number between the ARV-HIV-1 and ARV-HIV-1/TB study 
groups was also not observed which may indicate that HIV-1/TB co-infection does not affect CD8 T cell 
numbers more profoundly than an HIV-1 mono infection.  
 
ARV associated recovery/restoration of CD4 T lymphocytes in peripheral blood was not mirrored by DC 
subsets 
Although ARVs are effective at controlling viral replication and are largely reparative (at the CD4 T 
lymphocyte level) they do not fully restore the immune status to pre-infection levels. Comparing the CD4 T 
lymphocyte number distribution between the control and ARV-HIV-1 study group, for treatment to effectively 
restore CD4 T lymphocyte numbers (in other words replenish the reported 80% loss observed in the ARV-
HIV-1 study group), an approximate 4 fold gain in median CD4 T lymphocyte count would be required. 
Nonetheless, by comparing the CD4 T lymphocyte count of the ARV+HIV-1 to ARV-HIV-1 and ARV+HIV-1/TB 
to ARV-HIV-1/TB study groups we observed that current ARV therapy was able to induce a 89% (p  0.01) 
and 63% (p  0.01) gain in median CD4 T lymphocyte numbers, respectively. Although, the increase in CD4 
T lymphocyte number was statistically significant, the gain was nowhere sufficient to completely restore the 
CD4 T lymphocyte compartment during HIV-1 infection and, compared to the control study group, adjusted 
median numbers were still 61% (p  0.001) and 67% (p  0.001) lower in the ARV+HIV-1 and ARV+HIV-1/TB 
study group, respectively (refer to Table 3.5; Figure 3.3 A). Notably, the median time on ARV therapy for the 
ARV+HIV-1 and ARV+HIV-1/TB study groups was 9 and 15 months, respectively (refer to Table 3.2). This 
finding showed that an approximate 1 year ARV treatment period seemed insufficient for the complete 
restoration of the immune system. It was also proposed that the observed slow rate/level of restoration may 
also be dependent on the CD4 T lymphocyte number at time of initiation of therapy - with low CD4 T 
lymphocyte numbers associated with slow rate of restoration.  
 
Despite relatively successful CD4 restoration on ARVs, no significant recovery of pDC and mDC numbers 
was detected in the ARV+HIV-1 and ARV+HIV-1/TB study groups. Similar to the ARV untreated groups and 
compared to the control there were 51% (p  0.01) and 70% (p  0.001) lower median pDC numbers and 
22% (p  0.05) and 36% (p  0.01) lower median mDC numbers in ARV+HIV-1 and ARV+HIV-1/TB study 
groups, respectively. Although pDC and mDC numbers did not normalise during ARV therapy, we did 
observe a slightly higher (although not statistically significant) number of pDCs and mDCs in the ARV+HIV-1 
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compared to the ARV-HIV-1 study group, but not in the ARV+HIV-1/TB compared to the ARV-HIV-1/TB study 
group (refer to Table 3.5; Figure 3.3 C and D, respectively). 
 
Collectively, these cross-sectional findings indicated that short-term (<15 months) ARV treatment contributes 
to a partial but significant recovery in CD4 T lymphocyte and a low insignificant (ARV+HIV-1 study group) or 
absent (ARV+HIV-1/TB study group) recovery of the blood DC population during ARV+HIV-1 and ARV+HIV-
1/TB infection, respectively. Although we observed recovery in CD4 T lymphocyte numbers during ARV 
therapy, the lack of recovery in DC numbers seem to indicate the sensitivity of these cells to HIV-1 
associated changes such as persistent immune activation. If this should be the case then in view of a report 
by Vinikoor MJ, et al. (2013) showing that immune activation persists even during ARV therapy, it was 
proposed that peripheral blood number recovery of DCs rather than CD4 T lymphocytes might be a better 
predictor of effective treatment regimens. In clear contrast to the cell number changes, ARV therapy was, as 
expected, effective in controlling the viral load. The median ARV treatment period of participants in the 
ARV+HIV-1 and ARV+HIV-1/TB study group was 9 and 15 months (refer to Table 3.2), respectively, and most 
participants had a very low or undetectable HIV-1 viral load reading (refer to Table 3.5). In agreement with 
the ARV associated findings of the current study, Barron MA, et al. (2003) and Pacanowski J, et al. (2001) 
also showed that 6-12 months of HAART leads to an increase in CD4 T lymphocytes numbers and a decline 
in viral load which is accompanied by lack of recovery of both DC subsets. Another study showed also no 
recovery in blood DC numbers after 1-2 years of HAART (Lichtner M, et al. 2008).  
 
ARV therapy was more efficient in normalizing the CD8 than CD4 T lymphocyte numbers. The CD8 T 
lymphocyte numbers in the ARV+HIV-1 and ARV+HIV-1/TB study groups were reduced to levels similar to 
that of the control (median time on ARV treatment 9 and 15 months, respectively (refer to Table 3.2)). Hence, 
ARV therapy seemingly contributes towards restoring the CD8 T lymphocyte numbers observed during HIV-1 
infection (refer to Table 3.5; Figure 3.3 B). As CD8 T lymphocytes are pivotal in the control of viral infections, 
including HIV-1, it is anticipated that controlling viral replication via ARV therapy would/should lead to 
decreased CD8 numbers, if no other infection or condition is present. Jiao Y, et al. (2011) observed a decline 
in CD8 T lymphocyte count already 3 months after the initiation of ARV therapy, however, Almeida M, et al. 
(2006) reported on the lack of CD8 T lymphocytes number recovery after 1 year of therapy.  
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Table 3.5: Summary of the CD4 T and CD8 T lymphocytes, pDCs and mDCs absolute numbers; 
CD4:CD8 ratio and viral load (as applicable) of the control, HIV-1 and HIV-1-related 
study groups. 
Data indicated as 
Mea = Median cells/µl,  
Ra= Range cells/µl,  
Meb= Median % of CD45+CD3+ events,  
Rb =Range % of CD45+CD3+ events, 
Mec= Median ratio of CD4 Lymphocyte absolute number to CD8 T lymphocyte absolute number 
Rc=Range of CD4:CD8 ratio 
Med = Median x103cells/ml,  
Rd =Range x103cells/ml,  
Mee= Median % of CD45+HLA-DR_LIN1DIMevents,  
Re =Range % of CD45+HLA-DR_LIN1DIMevents, 
Mef = Median RNA copies/ml,  
Rf = Range RNA copies/ml 
 
 
 
 
 
 
 
 
 
 
 
Study groups 
 
Control ARV- HIV-1 ARV-HIV-1/TB ARV+HIV-1 ARV+HIV-1/TB 
CD4  T 
cells 
Mea 
Ra 
830 
392 – 1534 
169 
11 – 387 
166 
7 - 304 
320 
131 - 786 
271 
56 - 703 
Meb 
Rb 
41 
29 - 53 
12 
2 - 22 
10 
1 - 15 
22.5 
9 - 38 
17 
5 - 31 
CD8  T 
cells 
Mea 
Ra 
580 
125 - 1141 
848 
378 - 1535 
814 
289 - 2135 
657 
300 - 2194 
748 
236 - 2767 
Meb 
Rb 
29.50 
12 - 46 
60 
43 - 84 
64 
55 - 81 
48 
25 - 78 
49 
38 - 85 
CD4:CD8 
ratio  
Mec 
Rc 
1.48 
0.76-4.45 
0.19 
0.02-0.49 
0.17 
0.01-0.25 
0.47 
0.11-1.52 
0.35 
0.06-0.75 
pDC 
Med 
Rd 
8.84 
2.83 - 14.39 
3.25 
0.92 - 7.51 
2.99 
0.65 - 8.39 
4.34 
1.44 - 10.13 
2.63 
1.36 - 13.18 
Mee 
Re 
3.64 
0.68 - 10.15 
1.3 
0.14 - 6.9 
1.04 
0.19 - 6.24 
1.19 
0.12 - 4.82 
1.05 
0.23 - 2.47 
mDC 
Med 
Rd 
14.78 
8.3 - 34.19 
10.19 
5.21 -17.74 
9.61 
1.38 - 23.12 
11.47 
4.97 - 23.71 
9.52 
3.76 - 24.07 
Mee 
Re 
7.47 
3.63 - 14.97 
4.53 
0.97 - 10.84 
4.96 
0.66 - 14.51 
4.25 
1.05 - 16.19 
3.62 
0.9 - 7.89 
Viral 
load  
Mef 
Rf NA 
3.4 x104 
230 – 4 x106 
4,1 x104 
240 – 7 x105 
LOD 
LOD – 1.7 x103 
LOD 
LOD - 1.6 x103 
Stellenbosch University  https://scholar.sun.ac.za
 42 
 
 
 
 
Figure 3.3:  Changes in absolute number of CD4 and CD8 T lymphocytes, pDCs and mDCs during 
ARV untreated and treated HIV-1 mono and HIV-1/TB co-infection 
Peripheral whole blood was stained with the BD MultiTEST™ reagent (CD3, CD8, CD45 and CD4 mAb 
cocktail) to determine the absolute count (cells/µl) of CD4 and CD8 T lymphocytes. Similarly, staining with 
DCID markers (HLA-DR, LIN1, CD123/CD11c mAb cocktail) aided in determining the absolute count 
(cells/ml) of pDCs and mDCs. Analyses were performed using the BD TruCOUNT™ assay and 4-colour flow 
cytometry. The box and whiskers graph represents the absolute number of CD4 T lymphocytes (A), CD8 T 
lymphocytes (B), pDCs (C) and mDCs (D), respectively, of the control, ARV-HIV-1, ARV-HIV-1/TB, ARV+HIV-
1 and ARV+HIV-1/TB study groups.Each boxplot shows the 10-90 percentile range of data and the horizontal 
line represents the median value. Outliers are represented by black enclosed circles. Horizontal lines with 
diamond arrows indicate the specific study group comparison of interest and an asterisk(s) the significance. 
Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance. 
 
 
 
A   
CD
4 
T 
c
el
ls
: 
ce
lls
/µ
l 
 
 
 
 Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
B   
CD
8 
T 
c
el
ls
: 
ce
lls
/µ
l 
 
 
 
 
Control HIV-1 HIV-1/ TB  
HIV-
1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
      
 Control  ARV
- 
HIV-1 
 
ARV- 
HIV-1/TB 
 
ARV+  
HIV-1 
 
ARV+ 
HIV-1/TB 
C   
pD
C:
 
ce
lls
/m
l (x
10
3 ) 
 
 
 
 
 
Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
     
 
D   
m
D
C:
 
ce
lls
/m
l (x
10
3 ) 
 
 
 
 
Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-   ARV+  
 
      
 
0
10
20
30
40
 
0
500
1000
1500
2000
 
0
500
1000
1500
2000
2500
3000
 
**
*
0
10
20
30
40
 
***
***
**
***
**
**
*
**
**
**
***
***
***
***
 
  
 
 
Stellenbosch University  https://scholar.sun.ac.za
 43 
 
Absolute number vs. percentage data output 
Comparative analysis of the absolute number of CD4 T lymphocytes, pDCs and mDCs revealed very similar 
trends to the percentage data. Both HIV-1 infection (CD4 and CD8 T lymphocytes and DC subsets) and ARV 
therapy (CD4 T lymphocytes) significantly altered absolute numbers which also reflected in the percentage 
data (refer to Figures 3.3 A-D vs. 3.4 A-D). However, assessing immune recovery and the impact of ARV 
therapy and TB co-infection on CD8 T lymphocytes we found no significant difference in comparing relevant 
study groups using absolute CD8 T lymphocyte number data, while a different profile was observed with 
percentage data. Median cell number data indicated a trend towards normalisation of CD8 T lymphocytes 
whereas lack of immune recovery was observed with percentage data (ARV+HIV-1 (p  0.001) and 
ARV+HIV-1/TB (p  0.001) study group vs. control study group) (Figures 3.3 B vs. 3.4 B). More specifically, 
ARV therapy did show a significant reduction in the percentage CD8 T lymphocytes but it was not sufficient 
to induce full restoration (ARV+HIV-1 vs. ARV-HIV-1 (p  0.01) and ARV+HIV-1/TB vs. ARV-HIV-1/TB (p  
0.01)). TB co-infection seemed to induce a significantly higher percentage of CD8 T lymphocytes in 
peripheral blood compared to HIV-1 mono infection (HIV-1/TB vs. HIV-1; p  0.05; refer to Table 3.5; Figure 
3.4 B). 
 
The distribution pattern of the percentage pDC and mDC data was similar to that of the absolute number of 
pDCs and mDCs during HIV-1 infection. Expressed as a fraction of CD45+HLA-DR_LIN1DIM events, 
percentage pDCs and mDCs was found significantly lower in the ARV-HIV-1 study groups (pDCs: p  0.01, 
mDCs: p  0.05), ARV-HIV-1/TB study groups (pDCs: p  0.001, mDCs: p  0.05) as well as the ARV+HIV-1 
study groups (pDCs: p  0.01, mDCs: p  0.01) and ARV+HIV-1/TB study groups (pDCs: p  0.001, mDCs p 
 0.001) when compared to the control study group. The lack of recovery during ARV therapy was also 
observed as similar pDC and mDC percentages between the ARV+HIV-1 study group and ARV-HIV-1 study 
group as well as the ARV+HIV-1/TB study group and ARV-HIV-1/TB study group was observed (Figure 3.4 C 
(pDCs) and D (mDCs)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 44 
 
 
 
 
Figure 3.4:   Changes in percentage CD4 T and CD8 T lymphocyte, pDCs and mDCs during ARV 
untreated and treated HIV-1 mono and HIV-1/TB co-infection 
Peripheral whole blood was stained with the BD MultiTEST™ reagent (CD3, CD8, CD45, CD4 mAb cocktail) 
and analysed using 4-colour flow cytometry to determine CD4 and CD8 T lymphocytes as a percentage of 
CD45+CD3+cells. Similarly, staining with DCID markers (HLA-DR, LIN1, CD123 or CD11c mAb cocktail) was 
performed to determining pDCs and mDCs as a percentage of CD45+ HLA-DR_LIN1DIMevents. The box and 
whiskers graph represents the percentage of CD4 T lymphocytes (A), CD8 T lymphocytes (B), pDCs (C) and 
mDCs (C) of the control, ARV-HIV-1, ARV-HIV-1/TB, ARV+HIV-1 and ARV+HIV-1/TB study groups. Each 
boxplot shows the 10-90 percentile range of data and the horizontal line represents the median value. 
Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific 
study group comparison of interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of 
the method used to indicate the level of statistical significance. 
 
 
 Control  ARV
- 
HIV-1 
 
ARV- 
HIV-1/TB 
 
ARV+  
HIV-1 
 
ARV+ 
HIV-1/TB 
A   
CD
4 
T 
c
el
ls
: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
%
 
o
f  
CD
45
+
CD
3+
 
ce
lls
 
 
 
 
Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
      
B   
CD
8 
T 
c
el
ls
: 
 
%
 
o
f  
CD
45
+
CD
3+
 
ce
lls
 
 
 
 
Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
     
 
D   
m
D
C:
 
%
 
o
f C
D
45
+
H
LA
-
D
R
_
LI
N
1D
IM
 
ev
en
ts
 
 
 
 
 
Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
      
C   
pD
C:
 
%
 
o
f  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD
45
+
H
LA
-
D
R
_
LI
N
1D
IM
 
ev
en
ts
 
 
 
 
 
Control HIV-1 HIV-1/ TB  HIV-1 
HIV-1/ 
TB 
 
 
 
 ARV-  ARV+  
 
     
 
0
20
40
60
80
100
 
 
***
***
***
***
0
20
40
60
80
100
**
**
*
**
0
5
10
15
20
 
**
***
0
5
10
15
20
 
***
***
*
*
**
***
***
***
***
***
***
   
  
Stellenbosch University  https://scholar.sun.ac.za
 45 
 
CD4:CD8 ratio 
The median CD4:CD8 ratio was significantly lower in both the ARV-HIV-1 study group (p  0.001) and ARV-
HIV-1/TB study group (p  0.001) when compared to that of the control study group. As the CD4:CD8 ratio is 
a marker of efficient immune status, the observed change during infection is indicative of the poor 
immunological state of HIV-1 infected individuals. A similar profile was observed when the median CD4:CD8 
ratio of the ARV+HIV-1 (p  0.001) and ARV+HIV-1/TB (p  0.001) study groups were compared to that of the 
control study group. This was indicative of the lack of immune recovery during ARV therapy. In evaluating 
the effect of TB co-infection, the study observed a tendency (p = 0.12) of lower median CD4:CD8 ratio in the 
ARV-HIV-1/TB study group when compared to the ARV-HIV-1 study group. The median CD4:CD8 ratio was 
significantly higher in the ARV treated vs. untreated study groups, however, recovery did not reach a level 
comparable to the control study group (ARV+HIV-1 study group vs. ARV-HIV-1 study group: p = 0.001; 
ARV+HIV-1/TB study group vs. ARV-HIV-1/TB study group; p = 0.004) (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5:  Changes in CD4:CD8 ratio during ARV untreated and treated HIV-1 mono and HIV-1/TB 
co-infection 
Peripheral whole blood was stained with the BD MultiTEST™ reagent (CD3, CD8, CD45 and CD4 mAb 
cocktail) to determine the absolute count (cells/µl) of CD4 and CD8 T lymphocytes. Analyses were 
performed using the BD TruCOUNT™ assay and 4-colour flow cytometry. The ratio of CD4 T lymphocyte to 
CD8 T lymphocyte absolute number was determined. The box and whiskers graph represents the CD4:CD8 
ratio of the control, ARV-HIV-1, ARV-HIV-1/TB, ARV+HIV-1 and ARV+HIV-1/TB study groups. Each boxplot 
shows the 10-90 percentile range of data and the horizontal line represents the median value. Outliers are 
represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group 
comparison of interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method 
used to indicate the level of statistical significance. 
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The signature loss of CD4 T lymphocytes 
To date, research has not been able to fully elucidate the underlying cause(s)/mechanism(s) of CD4 T 
lymphocyte depletion. Notably, literature contains an immense amount of data on apoptosis and its 
association with the depletion of CD4 T lymphocytes during HIV-1 infection. Apoptosis is a controlled form of 
cell death, crucial for maintaining homeostatic balance in the host. It directs the elimination of activated cells 
upon clearance of an infection to prevent inflammation associated tissue damage. Furthermore, apoptosis is 
a “safe” form of cell death as apoptotic cells are phagocytosed – typically, “sealed off” cellular degradation 
occurs so to limit harmful inflammation. In view of this, it was questioned in which way a highly controlled 
process seemed to reach a stage of “instability”. It has been reported that the aberrant apoptotic events 
observed during HIV-1 infection appear to be steered by the virus itself. It seems that the virus has the ability 
to hijack the host’s apoptotic machinery, resulting in the uncontrolled demise of CD4 T lymphocytes. 
Specifically, the apoptotic properties of the HIV proteins Tat, Vpr, Nef, Vpu as well as protease have been 
defined (as reviewed by Mbita Z, et al. 2014). The reason for the virus initiated destruction of its primary 
“habitat” remains a mystery; though, it has been proposed a tactic of the virus to detain immune effectors 
(Gougeon ML, 2003).  
 
Adding to the apoptosis-associated decline of CD4 T lymphocytes is the reported disparity between number 
of productively infected cells and cell number loss. In view of the excessive decline of CD4 T lymphocytes 
during HIV-1 infection one would assume that it is driven by apoptosis of infected cells – cell suicide to 
eliminate the virus. However, as the level of productively infected CD4 T lymphocytes (0.1-1%) does not 
nearly “tally up” to the level of declining CD4 T lymphocyte numbers during HIV-1 infection (Brenchley JM, et 
al.2006; Finkel TH, et al. 1995), another mechanism steering the loss of CD4 T lymphocyte is implicated. 
Notably, numerous studies have shown that HIV pathogenesis was rather driven by the death of non-
productively infected CD4 T lymphocyte also referred to as bystander cells (as reviewed by Garg H, et 
al.2012; Finkel TH, et al. 1995). Some of these cells, as reported by Doitsh G, et al. (2010), are associated 
with abortive HIV-1 infection, a phenomenon which results in incomplete viral DNA transcripts present in the 
intracellular matrix. These antigens cause an innate immune response and the activation of death associated 
proteins. An additional mechanism of CD4 T lymphocyte loss is virus-independent deletion via activation-
induced cell death, either intrinsically or extrinsically (death receptor) regulated. These processes are linked 
to immune activation, which is both a direct and indirect consequence of viral replication. In an attractive 
report by Doitsh G, et al. (2013) it was shown that the demise of bystander CD4 T lymphocytes during HIV-1 
infection is particularly steered by a form of cell death referred to as pyroptosis. Notably, this form of cell 
death is associated with inflammation, and is believed to play a major part in promoting chronic inflammation 
associated with HIV-1 infection. Specifically, pyroptosis is a programmed cell executioner pathway 
associated with caspase 1 activity and the release of intracellular contents as well as pro-inflammatory 
cytokines (such as IL-1). In contrast, apoptosis is associated with caspase 3 activity and is an immune 
“silent” form of cell death. By examining tonsil tissue from HIV-1 infected patients Doitsh G, et al. (2013) 
found active caspase 3 in productively infected CD4 T lymphocytes, while caspase 1 was predominantly 
found in bystander non-productively infected CD4 T lymphocytes. This finding, along with the previous report 
from this group (2010) in which they showed that bystander CD4 T lymphocytes constituted 95% of the CD4 
T lymphocyte population of tonsil tissue of HIV-1 infected patients, illuminated the dominant and destructive 
role (high rate of cell death and inflammation) of pyroptosis during HIV-1 infection. Furthermore, it greatly 
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supports the paradigm of inflammation (in addition to cell death) being a strong driving force of HIV-1 
disease. In view of their findings Doitsh G and colleagues (2013) proposed a treatment strategy of targeting 
host-specific events rather than elimination of the virus to treat HIV-1 infection and showed that blocking of 
pyroptosis could be initiated by caspase 1 inhibitors. 
 
Another mechanism involved in bystander cell death during HIV-1 infection involves the env glycoprotein. It 
is expressed on the surface of infected cell and interacts with CD4 and the co-receptor CXCR4/CCR5 of 
bystander cells. Receptor/co-receptor binding are the initials steps for the induction of apoptosis, however, 
bystander apoptosis is also dependant on the process of hemifusion (joining of the outer membrane leaflets 
of two membranes with no merging of the inner membranes or development of a fusion pore (Chernomordik 
LV and Kozlov MM, 2005)) driven by the gp41 domain of Env glycoprotein. Joshi A, et al. (2011) showed that 
the degree of CCR5 expression also has an impact and found that with low level of CCR5 expression virus 
continues with absent bystander cell apoptosis. 
 
As mentioned, chronic immune activation also plays a role in the decline of CD4 T lymphocytes. Chapter 6 
describes the significant increase in the percentage CD8+ T lymphocyte subsets expressing the T 
lymphocyte activation associated antigen, CD38, during HIV-1 infection and also show the significant inverse 
relationship between the CD4 T lymphocyte counts and percentage CD8+CD38+ subset. 
 
The lack of cell number recovery during HIV-1 infection 
The lack of complete recovery of pDCs, mDCs and CD4 T lymphocytes during ARV therapy could indicate 
ongoing infection/inflammation which impacts on the cells. This may include 1) persistent viral replication in 
compartments where the HIV-1 escapes the suppressive effect of ARVs (i.e. reservoirs), 2) ongoing immune 
activation, 3) gut leakage and/or 4) other secondary infections.  In addition, hindrance in revival of pDC, 
mDC and CD4 T cell numbers in the peripheral blood could be due to a slow rate of replenishment from the 
bone marrow (DCs) or thymus (T lymphocytes) or irreversible damage caused by the HIV-1 infection. In a 
study by Zeng M, et al. (2012) it was observed that the loss of naïve CD4 T lymphocytes (CD4+CD45+) 
correlated with the destruction of the 1) FRC network in the T lymphocyte zone and 2)  follicular dendritic cell 
(FDC) network in the B cell follicle in the lymph nodes of pathogenic SIV infected Rhesus Macaque 
monkeys. In contrast, intact FDC networks were observed in the non-pathogenic SIV infected sooty 
mangabeys while having detectable SIV viral load and a stable CD4 T lymphocyte numbers. It should be 
noted that the maintenance of the FRC and FDC network is reliant on the production of lymphotoxin-, 
produced by naïve T lymphocytes (Ngo VN, et al. 1999). In return, the survival of naïve T lymphocytes is 
dependent on the production of IL-7 by the FRC (Link A, et al, 2007; Tan JT, et al. 2001). Hence, loss of the 
lymphotoxin- source results in a dysregulation of FRC and FDC events. This phenomenon may illuminate 
why immune abnormalities still persist during HIV-1 infection regardless of undetectable viral load. The FRC 
and FDC damage caused by the HIV-1 may explain the slow rate of CD4 T lymphocytes replenishment in the 
lymph nodes during ARV therapy. Further research is required to determine whether applicable therapy that 
aims to recover the FRC and FDC network, would also aid in CD4 T lymphocyte and DC subset number 
reconstitution.  
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3.4.2 Relationship of the absolute number of pDCs and mDCs to CD4 and CD8 T lymphocyte count 
and HIV-1 viral load 
Other studies investigating the decline of pDCs and mDCs in peripheral blood of HIV-1 infected patients 
have found a significant relationship between DC subsets, CD4 T lymphocyte count and viral load. pDCs and 
mDCs tend to directly correlate with CD4 T lymphocyte numbers while viral load inversely correlated with low 
CD4 T lymphocyte, pDC and mDC numbers (Mojumdar K, et al. 2010; Lichtner M, et al. 2008; Finke JS, et 
al. 2004). In the current study, similar to some other studies (Sabado RL, et al. 2010; Fontaine J, et al. 2009; 
Diop OM, et al. 2008) a significant relationship between the DC numbers, CD4 T lymphocyte counts and viral 
load during HIV-1 infection and ARV therapy was not observed. We proposed that the overall contrasting 
findings might be due to the small sample size of the study groups (refer to Table 3.2). As we observed 
similar frequencies (median and range, Table 3.2) of pDC and mDC counts, CD4 and CD8 T lymphocyte 
counts and viral load between the ARV-HIV-1 and ARV-HIV-1/TB as well as the ARV+HIV-1 and ARV+HIV-
1/TB study groups, we combined relevant data sets so to increase sample size for correlation statistical 
analyses. In re-evaluation of the correlation measurements between DC subsets and 1) CD4 T lymphocytes 
(Figure 3.6A), CD8 T lymphocytes (Figure 3.6B) and viral load (Figure 3.7A) of the combined ARV-HIV-1 
study group (ARV-HIV-1 and ARV-HIV-1/TB study groups) and 2) CD4 T lymphocytes (Figure 3.6C) and CD8 
T lymphocytes (Figure 3.6D) of the combined ARV+HIV-1 study group (ARV+HIV-1 and ARV+HIV-1/TB study 
groups), we observed a relationship not much different to what was obtained upon comparing individual 
study groups. Also, the relationship of CD4 and CD8 T lymphocytes to viral load in the combined ARV-HIV-1 
study group was similar to what was observed in the individual study groups (Figure 3.7B). The lack of 
significant association may be due to 1) difference in the stage of HIV-1 infection and/or 2) rate of disease 
progression of individuals comprising the study cohorts investigated. As our study had no specific 
inclusion/exclusion criteria on disease staging and CD4 T lymphocyte count of HIV-1 infected volunteers at 
the time of blood collection, the random selection of untreated HIV-1 infected patients (for both HIV-1 mono 
and TB co-infected) resulted in a cohort with median CD4 T lymphocyte count of less than 200 cells/µl. 
Therefore patients in later stages of chronic HIV-1 infection were predominant. A longitudinal study, 
monitoring participants from acute to early and late stage of chronic HIV-1 infection, would provide more 
clarity on the relationship of the DC subsets to CD4 and CD8 T lymphocyte numbers as well as HIV-1 viral 
load during HIV-1 infection. 
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Figure 3.6: Correlating DC numbers to CD4 and CD8 T lymphocyte numbers of the combined ARV-
HIV-1 and ARV+HIV-1 study groups. 
The absolute number of pDCs and mDCs was determined for each of the participants of the combined ARV-
HIV-1 (ARV-HIV-1 and ARV-HIV-1/TB) and combined ARV+HIV-1 (ARV+HIV-1 and ARV+HIV-1/TB) study 
groups and plotted together with its corresponding CD4 and CD8 T lymphocyte counts. The pDC and mDC 
counts were 1) represented by the symbols  and , and 2) their relationship to CD4 (A,C) and CD8 T 
lymphocyte count (B,D) indicated by a green and orange coloured linear regression lines, respectively. The 
non-parametric Spearman test was use to correlate the absolute number of the DC subsets to that of CD4 
and CD8 T lymphocytes. 
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Figure 3.7: Correlating pDC, mDC, CD4 and CD8 T lymphocyte numbers to HIV-1 viral load of the 
combined ARV-HIV-1 study group. 
The absolute number of pDCs, mDCs, CD4 and CD8 T lymphocytes was determined for each of the 
participants of the combined ARV-HIV-1 study group (ARV-HIV-1 and ARV-HIV-1/TB) and plotted together 
with its corresponding viral load. The pDC and mDC numbers were 1) represented by the symbols  and 
, and 2) their relationship to viral load indicated by green and orange coloured linear regression lines, 
respectively (A). The CD4 and CD8 T lymphocyte counts were 1) represented by the symbols  and , and 
2) their relationship to HIV-1 viral load indicated by pink and blue coloured linear regression lines, 
respectively (B). The non-parametric Spearman test was use to correlate the absolute number of CD4 and 
CD8 T lymphocytes, pDCs and mDCs to viral load. 
 
However, what was evident from the current study is the disruption in the relationship of mDCs to CD4 and 
CD8 T lymphocytes during HIV-1 infection. Upon comparing the correlation data of the combined ARV-HIV-1 
study group to that of the control study group the latter study group showed a direct correlation between 
mDC and both the CD4 (p = 0.01, r = 0.47, Figure 3.8A) and CD8 T lymphocytes (p= 0.004, r = 0.67, Figure 
3.8B) which was absent in the combined ARV-HIV-1 study group (mDC vs.CD4 T lymphocytes: p = 0.45, r = 
0.08, Figure 3.6A; mDC vs.CD8 T lymphocytes: p = 0.27, r = 0.11 Figure 3.6B). We also found that the 
relationship was not restored during ARV therapy as there was no correlation between the mDC and both 
the CD4 and CD8 T lymphocytes in the combined ARV+HIV-1 study group (mDC vs.CD4 T lymphocytes: p = 
0.31, r = 0.14, Figure 3.6C; mDC vs.CD8 T lymphocytes: p = 0.41, r = 0.21, Figure 3.6D). In contrast to 
mDCs, there was no relationship between pDCs and both the CD4 and CD8 T lymphocytes of the control 
study group (pDCs vs CD4 T lymphocytes: p = 0.69, r = 0.1; pDCs vs. CD8 T lymphocytes p = 0.28, r = 0.3, 
Figure 3.8 A and B, respectively). However, a trend towards direct correlation of pDCs to CD4 T lymphocytes 
was observed in the combined ARV-HIV-1 study group (pDCs vs CD4 T lymphocytes: p = 0.09, r = 0.28, 
Figure 3.6 A). pDCs showed further no correlation with the CD8 T lymphocyte count of the combined ARV-
HIV-1 study group (pDC vs.CD8 T lymphocytes: p = 0.18, r = 0.4, Figure 3.6B) as well as no correlation with 
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the CD4 and CD8 T lymphocytes of the combined ARV+HIV-1 study group (pDC vs.CD4 T lymphocytes: p = 
0.44, r = 0.27, Figure 3.6C; pDC vs.CD8 T lymphocytes: p = 0.74, r = -0.06, Figure 3.6D). 
 
 
Figure 3.8: Correlating DC numbers to CD4 and CD8 T lymphocyte numbers of the control study 
group. 
The absolute number of pDCs and mDCs was determined for each of the participants of the control study 
groups and plotted together with its corresponding CD4 and CD8 T lymphocyte count. The pDC and mDC 
counts were 1) represented by the symbols  and , and 2) their relationship to CD4 (A) and CD8 T 
lymphocyte counts (B) indicated by a green and orange coloured linear regression lines, respectively. The 
non-parametric Spearman test was used to correlate the absolute number of the DC subsets to that of CD4 
and CD8 T lymphocytes. 
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3.5.  Conclusion 
 
The decline of CD4 T lymphocyte from the peripheral blood of chronically HIV-1 infected patients is a well 
described phenomenon, as is the reduction of pDC and mDC numbers (Mojumdar K, et al. 2010; Sabado RL 
et al, 2010; Lichtner M, et al. 2008; Finke JS, et al. 2004; Soumelis V, et al. 2001).  In the current study, 
enumeration of pDC and mDC numbers in peripheral blood was performed in South African cohorts of 
uninfected as well as chronically HIV-1 infected and HIV-1/TB co-infected patients on or naïve for ARV 
therapy. Changes in pDC, mDC, CD4 and CD8 T lymphocyte absolute number as well as CD4:CD8 ratios 
across the study groups were investigated. In addition, the study also examined the relationship of blood 
pDCs and mDCs numbers to CD4 and CD8 T lymphocytes counts and viral load. In summary the following 
was found 
1) A significant decrease in both the blood pDC and mDC subsets, with the loss of pDCs being more severe 
than mDCs during HIV-1 infection.  
2) Similar DC cell number distribution during HIV-1 and HIV-1/TB infection, showing that TB co-infection 
does not per se exacerbate depletion of these cells.  
3) After 1 year of ARV therapy we found  
 3.1) a significant reduction in plasma viral load 
 3.2) a significant but partial recovery in CD4 T lymphocyte counts and CD4:CD8 ratio,  
 3.3) minimal (insignificant) increase of DC subsets during chronic HIV-1 infection, 
 3.4) no recovery in DC subsets during HIV-1/TB co-infection  
4) mDCs, but not pDCs, directly correlating with CD4 and CD8 T lymphocytes in healthy controls. However, 
this relationship was majorly altered in the untreated HIV-1 study group, where the mDCs no longer 
correlated with CD4 and CD8 T lymphocytes but now pDCs tended to directly correlate with CD4 T 
lymphocytes. No correlation was observed between both DC subsets and HIV-1 viral load. 
5) Frequency distribution of pDCs and mDCs in HIV-1 infection can also be determined with the use 
percentage gated events as the statistical significance profile obtained was similar to that of the absolute 
count. 
 
It is clear from this cross-sectional study that the DC compartment is detrimentally affected during HIV-1 
infection and it is proposed that the broader effect might relate to reduced immune responses. As mDCs are 
key role players in the initiation of adaptive immunity and pDCs are the principal produces of IFN-, reduced 
numbers may result in the down-regulation of these immune activities. The lack of recovery whilst under 
reduced viral load are also concerning and the reason needs to be established (e.g. due to physical damage 
caused by the HIV-1 infection or hindrance in development form the bone marrow) so to develop a treatment 
strategy for alleviating DC numbers to accordingly strengthen the immune system. 
 
As we were interested in gaining more insight into the decline of blood DCs during HIV-1 infection, it was 
proposed to phenotypically investigate the pool of pDCs and mDCs in current circulation.  We theorised that 
the loss of pDCs and mDCs from peripheral blood of HIV-1 infected patients could be due to increased or 
altered physiological activities characteristic of cellular waning such as activation, apoptosis and migration. 
Therefore, the second part of the study focused on examining cell surface markers related to these 
processes in an attempt to better define DC cell losses and HIV pathogenesis 
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Chapter 4 
 
Ex vivo phenotypic properties of pDCs and mDCs in the peripheral whole blood of HIV-1 mono-
infected and HIV-1/TB co-infected individuals 
 
4.1  Introduction 
Declining numbers of pDCs and mDCs in the peripheral blood of HIV-1 infected patients (reported by others 
and supported by the findings of the current study (chapter 3)) prompted investigation into possible 
underlying reason(s) for their loss from circulation. The current study hypothesised that this decline (as well 
other related DC changes) is due to chronic exposure/response to the HHF cocktail in circulation. This 
hypothesis was based on published in vitro studies demonstrating a level of reduced “fitness” in blood pDCs 
and mDCs isolated from HIV-1/SIV infected individuals/primates. In particular, these cells showed a higher 
susceptibility to undergo spontaneous apoptosis in culture (Dillon SM, et al. 2011; Brown KN, et al. 2007).  In 
evaluating viability (amine fluorescent staining assay) of DCs during SIV infection, Brown KN, et al. (2007) 
showed that the frequency of lymphoid tissue-associated viable pDCs (isolated from spleen) and mDCs 
(isolated from spleen and peripheral lymph nodes) of SIV naïve rhesus macaque monkeys were similar to 
animals with AIDS at the onset of culture. However, after 24h incubation, viable pDCs and mDCs of the SIV 
uninfected monkeys were reduced by 10-20% while a significant reduction of 40-45% in viable pDCs and 
mDCs was observed in monkeys with AIDS. Similarly, Dillon SM, et al. (2011) examined spontaneous 
apoptosis of DCs from HIV-1 infected patients by evaluating the viability of these cells 24h post-collection via 
the expression of the apoptotic markers 7-amino-actinomycin D (7-AAD) (apoptotic DNA-binding marker, 
indicative of late stage of apoptosis), Annexin V (apoptotic cell surface binding marker, indicative of early 
stage of apoptosis) and anti-apoptotic Bcl-2 (mitochondrial associated anti-apoptotic marker). The authors 
showed, compared to healthy controls, mDCs of HIV-1 infected individuals having a high tendency to be 
undergoing late stage of apoptosis. Furthermore, the level of anti-apoptotic Bcl-2 was significantly lower in 
mDCs from HIV-1 infected individuals. These studies have demonstrated the adverse effect of an HIV-1/SIV 
infection on blood and lymphoid tissue DCs. In view of these results, viral and host related factors that may 
contribute to the altered DC phenotype in circulation during HIV-1 infection was investigated. 
 
Viral elements contributing to DC apoptosis 
A viral associated factor that might predispose DCs of HIV-1 infected individuals to apoptosis are gp120 
immune complexes found in plasma. These represent shed particles of maturing HIV-1 virions (Gelderblom 
H.R, et al. 1985) which, upon binding with antibodies of the host, form immune complexes (Liu P, et al. 
2011). Chen Y, et al. (2013) reported on the significant increase in apoptotic activity of mo-DCs, treated with 
gp120 immune complex preparations (formed by cross-linking recombinant gp120 and anti-HIS tag mAb), 
upon interaction with autologous activated CD4 T lymphocytes. The authors established that the apoptotic 
activity was related to the interaction of the DC-SIGN molecule on DC with gp120 and activated via 
CD40/CD40L interaction. Similarly, the in vitro pulsing of purified blood DC-SIGN+CD40+ DC subset from 
healthy individuals cross-linked with gp120 immune complexes also showed elevated levels of apoptosis 
upon culture with CD40L transfected cells. Also, in the in vivo setting the DC-SIGN+CD40+ DC subset of HIV-
1 infected patients, naturally exposed to gp120 immune complexes, showed significantly higher fractions of 
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apoptotic cells when incubated with CD40L transfected cells compared to unexposed DC-SIGN+CD40+ DC 
subset of healthy controls. 
 
The gp120/antibody immune complex phenomenon may represent one mechanism justifying the loss of DCs 
from peripheral blood during untreated HIV-1 infection. Accordingly, the current study questioned in which 
way this phenomenon relates to the lack of DC number recovery during ARV therapy when accompanied 
with undetectable plasma viral load (presumably with parallel reduction of gp120 levels) as reported in 
Chapter 3. Some clarity came from a study conducted by Rychert J and colleagues (2010) who showed that 
the level of plasma gp120 detected during acute HIV-1 infection remained unchanged regardless of a decline 
in plasma viral load over prolonged use of ARV therapy. Hence, in view of this report it was proposed that 1) 
the continuous presence of viral antigens may have the potential of steadily draining DCs from circulation, 2) 
inhibition of viral replication may not be sufficient for the control of an HIV-1 infection and 3) removal of total 
viral products from circulation produced in acute (and during chronic) HIV-1 infection might be required for 
recovery of DC numbers (and other affected parts of the immune system) in circulation. 
 
Host elements contributing to DC apoptosis 
In studying host-specific elements produced during chronic HIV-1 infection with the aim of identifying those 
which could detrimentally impact blood DCs, an extensive array of publications reporting on changes in pro- 
and anti-inflammatory biomarkers during chronic HIV-1 infection was found. In view of this, it was proposed 
that the term “immunodeficient” might not give full “credit” to the state of the immune system during HIV-1 
infection. The increased cytokine plasma level is supportive evidence for the continuous attempt of the 
immune system to counteract the infection. Paradoxically, it is the chronic production of these factors that is 
presumed to be one of the driving forces of the HIV-1/AIDS disease and resulting mortality. Accordingly, it is 
proposed that the term “immunocompromised” better describes an HIV-1 exposed immune system triggered 
to aberrantly produce host factors. The destructive effect of persistent cytokine production has also been 
reported in other infectious diseases. Referred to as a cytokine storm (hypercytokinemia), this phenomenon 
has, specifically, been implicated as a contributing factor to the death of many people that have been 
infected with the phlebovirus (causing Severe Fever with Thrombocytopenia Syndrome (SFTS)), 
Ebolavirus (species Zaire) or H1N1 influenza strain (Sun Y, et al. 2012; Monsalvo AC, et al. 2011, Wauquier 
N, et al. 2010).  Also, the severe acute respiratory syndrome (SARS) outbreak of 2002 has been associated 
with an IFN- related cytokine storm (Huang KJ, et al. 2005). It should be noted that in HIV-1 infection the 
cytokine storm phenomenon is limited to the acute phase of the disease, which declines as a certain level of 
control is gained over the infection. This is followed by a steady increase in immune activation upon 
transition from the acute to the chronic disease phase. (Refer to Figure 2.1). Moreover, aberrant cytokine 
production is not infectious disease-specific as aberrant production of inflammatory cytokines has proven 
deleterious also in autoimmune diseases such as rheumatoid arthritis, atherosclerosis, psoriasis, 
periodontitis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus (Kaur S, et al. 2013; Su 
DL, et al. 2012; Ozbalkan Z, et al. 2010; Strober W, et al. 2010; Nishimura M, et al. 2009; Arican O, et 
al.2005). 
 
Among several changes in the cytokine milieu observed during HIV-1 infection, altered plasma levels of the 
IL-10 anti-inflammatory cytokine was interesting (Brockman MA, et al. 2009; Orsilles MA, et al. 2006; as 
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reviewed by Breen EC. 2002). A former study by Ludewig B, et al. (1995) showed that this anti-inflammatory 
cytokine induced apoptosis of DCs and a more recent study determined that IL-10 functions via suppressing 
the transcription of the three anti-apoptotic genes bcl-2, bcl-x and bfl-1 (Chang WLW, et al. 2007). Hence, it 
was proposed that aberrant production of IL-10 during chronic HIV-1 infection may contribute to the 
apoptotic-associated loss of DCs from circulation. Elevated plasma levels of IL-10 with associated apoptosis 
of DCs have also been reported in Plasmodium falciparum (Pf) and P. vivax (Pv) infected patients suffering 
from malaria. Interestingly, the authors showed reduced apoptosis of DCs upon in vitro IL-10 blocking. 
Despite the beneficial prospects of anti-IL10 treatment, employing IL-10 antagonists with the purpose to 
hinder apoptotic death of DCs so to re-establish the DC compartment should be approached with caution in 
HIV-1 infection as it has the potential to introduce adverse effects. This was reasoned on the basis of the 
following: IL-10 plays an immune-regulatory role by promoting intestine health, apparent from studies that 
showed IL-10 deficient mice developing intestine–related diseases (such as chronic colitis) due to an 
inappropriate immune responses to naturally occurring microflora/gut antigens (Gomes-Santos AC, et al. 
2011; Madsen KL, et al. 1999; Kühn R, et al. 1993). Also, colitis in IL-10 deficient mice coincided with 
increased intestinal permeability (Liu Z, et al. 2011; Arrieta MC, et al. 2009; Kennedy RJ, et al. 2000; 
Madsen KL, et al. 1999) which results in the sifting through of toxic gut antigens (e.g. LPS). This 
phenomenon is referred to as leaky gut. Notably, leaky gut is also a well-defined trademark of HIV-1 
pathogenesis, believed to be a major contributory factor driving chronic inflammatory responses (Brenchley 
JM, et al. 2006a, 2006b). Accordingly, anti-IL-10 therapy in HIV-1 infection might worsen the disease. 
 
The viral and host entities discussed here that may trigger DC cell death during HIV-1 infection represent a 
few possible apoptotic related factors that may contribute to low cell number distribution. In addition, it is 
proposed that these HHF entities may also drive DC loss in a non-apoptotic manner viz. chemotactic 
mobilisation and activation-induced export. Accordingly, the current study proposed that DC responses to 
HHF elements may reflect as modified marker expression with regard to ex vivo markers related to 
apoptosis, chemotaxis, activation and maturation when compared to the marker profile obtained from an 
uninfected system. This concept marks the principal aim of the study and the specific markers of interests 
investigated linked to these processes are discussed in sections 4.1.1 to 4.1.3. 
 
4.1.1  Investigating ex vivo apoptotic marker expression on blood mDCs and pDCs 
This part of the study aimed to determine whether blood DCs of HIV-1 infected individuals circulate with 
altered death-associated marker expression. The markers of interest included FAS and its ligand (FASL), 
TNF-R2, TRAIL-R1 and –R2 (both pro-apoptotic markers). In addition, the study was also interested in 
examining subsets of DCs expressing TRAIL-R3 and -R4, markers of decoy/anti-apoptotic receptor 
expression, so to assess the inter-relationship between pro- and anti-apoptotic marker expressions during 
HIV-1 infection. Notably, in HIV-1 infection significantly raised plasma levels of the cognate ligands to these 
apoptotic markers namely: FASL (cognate receptor FAS), TNF- (TNF-R2) and TRAIL (TRAIL R1, -R2, -R3 
and –R4) have been reported (Piddubna AI, et al. 2013; Gasper-Smith N, et al. 2008; Herbeuval JP, et al. 
2005). As an HIV-1 infection is not cleared, it was proposed that these raised levels persist throughout the 
course of the disease. This may result in a progressive rate of cell death, leading to the steady drainage of 
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affected immune cells from circulation and weakening of the immune system. A brief description on the 
apoptotic markers investigated follows. 
 
FAS and its cognate ligand, FASL, are both transmembrane proteins with an atomic mass of 48-kDa and 
40-kDa, respectively. Their interaction activates an apoptotic pathway in the cell that expresses the FAS 
receptor. The latter is moderately expressed on resting T lymphocytes, while functional expression of FASL 
is only found in activated T lymphocytes. This may be indicative of FASL expression being a more stringently 
controlled process. Notably, constitutive expression of FASL is restricted to immune privilege sites where it 
directs cell death in FAS bearing immune cells that enter these sites in response to infection/inflammation. 
This form of FASL expression has been associated with the eyes (Ferguson TA and Griffith TS, 2006; 
Gregory MS, et al. 2002), central nervous system (as reviewed by Gimsa U, et al.2013) and placenta 
(Stenqvist AC, et al. 2013). In contrast, constitutive FASL expression is also significant of certain 
pathological conditions. Fang L, et al. (2013) and Das SN, et al. (2011) reported that in contrast to normal 
squamous epithelia of the oral cavity, malignant tissue expresses FASL. Upon interaction with FAS 
expressing cytotoxic T lymphocytes, the very cell responsible for the destruction of cancer cells is destroyed 
which may lead to persistent tumour growth. 
 
Two circulating formats of the FASL molecule have been identified, namely, membrane-bound (mFASL) and 
soluble FASL (sFASL) which were found to play opposing roles with regard to cell death. It has been 
reported that the former promotes while the latter blocks cell death (O’ Reilly LA, et al. 2009; Suda T, et al. 
1997). In glaucoma, an autoimmune/neurodegenerative disease of the eyes, sFASL was found to protect 
while mFASL enhanced death of retinal ganglion cells (Gregory MS, et al. (2011). This “protective role” of 
sFASL, however, has been found to play to host’s disadvantage in certain cases. In large granular 
lymphocyte (LGL) leukaemia, a lymphoproliferative disorder associated with apoptosis resistance, sFASL 
were found as the central role player in blocking cell death of malignant cells regardless of the high FAS 
expression by LGLs (Liu JH, et al. 2002).  
 
In HIV infection, increased plasma level of sFASL as well as another apoptosis blocker, sFAS (functions by 
inhibiting the binding of FAS and FASL), has been observed (Ikomey GM, et al. 2012; de Milito A, et al. 
2000; Hosaka N, et al. 1998). However, in view of the extensive cellular loss reported during HIV infection 
the protective actions of these seemed to be overpowered by an HIV infection. It was proposed that sFAS-
sFASL aggregates form in the plasma of HIV-1 infection patients, leading to a deficient restrain in aberrant 
apoptotic events associated with HIV-1 infection. However, intensive literature search could not elaborate on 
this suggested concept. 
 
TRAIL-R1 and TRAIL-R2 (the former known as DR4, Apo-2 or CD261 and the latter known asDR5, TRIC2, 
KILLRT or CD262) engage with their natural ligand, TRAIL, to initiate TRAIL-mediated apoptosis (Pan G, et 
al. 1997; Walczak H, et al. 1997). Conversely, TRAIL’s interaction with TRAIL-R3 (also known as DcR1, 
TRID, LIT and CD263) or TRAIL-R4 (DcR2, TRUNDD and CD 264), collectively referred to as TRAIL decoy 
receptors (DcR), promotes anti-apoptotic signalling (i.e. survival) (Degli-Esposti MA, et al. 1997a, 1997b). 
The anti-apoptotic function of these receptors has been ascribed to an absent (TRAIL-R3) or truncated 
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(TRAIL-R4) intracellular death domain (as reviewed by de Vries EGE, et al. 2006). TRAIL, also known as 
CD253, is a type II membrane protein of which the C terminal in the extracellular domain are homologous to 
members of the TNF-R family of death proteins. It was cloned and characterised by Wiley SR and colleagues 
(1995) who also determined that both the cell surface and soluble forms induced rapid apoptosis in several 
cell lines. The TRAIL receptor family share a sequence homology of > 50% with regard to their cysteine-rich 
extracellular domain. Specifically, TRAIL-R1 and TRAIL-R2 share an overall sequence homology of 58% (as 
reviewed by Falschlehner C, et al. 2007) and these share a sequence identity of 58% and 54% with TRAIL 
R3, respectively (Degli-Esposti MA, et al. 1997a). TRAIL-R4 shares an identity of 58%, 57% and 70% to 
TRAIL-R1, TRAIL-R2 and TRAIL-R3, respectively (Degli-Esposti MA, et al. 1997b).  
 
TRAIL-mediated apoptosis have recently gained much attention as a therapeutic agent in cancer therapy (as 
reviewed by Holland PM, 2014). TRAIL seems to selectively target apoptosis of transformed cells such as 
tumour cells. Zhang XD, et al. (2000) investigated TRAIL mediated apoptosis in the TRAIL-R2+ 
cancerous/transformed T cell line (Jurkat cells) and TRAIL-R2+ non-cancerous cell line (human umbilical vein 
endothelial cells (HUVECs)). Significant apoptotic activity upon in vitro TRAIL treatment was only observed 
with the transformed Jurkat cell line. It became apparent that HUVEC cells were protected from apoptosis via 
its intrinsic decoy receptor, TRAIL-R3, as chemical removal of this receptor resulted in increased apoptosis 
of HUVECs. Jurkat cells characteristically lack decoy receptors, justifying their sensitivity to TRAIL mediated 
apoptosis (Sprick MR, et al. 2000; Zhang XD, et al.2000).  
 
In contrast to the beneficial effect of TRAIL-mediated killing of “unwanted or distressed” cells, it has been 
shown to play a role in the obstruction of, particularly, antiviral immune responses. Hosts bearing hepatitis B 
(HBV) or hepatitis C (HCV) virus infection exhibits dysfunctional HBV/HCV-specific CD8 T lymphocyte 
responses (Boni C, et al. 2007; as reviewed by Rehermann B, 2009). This is due to the killing of TRAIL-R2+ 
HBV-specific CD8 T lymphocytes upon interaction with TRAIL+ NK cells. HBV chronically infected individuals 
have a significantly higher frequency of TRAIL-R2+ HBV-specific CD8 T lymphocytes (Peppa D, et. al.2013) 
and their NK cells upregulate expression of TRAIL as a result of the cytokine milieu (significantly higher 
concentrations of IFN- and IL-8) induced during HBV infection (Dunn C, et al. 2007). Accordingly, TRAIL+ 
NK cells kill TRAIL-R2+ HBV-specific CD8 T lymphocyte upon ligand-receptor contact.  
 
TNF-R2, similar to TRAIL-R3 and –R4, does not bear an intracytoplasmic death domain (as reviewed by 
Faustman DL and Davis M, 2013; as reviewed by Pfeffer K, 2003). The TNF-R2pathway activation is 
dependent on interaction with its cognate ligand, TNF-. This cytokine plays an important role in host 
defence and inflammation as a pluripotent mediator. However, if TNF- levels are not sufficiently moderated, 
it has the ability to cause major tissue/organ damage. It is well documented that HIV-1 infection is 
characterised by persistent levels of inflammatory agents, which includes TNF-. The effects thereof have 
been investigated in the HIV-1 transgenic mouse line, Tg 26. The latter, in contrast to the non-transgenic 
mouse line, manifest with a 50-fold increase in TNF- serum levels (De SK, et al. 2002). Also, these animals 
exhibit severe pathologic conditions related to disorders of the kidneys (proteinuria, glomerulosclerosis 
(Dickie P, et al. 1991)) and skin (e.g. epidermal papillomas and diffuse hyperkeratosis (Kopp JB, et al.1993)) 
which is accompanied by a high mortality rate. Interventions (treatment with TNF- antibody) targeting the 
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TNF- storm in Tg26 showed profound suppression of HIV-1 induced conditions. A major decrease in the 
serum levels and mRNA transcripts of TNF- as well gp120 in the skin was observed, promoting the survival 
of the host. In parallel, employing cytokine blockers in autoimmune disease seem promising in hindering host 
tissue damage. Prospective studies that addressed aberrant production of TNF- in autoimmune disease in 
humans have proved promising in alleviating the harmful effects associated with the disease. Reimold AM, 
(2003) employed TNF- blockers in treating rheumatoid arthritis (a disease driven by aberrant levels of TNF-
 and characterised by inflammation of the joints causing damage to cartilage and bones) and reported on a 
significant reduction in the symptoms associated with the disease with limited side effects. Crohn’s disease is 
another inflammatory condition that have benefitted from the use of anti-inflammatory agents. Accordingly, it 
was debated, whether the use of antagonist would translate beneficial when applied to chronic inflammation 
caused by infectious disease. The question was raised whether inhibition of the cytokine response during 
infectious disease would give the infectious agent a greater upper hand during antagonist treatment.  Most 
intervention strategies employed to combat infectious diseases focus on elimination of the pathogen as it is, 
plausibly, safer and “easier” to target the sole non-host-inherent infectious particle (HIV-1) than suppressing 
any one or selected few of the array of post-stimulatory host-inherent molecules produced via stringently 
controlled and interlinked processes.  
 
4.1.2  Investigating ex vivo chemotactic marker expression on blood mDCs and pDCs 
As HIV-1 infection is driven by chronic inflammation, it was proposed that inflammatory signals may drive 
chemotactic export of blood DCs to sites of infection. It was further suggested that continuous export could 
reach a stage where it overtakes the rate of replenishment from the bone marrow, hence, maintaining 
significantly low DC numbers in circulation. Accordingly, the aim of investigating markers of cellular migration 
was so to ascertain whether the decline of blood DCs during HIV-1 infection may be due to amplified export 
of these cells from peripheral blood. Specifically, the study hypothesised that infection/inflammatory signals 
(either aberrant levels of host elements and/or whole or products of pathogens (viral/other)) associated with 
HIV-1 infection are recognised by blood DCs and in response induces a change in specific homing markers 
expressed on these cells. It was proposed that these signals would initiate two principal routes of migration 
namely 1) to the sites of infection and/or 2) lymphoid tissue, ensuring that antigen captured DCs interact with 
naïve T lymphocytes in the lymph nodes, the primary site for the initiation of adaptive immune responses.  
 
Acknowledging that a compromised immune system may have multiple sites of ongoing infection, the study 
focused on examining chemokine markers reported to direct homing to, specifically, the GIT and pulmonary 
tissue. Homing of DCs to the GIT may be related to the leaky gut phenomenon associated with HIV-1 
infection. This refers to the translocation of microbial products from the lumen of the gut to the portal blood 
stream due to a breach in the integrity of the mucosal barrier initiated during acute HIV-1 infection. The 
breach is the result of excessive loss of intestinal CD4 T lymphocytes (Guadalupe M, et al. 2003). It is 
believed that the continuous sifting through of bacteria and bacterial products from the intestinal lumen to the 
blood stream subsequently induces and fuels chronic immune activation and inflammatory responses during 
HIV-1 infection (Brenchley JM, et al. 2006a, 2006b). In addition, the current study also aimed to investigate 
blood DC depletion via homing to pulmonary tissue. Defining blood DC loss via chemokine markers that 
direct leukocyte homing to pulmonary tissue was of particular interest for the HIV-1/TB co-infection arm of 
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the study. This was performed in view of the fact that the majority of South African HIV-1 infected individuals 
succumb to a TB co-infection. For this part of the study chemotactic markers associated with migration to the 
GIT and pulmonary tissue needed to be sourced. Accordingly, it was decided to investigate the expression of 
chemokine receptors CCR9 and CXCR6, as putative homing markers to GIT and lungs, respectively. CCR9, 
also known as CD199, has been identified as a putative GIT chemokine marker in view of reports linking this 
chemokine receptor to the mobilisation of CD4 T lymphocyte and pDC to the small intestine (Wendland M, et 
al. 2007; Stenstad H, et al. 2006). The role of this chemokine marker in directing cell mobilisation to, 
specifically, the intestines was also supported by studies showing that its natural ligand, CCL 25 (referred to 
as the thymus expressed chemokine), is preferentially expressed by the epithelia of the small intestine 
(Papadakis KA, et al. 2000).  In view of the localised expression of CCL25 and given that aberrant plasma 
levels of other localised enteric-associated host factors such as intestinal fatty acid binding protein (a 
molecule expressed by enterocytes and released in circulation upon damage to the intestine (as reviewed by 
Pelsers MMAL, et al. 2005) have been observed during HIV-1 infection (Mavigner M, et al. 2012), it was 
proposed that the components leaking from the gut might also introduce aberrant CCL25 into circulation. 
This may induce enhanced blood DC export from circulation by gradient attraction to the GIT site of infection. 
CXCR6, also known by alternate names Bonzo/STRL33/TYMSTR/CD186, has been characterised as a 
putative pulmonary tissue chemokine marker. A study investigating the expression of several chemokine 
receptors on T lymphocytes from bronchoalveolar lavage (BAL) and peripheral blood in patients with the 
respiratory disease, Sarcoidosis, found a significant increase in the expression of CXCR6 in T lymphocytes 
from BAL fluid compared to those in blood. Similar results were also found with interstitial lung disease. 
Furthermore, the authors determined that alveolar macrophages are the prime source of its natural ligand, 
the transmembrane CXCL16 chemokine and also identified two soluble isoforms (60kDa and 35kDa) in BAL 
fluid (Agostini C, et al. 2005; Morgan AJ, et al. 2005). 
 
In addition to investigating putative chemokine marker expression related to tissue mobilisation, this study 
also aimed at profiling blood DCs on chemotactic receptors known to respond to chemotactic gradient that 
directs mobilisation of leukocytes to secondary lymphoid tissue. The latter is the primary site for the initiation 
of adaptive immune responses which is greatly reliant on the interaction of DCs that have captured antigen 
at sites of infection and migrated to present processed antigen to naïve T lymphocyte. In this part of the 
study ex vivo profiling of chemokine receptors, CCR5 and CCR7, on blood DCs was of interest. In view of 
publications that have reported on significantly increased serum levels of natural ligands to CCR5 and CCR7 
during HIV-1 infection, the study proposed 1) this to result in a heightened migration of DCs to secondary 
lymphoid tissue and 2) signified by altered CCR5 and/or CCR7 ex vivo marker expression (Damås JK, et al. 
2009; Montes de Oca Arjona M, et al. 2005; Ye P, et al. 2004). CCR5 is a chemokine marker that binds to 
RANTES, macrophage inflammatory protein-1 (MIP-1) (also known as CCL-3) and MIP- (CCL4). It is 
closely related to CCR2b (71% identity) and shares an amino acid sequence homology of 55, 49 and 48% to 
the CCR1, CCR3 and CCR4 chemokine receptors. Sequence homology seems to involve the intracellular 
structure as the divergent sequences are found in the amino-terminal extracellular domains which are the 
sites associated with ligand binding (Raport CJ, et al. 1996).CCR5 and its ligands are major role players 
during inflammation. In a rat model that investigated colitis (induced with trinitrobenzene sulfonic acid) 
increasing RANTES levels and macrophages and monocytes numbers were observed in colonic tissue over 
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a period of 2 weeks. Treatment with a CCR5 antagonist (Met-RANTES) showed recuperation of colonic 
tissue and a reduction in mast cells and monocyte numbers (Ajuebor MN, et al. 2001). In HIV-1 infection 
CCR5 also acts as a co-receptor for viral entry. The discovery of a 32-base pair deletion (refer to CCR5 
delta-32 (	32)) resulting in a non-functional CCR5 receptor that hinders viral-host membrane fusion (refer to 
the HIV life cycle as described in Chapter 2) confers protection against infection. In one particular case, 
resistance to HIV infection was seemingly introduced in an HIV infected individual who received a bone 
marrow transplant from an individual homozygous for the CCR5 	32 mutation. The bone marrow recipient 
remained cleared from the virus even after ARV therapy was discontinued (Hütter G, et al. 2009).  
 
CCR7 is a lymphoid homing marker that interacts with the chemokines, CCL19 and CCL21, which are 
expressed by high endothelial venules (HEV) on lymph nodes in a constitutive manner. This persistent 
CCR7 ligand gradient sustains immune cell immigration to and retention in secondary lymphoid tissue (the 
central congregating point of processed antigens captured at diverse sites of the host) where these cells are 
“educated” by DCs on the antigen milieu present in the host. In HIV-1 infection it has been shown that gp120 
plays a role in enhancing the response of CD4 T lymphocyte to CCL21, while hindering CD4 T lymphocyte 
responses to the sphingosine 1-phosphate (S1P) receptor. The latter plays a role in overriding the CCR7 
signal to endorse cellular emigration from secondary lymphoid tissue (Pham THM, et al. 2008; Matloubian M, 
et al. 2004). Accordingly, the enhanced migration to and declining emigration from lymphoid tissue results in 
cellular accumulation in the lymph nodes which may contribute to the manifestation of lymphadenopathy, a 
clinical condition significant of abnormal enlargement of the lymph nodes and characteristic of HIV-1 
infection (Green DS, et al. 2009). Furthermore, CCR7 receptor expression is one of various factors that differ 
between pathogenic and non-pathogenic SIV infection. Mandl JN, et al. (2008) observed no significant 
change in CCR7 expression by blood pDCs and mDCs of the natural host, sooty mangabeys, infected with 
SIV. In contrast, SIV infection of the non-natural host, rhesus macaque, showed upregulated expression of 
CCR7 on both, pDCs and mDCs. It seemed, from these findings, that stable CCR7 expression on DCs play a 
role in the immune control over SIV infection. Accordingly, it was deliberated whether SIV-associated 
immune control can be mimicked in HIV-1 infection by, for one, antagonizing the CCR7 receptor. According 
studies in CCR7 deficient mice have shown paradoxical immune control in viral vs. bacterial/fungus infection. 
In viral infection arrested immune response in CCR7-deficient mice was observed (Kocks JR, et al. 2009; 
Junt T, et al. 2004) whereas these subjects were able to clear bacterial infection more efficiently than the 
wild type (Eppert BL, et al. 2010). Accordingly, increased cytokine levels of IL-12/23p40, IFN- and IL-1 in 
BAL fluid of CCR7 deficient mice infected with Pseudomonas aeruginosa (causative agent of hospital 
acquired respiratory infection) was observed (Eppert BL, et al. 2010). Also, lung tissue showed a significant 
decline in bacterial load at 16h post infection, a significant increase in neutrophilic respiratory burst activity 
and higher numbers of mDCs (with greater upregulated CD80 and CD86 expression) and T lymphocytes 
compared to the wild type. The “control over infection” in CCR7 deficient mouse has also been reported in 
studies investigating invasive Aspergillus fumigatus (fungus infection affecting pulmonary tissue and known 
to cause fatality in bone marrow transplant) (Hartigan AJ, et al.2009) as well as M. tuberculosis (Kahnert A, 
et al.2007). Possibly, the enhanced immune control observed in CCR7 deficient mice may be due to atypical 
cellular containment at the site of infection, resulting in higher phagocytic activity and levels of pro-
inflammatory cytokines. Although, these findings may stimulate anti-CCR7 immuno-therapy approaches; a 
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yet undefined level of risk is involved as other studies have observed the development of autoimmunity in 
CCR7 deficient mice (Winter S, et al. 2011; Davalos-Misslitz ACM, et al. 2007). Nevertheless, it would be 
interesting to investigate the effect of transient blocking of CCR7 receptors during viral infection of the 
human host. 
 
4.1.3  Investigating ex vivo activation and maturation marker expression on mDCs and pDCs 
In the final part of the study focus was placed on ex vivo profiling of DC specific markers associated with 
activation and maturation during HIV-1 infection. The aim was to determine whether blood DCs of HIV-1 
infected individuals circulate with altered expression of these markers. This change may be indicative of 1) 
response to host and/or viral associated signals, 2) antigen encounter and capture and/or 3) activation-
induced export of DCs from peripheral blood to transport captured antigen to secondary lymphoid tissue for 
presentation to naïve T lymphocytes. The latter concept builds on the study’s hypothesis of persistent signal 
(in this case viral antigens) leading to persistent export that in time overtakes the rate of DC replenishment 
resulting in low DC numbers in circulation. Profiling the residual pool of blood DCs of HIV-1 infected patients, 
exposed to HHF, might provide clues to whether the decline of blood DCs may be due to activation-induced 
export steered by the altered matrix created by an HIV-1 infection. The DC specific markers investigated that 
is associated with activation included CD80 and CD86. Also, the expression of the activation associated 
marker, CD62L, on blood DCs was investigated. CD83 was the DC specific maturation marker examined. 
 
CD80 (also known as B7-1), CD86 (B7-2) and CD83 are ligands expressed by DCs which play an 
interactive role in the formation of the immunological synapse (the interface between antigen primed 
(activated) DC and naïve T lymphocytes) involved in the “dual signal” initiation of adaptive immune 
responses in secondary lymphoid tissue. This entails the interaction of 1) the peptide-MHC composite on 
activated DCs with the T lymphocyte receptor and 2) CD80 and CD86 ligands, also referred to as co-
stimulatory ligands, on activated DCs with the CD28 receptor on T lymphocytes. The outcome of these 
interactions is the establishment of a systemic response to eliminate the pathogen which includes 1) the 
production of cytokines and up-regulation of cognate receptors, 2) generation of antibodies and 3) the clonal 
expansion of antigen-specific lymphocytes from which vital effector T lymphocytes (short lived cells that 
undergo apoptosis upon clearance of the antigen) and memory T lymphocytes (remain in circulation to 
protect and respond more rapidly in the event of a secondary infection) differentiates (Abbas AK, et al. 
2012).  
 
CD62L, also referred to as L-selectin, together with E- and P-selectin are members of the selectin family of 
adhesion molecules (as reviewed by Rosen SD. 2004). CD62L is found constitutively expressed by 
circulating T lymphocytes (Klinger A, et al. 2009) and E- and P-selectin are found on activated epithelial cells 
with P – selectin also expressed by activated platelets (as reviewed by Ivetic A and Ridley AJ. 2004). CD62L 
has been described to facilitate immune surveillance - directing the transitional circulation of lymphocytes 
between blood and lymphoid tissue at the level of cellular transmigration also referred to as diapedesis. 
Briefly, this process entails interaction between CD62L and its ligands (CD34, Glycosylation-dependent cell 
adhesion molecule-1(GlyCAM-1), sialylated glycoprotein of 200 kD (Sgp200) or podocalyxin-like protein 
(PCLP) (collectively referred to as peripheral-node addressin (PNAd) adhesion molecules) expressed on 
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endothelia which stimulates deceleration of cellular flow. The low affinity binding between CD62L and its 
ligand results in the rolling or tethering of lymphocytes, which in combination with other immune markers, 
eventually leads to steady adhesion of these cells to the cell wall and subsequent transmigration (Raffler NA, 
et al. 2005; as reviewed by Rosen SD, 2004). CD62L driven diapedesis allows lymphocyte mobilisation 
across the HEV and entry into lymph nodes, the primary site where these immune cells can “browse” the 
array of antigens presented by mature DCs. Hence, it is a molecule of major importance as immune 
response cannot be initiated without the extravasation of leucocytes across the venule barrier (as stated by 
Muller WA. 2013). In the absence of interacting with their cognate antigen, lymphocytes exit the lymph node 
via the efferent lymphatics and return to circulation to continue with immune surveillance.  
 
In addition to its role as immune surveyor, CD62L has also been categorised as a marker of immune 
activation. This is related to the characteristic shedding of CD62L upon cellular activation. The phenomenon 
was recently reported to be associated with the acquisition of CD107a, a marker of lytic activity, by CD4 T 
lymphocytes (Yang S, et al. 2011). Notably, higher levels of soluble CD62L have been reported during 
disseminated Cryptococcus Neoformans and respiratory infection (Jackson LA, et al. 2005; Malaponte G, et 
al. 2004). This phenomenon has also been reported during HIV-1 infection (Kourtis AP, et al. 2000). 
 
Most interestingly, CD62L has been implicated in the transmission of virus to T lymphocytes during HIV-1 
infection. Thibault S, et al. (2007) reported on the ability of the HIV-1to integrate host associated and 
functional CD62L into its envelope membrane. This phenomenon on adsorption of host factors during 
infection has been observed in several virus species. These include Ebstein Barr virus (incorporates HLA-
DR) and human cytomegalovirus (CD55 and CD59) (as reviewed by Cantin R, et al. 2005). The adsorption of 
host associated CD62L is proposed as an adapted/expanded tactic of the virus - by acquiring this molecule 
the virus gains the ability to bind to the same cognate ligands on endothelia that lymphocytes specifically use 
to perform their immune surveillance function. This ensures maximum contact with lymphocytes, the virus’s 
preferential target of infection, and sets a supreme platform for trans-infecting lymphocyte. Thibault S, et al. 
(2007), also suggested that trans-infection of lymphocytes might be intensified by the inflammatory state 
during HIV-1 infection as some dormant CD62L ligands become functional in the presence of inflammatory 
molecules. 
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Main research interest 
In view of the declining blood DC numbers during HIV-1 mono infection and HIV-1/TB dual infection 
and lack of restoration on short term ARV therapy, the current study proposed that this phenomenon 
stems from an anomaly in activity related to apoptosis, cellular activation and/or chemotactic export 
in response to signals generated at sites of infection/inflammation. The study proposed that further 
phenotypic analysis of the circulating pool of blood pDCs and mDCs during HIV-1 infection may 
provide “clues” to the underlying reason for their loss from/lack of recovery in peripheral blood.  
 
The study aim: 
The aim of the current study was to phenotypically characterise the (HHF exposed) pool of blood 
pDCs and mDCs of chronically HIV-1 mono, HIV-1/TB dual infected as well as ARV treated 
individuals. 
 
The study objectives: 
to examine pDC and mDC subsets in relation to their expression the  phenotypic markers associated 
with   
- apoptosis, which included FAS and its natural ligand (FASL), pro-apoptotic TRAIL-R1 and -R2, anti-
apoptotic (survival) TRAIL-R3 and -R4 and TNF-R2 (implicated as death or survival receptor),  
- migration, which included CCR9 (a putative GIT homing chemokine maker), CXCR6 (a putative PT 
homing chemokine marker), CCR5 (lymphoid homing chemokine marker), CCR7 (implicated in 
lymph node migration) and  
- activation/maturation, which included CD86, CD80 (both characterised as markers of DC activation), 
CD83 (marker of DC maturation) and CD62L (immune activation marker).  
 
In addition, the cell surface expression of immunemodulatory neuropeptide receptors VPAC1 and 
VPAC2 was also examine of which the outcome was further discussed in Chapter 5.  
 
The current study proposed that a significant change in frequency distribution (% output) of blood 
pDCs and mDCs, analysed for the expression of the selected apoptotic, migratory and activation cell 
surface markers, in current circulation in HIV-1 and HIV-1-related study groups may correlate with 
underlying loss of DCs from peripheral blood and thus establish any underlying mechanistic link. 
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4.2 Outline of the study 
Refer to sections 4.3.1 - 4.3.11 for a detailed description on sample collection and processing 
 
*Refer to Chapter 5  
 SAMPLE COLLECTION  
Patient recruitment, blood collection by venesection at various clinics in the Western Cape, South Africa 
5 Study groups: Control, ARV-HIV-1, ARV-HIV-1/TB, ARV+HIV-1 and  ARV+HIV-1/TB 
 
 
 
WHOLE BLOOD PLASMA 
50µl 7 x 200 µl 1ml 
   
4-COLOUR FLOW 
CYTOMETRIC 
QUANTIFICATION  
8-COLOUR FLOW CYTOMETRIC PROFILING REAL TIME PCR QUANTIFICATION ASSAY 
CD4 and CD8 T cells 
 
ASSAY: Staining with  BD 
MultiTEST™ mAbs:           
CD3 FITC, CD8 PE, CD45 
PerCP, CD4 APC in BD 
TruCOUNTTM tube 
pDCs and mDCs 
 
ASSAY: Staining with DCID markers and marker specific mAbs set out in the table below 
Viral load 
 
ASSAY: ABBOTT Real Time 
HIV-1 PCR assay (ABBOTT 
m2000rt)/ bioMérieux 
NucliSens EasyQ® HIV-1, v1.2 
test) 
Panel A Panel B Panel C Panel D Panel E Panel F Panel G 
CCR5, 
CCR7,  
CD80  
CXCR6, 
CCR9,  
CD83 
TRAIL-R1, 
TRAIL-R3 
 
TRAIL-R2, 
TRAIL-R4 
 
TNF-R2 
 
CD86,  
FASL, 
FAS 
CD62L,  
VPAC1*,  
VPAC2* 
   
 DATA COLLECTED  
CD4 and CD8 T cells 
- cells/µl 
pDC and mDCs  
- % of pDCs/mDCs positively expressing cell surface markers of interest 
Viral load 
- RNA copies/ml 
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4.3  Material and Methods 
 
4.3.1  Study groups and clinical data 
A new cohort of patients were recruited and similar to the previous chapter also five different study groups, 
(Control (n=38), ARV-HIV-1 (n=62), ARV-HIV-1/TB (n=14), ARV+HIV-1 (n=40) and ARV+HIV-1/TB (n=25) 
study groups) were included for this second part of study. Table 3.1 defines the criteria used for the 
enrolment of candidates for the different study groups employed in this part of the study. Recruited patients 
on ARVs were using one of the following treatment regimens: Tenofovirdisoproxil fumarate(TDF), 
Lamivudine, EFV (39% of the total ARV users); Stavudine, Lamivudine, EFV (32%); Stavudine, Lamivudine, 
NVP (11%); TDF, Lamivudine, NVP (7%) and less than 11% were using different combination of ARV 
therapy. TB co-infected patients were either using Pyridoxine or Rifafour (Combination of four agents: 
Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) drugs. Participants were recruited (May 2010 – Mar 
2012) from state clinics in a peri-urban area of Cape Town, South Africa, which included Tygerberg (2% of 
the total recruits), Idasvalley (17%), Durbanville (29%), Kuilsriver (2%) and Kraaifontein (8%) as well as the 
Desmond Tutu Emavundleni Clinic Site in Khayelitsha (41%). Participants from the latter site were 
predominantly enlistees of the and ARV-HIV-1 study groups. Demographic and clinical data of the 
participants in each study group are shown in Table 4.1.  
 
Informed consent was obtained from all the study participants. The study was reviewed and approved by the 
HREC of the Faculty of Medicine and Health Sciences of Stellenbosch University (Ethics reference number 
N08/02/057). Ethical approval for the collection and analysis of blood samples from participants recruited at 
the Desmond Tutu Emavundleni Clinic Site in Khayelitsha was initially obtained from the Research Ethics 
Committee (REC) of the Health Sciences Faculty of the University of Cape Town (UCT) (Ethics reference 
number 417/2006) with subsequent amendments to the project approved by the HREC of US. 
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Table 4.1:  Demographic and clinical data of participants in the study groups analysed for the 
phenotypic profiling of pDCs and mDCs 
 Study Groups 
 Control 
ARV- ARV+ 
HIV-1 HIV-1/TB HIV-1 HIV-1/TB 
Total (n) 38 62 14 40 25 
Male: Female 
nr 
% 
17:21 
45:55 
9:53 
15:85 
7:7 
50:50 
17:23 
42:58 
12:13 
48:52 
Agea 
Median 
Range  
29 
19 - 58 
31 
18 - 50 
34 
23 - 69 
37 
13 - 56 
37 
25 - 50 
Time on ARV therapyb 
Median (m)  
Range 
N/A N/A N/A 18 
<1 - 75 
5.5 
<1 - 76 
Time on anti-TB therapyb 
Median 
Range  
N/A N/A 0.5 
<1  - 8 N/A 
3 
<1  - 8 
aAge median and range expressed in years 
bTime on treatment median and range expressed in months 
 
4.3.2 General specimen processing 
Each of the participants enrolled in the study was allocated a patient number and all laboratory procedures 
were performed in reference to this number. Whole blood was collected aseptically by venisection into either 
EDTA or Lithium Heparin vacutainer tubes. Blood specimens from the Desmond Tutu Emavundleni Clinic 
Site were provided in (1x10 ml) Lithium Heparin vacutainer tubes (BD Biosciences, San Jose, CA) of which a 
volume of 1.4 ml was allocated for phenotyping blood pDC and mDC (The remaining blood volume was used 
in other ethically permitted studies). Additionally, blood (1x5 ml) collected in the EDTA vacutainer tubes (BD 
Biosciences, San Jose, CA) were provided for CD4 and CD8 T lymphocyte count (refer to section 3.3.6)  and 
plasma collection for viral load quantification (refer to section 3.3.7)  and/or storage at -80°C. Whole blood 
specimens from other clinics (refer to section 4.3.1) were collected in (1x10 ml) EDTA vacutainer tubes (BD 
Biosciences, San Jose, CA) of which 500µl were aliquoted into screw cap tubes for the CD4 and CD8 T 
lymphocyte count application (refer to section 3.3.6)  and 1.4 ml used for profiling blood pDC and mDC. The 
remaining blood volume was used for plasma collection to determine the viral load (refer to section 3.3.7) 
and/or storage at -80°C. Processing of samples was at all times performed in a biosafety cabinet (NUAIRE 
biological class II safety cabinet).  
 
4.3.3 mAbs used for the phenotypic profiling of pDCs and mDCs 
A total of 15 different mouse anti-human mAbs were included in the study which aided in investigating 
specific phenotypic properties of pDCs and mDCs during HIV-1 infection. These were grouped into seven 
panels, labeled A to G, and were used in conjunction with the DCID mAbs to directly stain whole blood. 
Refer to Table 4.2 for a summary on these panels and corresponding markers as well as details on the clone 
and isotype of the mAbs. The mAbs were obtained from Biolegend1 (San Diego, CA), BD Biosciences2 (San 
Jose, CA) and R&D systems3 (Minneapolis, MN).   
Stellenbosch University  https://scholar.sun.ac.za
 71 
 
 
In reference to the sub-project of the larger study, which aimed at examining the effect of the 
immunemodulatory protein VIP upon TLR activated pDCs and mDCs (refer to Chapter 5), mAbs for the VIP 
receptors, VPAC1 and VPAC2, were included in the phenotypic staining panel. These mAbs were purchased 
as unlabeled antibodies from MerckMillipore (Temecula, CA) and R&D systems (Minneapolis, MN), 
respectively (refer to Table 4.2 for clone and isotype information). The Lightning-Link™ fluorochrome 
conjugation kit from Innova Biosciences (Babraham, Cambridge, UK) was used to label VPAC1 to the 
fluorochrome PE and VPAC2 to PerCP according to the manufacturer’s instructions. A VPAC1 PE and 
VPAC2 PerCP stock concentration of 50µg/ml was prepared in 1 x Phosphate buffer saline (PBS) pH 7.4 
(Gibco® Carlsbad, CA, USA). To simplify data reporting, the staining profile of these receptors on pDCs and 
mDCs in fresh whole blood was discussed in Chapter 5. 
 
Table 4.2:  mAb panels used for the phenotypic profiling of pDCs and mDCs. 
Panels mAb Clone Isotype Alternate names 
DCID 
HLA-DR APC-Cya™7 1 
CD123 PE-Cy™7 1 
CD11c Pacific blue™ 1 
LIN1 FITC 2 
L243 
6H6 
Bu15 
Refer to chapter 3 
mouse IgG2a,  
mouse IgG1,  
mouse IgG1,  
Refer to chapter 3 
- 
- 
- 
- 
Panel A  
CCR5 APC 2 
CCR7 PerCP 3 
CD80 PE 1 
3A9 
150503 
2D10 
mouse IgG2a,  
mouse IgG2a 
mouse IgG1,  
CD195 
CD197 
- 
Panel B 
CXCR6 APC 3 
CCR9 PE 3 
CD83 PerCP-Cy™5.5 1 
56811 
112509 
HB15e 
mouse IgG2b 
mouse IgG2a 
mouse IgG1,  
CD186 
CD199 
- 
Panel C 
TRAIL-R1 APC 1 
TRAIL-R3 PE 1 
DJR1 
DJR3 
mouse IgG1,  
mouse IgG1,  
CD261/DR4 
CD263/DcR1 
Panel D 
TRAIL-R2 APC 1 
TRAIL-R4 PE 3 
DJR2-4 (7-8) 
104918 
mouse IgG1,  
mouse IgG1 
CD262/DR5 
CD264/DcR2 
Panel E TNF-R2 PE3  22235 mouse IgG2a CD120b 
Panel F 
CD86 PerCP-Cy™5.5 1 
FASL PE 1 
FAS Alexa Fluor®647 1 
IT2.2 
NOK-1 
DX2 
mouse IgG2b,  
mouse IgG1,  
mouse IgG1,  
- 
CD178/CD95L 
CD95 
Panel G 
CD62L APC 2 
VPAC1b PE 
VPAC2b PerCP 
DREG-56 
- 
476031 
mouse IgG1,  
mouse IgG2a 
mouse IgG1 
- 
VIP R1 
VIP R2 
aCy refers to Cyanine 
bRefer to Chapter 5 
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4.3.4 Optimization of mAb volume for multi-parameter flow cytometry (mAb titration) 
The minimum volume of mAb that would produce the greatest signal- to- background ratio was determined 
for all the mAbs used in this study. Each of the mAbs listed in Table 4.2 were serially diluted (2-fold) in 
staining buffer with the highest titer representing a volume equal to the manufacturer’s recommendation and 
the lowest titer equal to a 1:256 dilution. Whole blood (EDTA, 200µl/titration) was separately stained with 
each of the titrated mAbs (dilution series prepared in staining buffer (0.4% heat-inactivated foetal calf serum 
in 1 x PBS pH 7.4 (Gibco® Carlsbad, CA, USA) in a 50µl total volume) following the procedure described in 
section 4.3.5. The samples were acquired uncompensated on the BD FACSCanto™ II 8-colour flow 
cytometer (BD Biosciences, San Jose, CA). In determining the optimal volume of mAb one requires the 
median fluorescent intensity (MFI) value of both positive (marker bound) and negative (marker unbound) 
fluorescent signals generated by the populations of interest, therefore, an unstained sample was also 
prepared. Furthermore, as this procedure entailed the use of single marker stains, identification of rare DC-
related events was required in the absence of the four DCID surface markers. This was performed by 
targeting events in the relative position in which DCs are found in a SSC – Area (A) vs. Forward Scatter 
(FSC) - A density plot. Recall that in this platform, due to the morphological properties (granularity and size) 
of the DCs, these cells are scaled between the monocyte and lymphocyte population. Accordingly, DC-
related events were collected using a tight polygon gate and displayed in a SSC - A vs. titrated marker 
density plot. Interval gates were used to collect negative and positively stained DC events for each of the 
titer points of the titrated mAb and to obtain the according MFI values. The ratio of positive to negative MFI 
for each titration point was plotted on a line graph, with the antibody concentrations on the x-axis and the 
MFI ratio on the y-axis. The corresponding titrated value at the point where the curve reached a plateau was 
selected as optimal.  
 
4.3.5 Whole blood staining procedure for the phenotypic profiling of pDCs and mDCs 
Staining of whole blood was performed in 12 x 75 mm, 5 ml polystyrene round bottom capped Falcon™ tube 
(BD Biosciences, San Jose, CA). For each patient, seven of these tubes were prepared and appropriately 
labeled with the patient number and name of the specific staining panel. Whole blood (200
l) was added to 
each of these test tubes followed by 50
l of the relevant freshly prepared mAb cocktail. These cocktails were 
prepared in seven appropriately labeled Eppendorf tubes (Hamburg, Germany) each consisting of staining 
buffer (0.4% heat-inactivated foetal calf serum in 1 x PBS pH 7.4 (Gibco® Carlsbad, CA, USA)), DCID mAbs 
and the relevant mAbs defined for each of the staining panels A-G (refer to Table 4.2). The volume of the 
mAbs (predetermined via titration) was as follows: a volume of 2
l was used for mAbs CCR5 APC, CD80 
PE, TRAIL-R1 APC, TRAIL-R3 PE, TRAIL-R2 APC, FASL PE, CD62L APC, VPAC1 PE and VPAC2 PerCP; 
a volume of 1
l was used for mAbs CCR7 PerCP, CXCR6 APC, CCR9 PE, TRAIL-R4 PE and TNF-R2 PE; 
and a volume of 0.5
l was used for mAbs CD83 PerCP-Cy™5.5, FAS Alexa Fluor®647 and CD86 PerCP-
Cy™5.5. The predetermined titrated volumes for the DCID surface markers were as follows, 2
l for the LIN1 
FITC, HLA-DR APC-Cy™7 and CD123 PE-Cy™7 mAbs and 0.5 
l for CD11c Pacific blue™ mAb.  
 
Whole blood was incubated with the prepared cocktails for 30 min at room temperature in the dark. Red 
blood cell lysing and cell fixation was performed with 1.8 ml of 1x BD FACS Lysing solution (BD Biosciences, 
San Jose, CA) and incubated for 10 min at room temperature in the dark. Centrifugation at 400 x g (Hettich 
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Rotanta 460R, Massachussets, USA) for 5 min allowed for the collection of the leukocyte pellet and after 
discarding the supernatant, 2 ml staining buffer (0.4% heat-inactivated foetal calf serum in 1x PBS pH 7.4 
(Gibco® Carlsbad, CA, USA)) was added. The wash step was repeated and the supernatant discarded by 
inverting the tube and blotting the inverted tube dry on absorbent paper. The sample was resuspended in 
500
l staining buffer and immediately acquired on a BD FACSCanto™ II 8-colour flow cytometer (BD 
Biosciences, San Jose, CA). Debris was excluded from the acquired data by placing a threshold value of 0 - 
50 000 on the FSC - A scale. A total of 750 000 total events were acquired per sample. Data on the height 
(H), area (A) and width (W) of the fluorescence pulse generated in the different channels was collected.  
 
4.3.6 Instrument controls: Daily set up and performance monitoring of the flow cytometer 
Optimal performance of the 8-colour BD FACSCanto™II digital flow cytometer was monitored by the use of 
BD Cytometer Setup and Tracking beads. These beads, stained by the manufacturer with a mixture of 
specific fluorochromes, are excited by the lasers of the flow cytometer and emits in all the detectors. 
Accordingly, several automated measurements were taken to establish optimal baseline photomultiplier tube 
voltages to maximise population resolution in each detector.  The application of CST beads allowed for 
monitoring cytometer performance on a daily basis. 
 
4.3.7  Assay controls for the analysis of marker expression by pDCs and mDCs 
 
4.3.7.1 Assay control 1: fluorochrome single stains to assess bead-based compensation settings 
Compensation in flow cytometry refers to the mathematical “removal” of the fluorescent spillover occurring 
when the emission spectra of a specific fluorochrome overlaps into an unassigned (secondary) detector. 
Corrected compensation results in the detection of fluorescence only in the assigned (primary) detector and 
in multi-color flow cytometry this is calculated with the use of BD™ CompBeads (BD Biosciences, San Jose, 
CA). Single stains of these polystyrene micro-particles are prepared, according to the manufacturer’s 
instructions, using the same fluorochrome conjugated antibodies intended to stain samples in a proposed 
multi-color experiment. Two sets of these beads are simultaneously stained; one set binds to any anti-mouse 
 light chain antibody while the other set lacks binding properties. This allows for the detection of distinct 
positive and negative fluorescence signals required for calculating compensation settings. In the current 
study these settings were determined by BD FACSDiva™ software v6.1.3 (BD Biosciences, San Jose, CA).  
 
Next, single stain controls were again applied but in this case they were used to determine whether the 
bead-based compensation settings sufficiently withdrew the spectral overlap from unassigned detectors 
when applied to cell analysis. These single stain controls were prepared by staining aliquots of whole blood 
(as outlined in section 4.3.5) individually with the pre-determined optimal volume of mAbs for the DCID and 
markers of Panels A-G (this was also performed for Panel 5 and 6 (refer to Table 5.4)). These samples were 
acquired on the BD FACSCanto™ II 8-colour flow cytometer (BD Biosciences, San Jose, CA) with the pre-
determined bead-based compensated settings applied. The gating strategy as described in section 4.3.4  
was employed to identify the DC population from total acquired events, which was then displayed in a 
combination of 6 density plots, assigning the specific single stain control to the x-axis and the parameters of 
the remainder detectors to the y-axis. Detection of spillover entailed evaluating the signal produced by the 
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single stain in each of the detectors employed in a specific staining panel. A positive signal produced in 
detectors other than that of the single stain control was identified spillover and required manual adjustment 
of the bead-based compensation value. A (false) positive signal in an unassigned detector defines the 
overlap as under-compensated. In addition, single stains can also be used to identify over-compensation 
which can also be rectified manually.   
 
In the current study, bead-based compensation, in most cases, was optimal for the analysis of cells. 
However, the calculated value was not sufficient to correct the overlap of APC-Cy™7 fluorescence into 
APC/Alexa Fluor®647 detectors and further adjustment was required (in the current study this fluorochrome 
was used conjugated to the antibody HLA-DR, one of the DCID surface markers. As DCs positively 
expressed this marker, the positive fluorescent signal generated in the APC-Cy™7 channel overlapped into 
APC/Alexa Fluor®647 detectors. Hence, the correct removal of the overlap was essential as APC/ 
Fluor®647 was used conjugated to mAbs directed towards the analyses of the phenotypic markers of 
interest). Accordingly, manually correcting compensation entailed tweaking (using BD FACSDiva™ software 
v6.1.3 (BD Biosciences, San Jose, CA) the initial bead-based compensation value for removal of overlapping 
primary fluorescence, APC-Cy™7, from the unassigned secondary detector, APC/Alexa Fluor®647, so that 
the median APC/Alexa Fluor®647 fluorescence of the APC-Cy™7 positive population is similar to that of the 
APC-Cy™7 negative population (Hulspas R, et al. 2009; Herzenberg LA, et al. 2006). This procedure of 
adjusting compensation values required the specific use of unstained and APC-Cy™7 single stained  DC 
events, to obtain a negative and positive APC-Cy™7 signal for manually adjusting compensation. This 
preparation would then entail identifying DCs upon morphological properties (as described in section 4.3.4). 
However, as it was later found that this procedure does not maximally identify DCs (gating DCs using this 
method results in DC events contaminated with monocytes and lymphocytes) and foreseeing that this 
method of collecting DCs might become more complex upon daily compensation checks, especially with 
samples from HIV-1 infected patients being limited in number due to HIV-1 induced cellular changes, the 
current study sought for an alternative method to correct and check compensation on DC events, 
specifically.  
 
In analyses of FMO staining controls, the influence of overlapping fluorescence in DC specific events could 
be clearly observed and corrected. The purposes of these controls in multi-parameter flow cytometry are 
discussed in more detail in section 4.3.7.2. Briefly, it entails staining cells with all the markers in a specific 
multi-color panel with the simple exclusion of one marker at a time. However, in the current study these 
controls were prepared by staining whole blood with all the DCID markers, but applying FMO staining only to 
the markers of interest in each panel. Hence, the influence of e.g. overlapping APC-Cy™7 fluorescence in 
the APC/Alexa Fluor®647 channel, when the latter fluorochrome was omitted from the staining assay, could 
be detected with DC events, specifically. Attempting to adjust the abovementioned overlap observed in the 
DC events using randomly selected events negatively stained with APC-Cy™7 (recall that a negative and 
positive signal are required to adjust compensation) was not optimal (observing mostly an overcompensation 
profile in the DC subsets), presumably due to differential autofluorescence properties of events. In view of 
this, the study approached several strategies similar and different to the conventional method to correct 
compensation and found the following most optimal. In analyses of FMO controls of the APC/Alexa 
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Fluor®647 fluorochrome the study observed that in addition to the high intensity of APC-Cy™7 positive DC 
events overlapping into the unassigned secondary APC detector (refer to Figure 4.1: green-coloured events 
A1 (pDCs) and B1 (mDCs), a portion of these events showed minor to zero frequency of overlapping events 
(pink and blue events, Figure 4.1 A1 and B1, respectively). Consequently, and as expected, the APC 
fluorescence intensity of these opposing events was very different. Conversely, amongst fluorochrome 
combinations with non-overlapping properties or where bead-based compensation sufficiently corrected 
overlapping fluorescence, e.g. PE and APC-Cy™7, it was observed that the signal generated in the 
secondary unassigned detector (e.g. PE), when comparing 50% of events lower to 50% of events higher 
than the fluorescence peak of the positive events generated from the primary assigned detector (APC-
Cy™7), had similar fluorescence signal intensities. (Figure 4.1 A2 and B2, comparing the MFI of green 
events to pink and blue events, respectively).  Accordingly, using a histogram to display APC-Cy™7 positive 
pDC and mDC events an interval gate was used to collect 50% of APC-Cy™7 positive pDC and mDC events 
lower than peak APC-Cy™7 fluorescence, which mostly included the non to minimal overlapping and lower 
fluorescent intensity portion of events. Similarly, events that included the higher fluorescing and, 
subsequently, greater overlapping APC-Cy™7 events (Figure 4.1 A3 and B3) were also collected. The 
compensation value was adjusted using BD FACSDiva™ software v6.1.3 (BD Biosciences, San Jose, CA) 
so that the APC MFI value of these events closely matched (Figure 4.1 A4 and B4). This technique was 
effective for correcting compensation and removing overlapping events, yet proved to be time-consuming as 
gates to collect 50% of lower and higher than APC-Cy™7 fluorescent peak events had to be slightly adjusted 
for every sample. However, further analyses confirmed that equalizing the APC MFI value of total pDC or 
mDC events to that of the relevant lower intensity fluorescent peak events was also effective and a more 
rapid technique for correcting overlapping fluorescence.  
 
In addition to the removal of the APC-Cy™7  fluorescence overlap from the APC detector, certain batches of 
antibodies required removal of overlapping PE-Cy™7 and PerCP/PerCP-Cy™5.5 fluorescence from the PE 
channel. Similar adjustments, as described above, were performed to correct compensation. 
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Figure 4.1: Compensating the fluorescence overlap of APC
A1 and B1 show the profile of the influence of overlapping (green
primary detector, APC-Cy™7, into the secondary unassigned detector, APC, upon DC events specifically. Refer to the MFI (APC) values, which show the different
APC MFI values between the overlapping and non-overlapping fluorescence. A2 and B2 show the profile of non
Cy™7 and secondary PE detector with corresponding APC MFI when comparing green to pink and blue events. A3 and B3 illustrate 
overlapping green (corresponding to 50% higher than peak pDC and mDC events ) and non
pDC and mDC events, respectively) so to compare and equate APC MFI values and eliminate false positive data. A4 and B4 show t
mDCs events upon removal of the overlapping fluorescence.
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4.3.7.2 Assay control 2: The role of Fluorescence Minus One (FMO) 
Prior to the analysis of expression of marker of interest by pDCs and mDCs (or any other cell type), 
background or artefact fluorescence in relevant detectors must be defined as this could lead to false positive 
results. Recognition of these artefacts is mainly important where marker expression is negative and is 
characteristic of events having slightly higher fluorescent intensity than negative expressing events. 
Specifically, the tandem dyes (Cy™5, Cy™7, Texas red®) have been implicated as contributors of either 
direct (Forman MA or Gupta RK, 2007) or indirect (Maecker HT, et al. 2004) background fluorescence. Note 
that tandem dyes, in contrast to the conventional fluorochromes, consist of two fluorescent molecules, 
namely the donor (i.e. APC) and acceptor (i.e.Cy™7). This combined fluorochrome has the excitation 
properties of the donor but the emission properties of the acceptor.Forman MA and Gupta RK (2007) 
showed in staining leukocytes with CD3 PE-Cy™5, atypical CD3 positive expression by monocyte was 
observed, a cell type characteristic of negative CD3 expression. It was concluded to be the result of non-
specific binding of the CD3 conjugated tandem dye to monocytes. A detailed report by Maecker HT, et al. 
(2004) showed how false positive events observed in the APC and PE detectors were dependent on cells 
positively stained with APC-Cy™7 andPE-Cy™7, respectively. They proposed that this phenomenon might 
be due to a break in the bond between the donor (APC or PE) and acceptor dye (Cy™7) with resulting 
fluorescence in the donor detector.  It should also be noted that 1) background staining may differ between 
new batches of tandem dye conjugated antibodies and 2) these dyes are sensitive to unfavourable 
conditions. Excessive exposure to light and fluctuating temperature can cause a break in their chemical 
structure resulting in enhanced non-specific binding. This is a specific problem with tandem dyes. 
 
The procedure performed to detect for possible false positive events entails the application of FMO controls. 
These controls, in contrast to single stain controls, were prepared by staining cells with all the markers in a 
specific multi-color panel with the simple exclusion of one marker at a time. In doing so total background 
fluorescence, contributed either directly or indirectly (as described above), can be detected in the channel in 
which the corresponding fluorochrome was omitted. In the current study FMO staining controls were 
prepared for the markers of interest but not for the DCID markers as 1) exclusion of any one of the 4 DCID 
markers would hinder the identifications of DCs per se from total events and 2) primarily, 
detection/evaluation of total background fluorescence, contributed by the fluorescence from the DCID 
markers and/or other positively expressed markers, in the FMO applied channel of the markers of interest 
was of relevance. Recognizing which fluorochrome(s) specifically contributed towards background 
fluorescence in the channels dedicated to examine expression of the markers of interest was not important. 
The main aim of this procedure was to monitor background fluorescence and guide placement of the gates 
so to exclude false positive events generated by background fluorescence. 
 
In addition to FMO controls serving to identify background fluorescence, this technique (reported more 
accurate than isotype controls) also aids in defining the staining boundary of negative expressing events and 
are most valuable in cases were positive events do not separate well from negative events (Herzenberg LA, 
et al. 2006; Perfetto SP, et al. 2004). Also, in drawing combination two-parameter density plots using the 
FMO control stain vs. the other markers of a relevant panel, enabled detection and examination of 
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fluorescence overlap specific to the DC events which was adjusted  following the method as discussed in 
section 4.3.7.1. 
 
In the current study, FMO controls were prepared following the procedure on whole blood staining and 
sample acquisitions as described in section 4.3.5. Whole blood from an HIV-1 seronegative individual was 
used. Post-staining sample analyses required 1) defining the pDCs and mDCs from the total acquired events 
using the gating strategy as shown in section 4.3.9 (Figure 4.20) followed by 2) examining DC events for 
possible background fluorescence caused by non-specific binding (especially were marker expression is 
found negative (FMO vs. marker stain) and 3) setting gates on the negative staining boundary. Density plots 
with gates were created for each of the FMO staining controls prepared for the 15 phenotypic and 2 
immunemodulatory markers of interest (Table 4.2) and the profile obtained compared to staining profile of 
marker stained samples.  Accordingly, events of marker stained samples displayed outside the staining 
boundary of these gates and displaying strong increased signal intensity were regarded as positively 
expressing the marker of interest. Marker expression that displayed the same profile as the relevant FMO 
control was regarded as evidence for the lack of expression of marker of interest. Events collected via the 
gate of marker stained samples were used for statistical analyses. 
 
Certain literature (Baumgarth N& Roederer M, 2000) recommends performing single stains (refer to section 
4.3.7.1) and FMO controls with daily experiments. Notwithstanding the fact that preparation of these controls 
is labour intensive and time-consuming it is also a prohibitively expensive routine. In an attempt to preserve 
resources, single stain and FMO controls were performed once after bead-based compensation setting was 
established to take note of the 1) markers with potential risk of overlapping into unassigned secondary 
detectors, 2) approximate staining boundary of positive and negative events and 3) channels prone to 
background staining. Upon exclusion of FMO controls from the assays, internal controls were sought to aid 
in accurately distinguishing between negative and positive events for the marker of interest in daily 
experiments. These internal controls were required to have a data spread profile (related to autofluorescence 
and/or compensation-induced) similar to that of the DCs upon FMO staining of markers of interest. It was 
determined that basophils and negative events collected from a LIN1-HLA-DR- gate as well as events from a 
LIN1+HLA-DR+ gate were suitable to employ as internal controls. Specifically, it was found that the data 
spread of negative events collected from a LIN1-HLA-DR- gate were similar to the event distribution of both 
DCs in the PE channel and mDC events in the PerCP and PerCP-Cy™5.5 channel. The data spread of 
basophils in the latter two channels corresponded to that of pDCs. Furthermore, the data spread of events 
within the LIN1+HLA-DR+ population was similar to that of pDC and mDC events in the APC and Alexa 
Fluor®647 channel (refer to Figure 4.2 in which the data spread in the APC/Alexa Fluor®647, PerCP/PerCP-
Cy™5.5 and PE channels are displayed: the basophil and negative population captured from the LIN1-HLA-
DR- gate are shown as grey and black coloured events, respectively, and the control population from the 
LIN1+HLA-DR+ gate are represented as brown-coloured events). In cases were the data spread of the 
internal control coincided with that of the DC events, marker expression was regarded as negative and 
where a shift in the distribution of pDC and/or mDC events (accompanied by increase in MFI) in relation to 
the control occurred, marker expression was determined as positive.  
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Figure 4.2:   Data spread profile of FMO control stains related to the APC/
PerCP/PerCP-Cy™5.5 and PE channels
The graph shows the data spread (purple
coloured) events in the APC (A1), 
channel in relation to negative stained (black
(brown-coloured). 
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4.3.8 Analysis method of acquired events 
In analysis of the FMO control and marker stained samples, the use of two-parameter density plot and 
Height (H) vs. Area (A) parameters of the fluorescent signal related to the marker of interest, e.g. TNF-R2 PE 
– H vs. TNF-R2 PE – A, were found to give better resolution in characterizing negative/positive events than 
the conventional marker X - Area vs. marker Y - Area (e.g. HLA-DR APC-Cy™7 - A vs. TNF R2 PE – A) 
assessment. Latter analyses produced a dispersed profile (due to characteristic rare number distribution) of 
DC events, while the former analysis method produced a profile of condensed events simplifying, to a 
degree, event analyses. Also, by employing two entities of the fluorescent signal, height and area, negative 
and positive events with a more distinct discrimination profile was obtained. Refer to Figure 4.13 for an 
illustration on mDC events in a TNF-R2 PE – H vs. TNF-R2 PE – A density plot with (marker stain) or without 
(FMO control stain) TNF-R2 PE staining to observe the different event profile of negative and positive TNF-
R2 marker staining on mDCs using this platform of analyses. This method was also found optimal in analysis 
of samples when slight shifts in fluorescence occurred due to instrument related changes or upon staining 
with new batches of antibodies. Furthermore, in analyses of events two gates, solid and dashed line 
parallelograms, were used to identify the staining boundary and collect positive events, respectively. Refer to 
Figures 4.3 – 4.19 which illustrate the marker and FMO control stain for the 17 markers investigate. Graphs 
A1, B1 and C1 display the internal control, pDC and mDC events as per FMO control stain, respectively. 
Graphs A2, B2, C2 display the internal control, pDC and mDC events as per marker stained sample, 
respectively.
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Figure 4.3:   pDC and mDC staining profile of CD80 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CD80 FMO control and marker staining, respectively. 
B1-2 and C1-2contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of pDCs and 
mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as 
positive. 
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Figure 4.4:   pDC and mDC staining profile of CCR7 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CCR7 FMO control and marker staining, respectively. 
B1-2 and C1-2contains DCs (to the front) and control events (grey-coloured for pDCs and black-coloured for mDCs, displayed to the back of the DC population) to 
show the relationship of pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the 
solid gate were not regarded as positive. 
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Figure 4.5:  pDC and mDC staining profile of CCR5 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CCR5 FMO control and marker staining, respectively. 
B1-2 and C1-2 contains DC (to the front) and control events (black and brown-coloured and displayed to the back of the DC population) to show the relationship of 
pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not 
regarded as positive. Note the different placement of the gate in the FMO control vs. the marker stain for the pDCs and mDCs. In the latter stain the gate 
was placed in reference to the tail of positive events displayed by the brown coloured control events as the gate placed according to FMO control was 
not sufficient in capturing pDC and mDC positive CCR5 events, attributed to data spread difference in the channel upon negative and positive expression 
of the marker. 
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Figure 4.6:  pDC and mDC staining profile of CCR9 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CCR9 FMO control and marker staining, respectively. 
B1-2 and C1-2contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of pDCs and 
mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as 
positive. 
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Figure 4.7:  pDC and mDC staining profile of CD83 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CD83 FMO control and marker staining, respectively. 
B1-2 and C1-2 contains DC (to the front) and control events (grey-coloured for pDCs and black-coloured for mDCs, displayed to the back of the DC population) to 
show the relationship of pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the 
solid gate were not regarded as positive. 
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Figure 4.8:  pDC and mDC staining profile of CXCR6 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CXCR6 FMO control and marker staining, respectively. 
B1-2 and C1-2contains DC (to the front) and control events (brown-coloured and displayed to the back of the DC population) to show the relationship of pDCs and 
mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as 
positive. 
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Figure 4.9:   pDC and mDC staining profile of TRAIL-R1 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon TRAIL-R1 FMO control and marker staining, 
respectively. B1-2 and C1-2 contains DC (to the front) and control events (brown-coloured and displayed to the back of the DC population) to show the relationship 
of pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not 
regarded as positive. 
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Figure 4.10:  pDC and mDC staining profile of TRAIL-R2 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon TRAIL-R2 FMO control and marker staining, 
respectively. B1-2 and C1-2 contains DC (to the front) and control events (brown-coloured and displayed to the back of the DC population) to show the relationship 
of pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not  
regarded as positive. 
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Figure 4.11:  pDC and mDC staining profile of TRAIL-R3 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon TRAIL-R3 FMO control and marker staining, 
respectively. B1-2 and C1-2contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of 
pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not 
regarded as positive. 
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Figure 4.12:  pDC and mDC staining profile of TRAIL-R4 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon TRAIL-R4 FMO control and marker staining, 
respectively. B1-2 and C1-2 contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of 
pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not 
regarded as positive. 
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Figure 4.13:  pDC and mDC staining profile of TNF-R2 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon TNF-R2 FMO control and marker staining, respectively. 
B1-2 and C1-2 contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of pDCs and 
mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as 
positive. Note the different placement of the gate in the FMO control vs. the marker stain for the mDCs. In the latter stain the gate was placed in reference 
to black coloured negative events as the gate placed according to FMO control was not sufficient in capturing positive TNF-R2 events, attributed to data 
spread difference in the channel upon negative and positive expression of the marker.  
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Figure 4.14:  pDC and mDC staining profile of FASL and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon FASL FMO control and marker staining, respectively. 
B1-2 and C1-2 contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of pDCs and 
mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as 
positive. Note the high level of non-specific binding in the FMO control of pDCs. 
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Figure 4.15:  pDC and mDC staining profile of CD86 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CD86 FMO control and marker staining, respectively. 
B1-2 and C1-2 contains DC (to the front) and control events (grey-coloured for pDCs and black-coloured for mDCs, displayed to the back of the DC population) to 
show the relationship of pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the 
solid gate were not regarded as positive. 
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Figure 4.16:  pDC and mDC staining profile of FAS and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon FAS FMO control and marker staining, respectively. B1-
2 contains pDC (to the front) and control events (brown-coloured events, displayed to the back of the DC population) and C1-2 contain mDC events (to the front) and 
control events (black and brown-coloured events, displayed to the back of the DC population) to show the relationship of pDCs and mDCs to control events. The 
white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as positive. Note the different 
placement of the gate in the FMO control vs. the marker stain for the mDCs. In the latter stain the gate was placed in reference to black coloured negative 
events as the gate placed according to FMO control was not sufficient in capturing mDC positive FAS events, attributed to data spread difference in the 
channel upon negative and positive expression of the marker.  
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Figure 4.17:  pDC and mDC staining profile of VPAC1 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon VPAC1 FMO control and marker staining, respectively. 
B1-2 and C1-2 contains DC (to the front) and control events (black-coloured and displayed to the back of the DC population) to show the relationship of pDCs and 
mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not regarded as 
positive. 
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Figure 4.18:  pDC and mDC staining profile of VPAC2 and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon VPAC2 FMO control and marker staining, respectively. 
B1-2 and C1-2 contain DC (to the front) and control events (grey coloured for pDCs, black-coloured for mDCs and displayed to the back of the DC population) show 
the relationship of pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid 
gate were not regarded as positive. 
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Figure 4.19:  pDC and mDC staining profile of CD62L and relevant FMO control 
Graph A1-C1 and A2-C2 represents the control, pDC (pink-coloured) and mDC (blue-coloured) events upon CD62L FMO control and marker staining, respectively. 
B1-2 and C1-2 contain DC (to the front) and control events (black and brown-coloured events, displayed to the back of the DC population) to show the relationship of 
pDCs and mDCs to control events. The white dash border gate was used to capture positive events for statistical analysis. Events within the solid gate were not 
regarded as positive. Note the different placement of the gate in the FMO control vs. the marker stain for both DC populations. In the latter stain the gate 
was placed in referenced to black coloured negative events as the gate placed according to FMO control was not sufficient in capturing CD62L events, 
attributed to data spread difference in the channel upon negative and positive expression of the marker. 
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4.3.9 Flow cytometric analyses: Gating strategy used to identify the DC subsets for phenotypic 
profiling 
An overall two step gating strategy was employed to, firstly, define the pDC and mDC subsets from the 
heterogeneous cell population in whole blood and, secondly to determine the expression profile of the 17 
markers listed in Table 4.2 for both DC subsets. The gating strategy entailed the use of two-parameter 
density plots (these plots allow for the graphical presentations of the properties of events or cells according 
to two defined parameters, simultaneously. One dot represents one event. The X-axis and Y-axis were 
scaled in four log decades from which the signal intensity (MFI) of the marker of interest can be determined.)  
Moreover, hierarchical gating was used to detect the pDC and mDC population, characterised as HLA-
DR+CD11c-CD123+LIN1DIM and HLA-DR+ CD11c+CD123DIMLIN1DIM, respectively. Recall that +refers to a 
bright positive expression of the relevant marker, DIM refers to an expression of intermediate intensity and - 
refers to the marker not being expressed. Data analyses were performed using the BD FACSDiva™ software 
v6.1.3 (BD Biosciences, San Jose, CA).  
 
Prior to defining the DC subsets, or any other cell population of interest, total acquired events should be 
separated into singlet and doublet populations and only the former selected for further analysis. Singlets are 
recorded by a flow cytometer as one event, consequently also doublets, which in fact are two or more bound 
particles which should be excluded from the data analyzed. Identification of singlets was performed by 
displaying total acquired events in a FSC – H vs. FSC - A and collected using a polygon gate, labeled as P1 
(Figure 4.20 A). Following this, P1 events were then displayed in a SSC – A vs. FSC - A density plot and a 
broad P2 polygon gate drawn to select the monocyte and lymphocyte population. The morphological 
properties (granularity and size) of pDCs and mDCs, position both the DC subsets between the monocyte 
and lymphocyte populations in such a density plot (Figure 4.20B). Events of the P2 polygon gate was then 
displayed in a HLA-DR - A vs. CD11c - A density plot and a broad  gate, P3 and P4 respectively, drawn to 
collect HLA-DR+CD11c- and HLA-DR+CD11c+ events, respectively (Figure 4.20 C and D). These events 
were then displayed, separately, in a CD123 - A vs. LIN1 - A density plot. The CD123+LIN1DIM events 
identified within the HLA-DR+CD11c- populations and the CD123DIMLIN1DIM events of the HLA-DR+CD11c+ 
population, defined the pDC and mDC populations respectively (Figure 4.20 E and F, respectively).  
 
This gating strategy is an adaption to the method described in a majority of DC related publications in which 
singlet events are collected in a HLA-DR+LIN1DIM density plot followed by identifying pDCs (CD123+CD11c-) 
and mDCs (CD123DIMCD11c+) from a CD123 vs. CD11c density plot. This gating strategy was found optimal 
for the identification of DCs from acquired events in the control study group but it was not sufficient for most 
of the HIV-1 and HIV-1-related study groups, presumably due to HIV-1- associated changes on cellular level. 
This prompted the design of the abovementioned gating strategy which enabled optimal identification of DCs 
from the control, HIV-1 and HIV-1-related study groups. 
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Figure 4.20:  Gating strategy to identify the DC subsets for phenotypic analyses
Singlets were collected in a P1 gate using a FSC 
vs. FSC - A density plot. A broad gate (P2) 
population. These events were further sequentially analysed in an HLA
vs. LIN1  - A density plots to collect 
events defined as pDCs (pink-coloured) and mDCs (blue coloured), respectively.
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4.3.10 Distinguishing between mDC and non-mDC contaminating events within the LIN1DIM 
population 
The described DC subset identification gating strategy (Figure 4.20) was optimal in differentiating pDCs and 
mDCs from total acquired flow cytometric events for subsequent analyses of expression of markers of 
interest, however, in some cases the study observed LIN1DIM mDC events with questionable high density 
(Figure 4.21 A vs. B, displaying HLA-DR+CD11c+ events in a CD123 vs. LIN1 density plot) which is in 
contrast to the well-described extreme low number distribution of these cells in peripheral blood. It became 
apparent via the analyses of TNF-R2 expression by mDCs that these events included two clearly different 
populations, a low density TNF-R2DIM (mDC events) and high density TNF-R2BRIGHT (non-DC events) (Figure 
4.21 D, blue and purple coloured events, respectively). In contrast TNF-R2 analyses of mDC events of the 
data set depicted in Figure 4.21 A only showed low density TNF-R2DIM mDC events (Figure 4.21 C). Hence, 
these non-DC events needed to be excluded from mDC gating events so to ensure analysis of exclusively 
mDC specific marker expression.  Also the differential expression of TNF-R2 made it possible to collect mDC 
specific events for further analyses of markers included in the related marker panel (Panel E, refer to Table 
4.2). However, for the remaining  panels where TNF-R2 was not present an alternative gating strategy had to 
be devised, preferably using markers present in all the panels, hence, relying on the differential expressing 
of DCID markers as tool to extract mDC specific events from contaminating non-DC events (refer to Figure 
4.21). The study evaluated the TNF-R2DIM mDC and TNF-R2BRIGHT non-DC population observed in the TNF-
R2 vs. LIN1 density plot (Figure 4.21 C, D), in a HLA-DR  vs. LIN1 density plot  and were able to locate “true” 
mDC events separate from non-DC events as these displayed a higher HLA-DR MFI than non-DC events 
(Figure 4.21 F; E depicts dataset without non-DC events). In addition, the current study also observed that 
analyses of events in a CD86 vs. HLA-DR density plot, allowed for distinguishing “true” mDCs from non-DC 
events (Figure 4.21 H; F depicts dataset without non-DC events). 
 
These findings suggested that in flow cytometric analysis of blood mDCs in HIV-1 studies the addition of 
TNF-R2 or CD86 to a marker panel could guide a more sensitive “isolation” of the mDC subset from acquired 
events. Its proposed that these contaminating events observed in the mDC defining gate are due to changes 
induced by HIV-1 infection on cells encompassing the LIN1+ population (T lymphocytes, macrophages, 
monocytes, neutrophils, B Lymphocytes, eosinophils and NKL’s) or natural differences between donors.  
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Figure 4.21:  Distinguishing between mDC and non-
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4.3.11 Statistical analyses 
Comparative analyses of the expression of markers of interest by pDCs and mDCs were performed as 
defined in section 3.3.8. These tests were performed using the Graphpad Prism version 5.00 software (San 
Diego, California, USA). Refer to Table 3. 4 for the summary of the method used to report significant and 
non-significant data as well as the corresponding p value range. 
 
 
. 
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4.4 Results and discussion 
 
4.4.1 Defining marker expression related to apoptosis, migration, activation/maturation on both 
DC subsets during HIV-1 infection. 
 
4.4.1.1  Expression profile of the activation markers: CD80, CD86, CD62L and maturation marker 
CD83 on blood DCs of the control, HIV-1 and HIV-1-related study groups. 
 
CD62L was found constitutively and positively expressed by pDCs and mDCs respectively. mDCs also  
positively expressed CD86 while no expression of this marker was found on pDCs. In both DC subsets CD80 
and CD83 expression was absent. 
Assessing activation/maturation marker expression in healthy controls found a significant shift in MFI 
between CD86 and CD62L staining of mDCs as well as CD62L staining of pDCs when compared to the 
relevant FMO stain/internal control. Accordingly, the staining profile showed positive expression of CD62L by 
mDCs (Figure 4.19 C1-C2) and constitutive expression of CD62L and CD86 by pDCs (Figure 4.19 B1-B2) 
and mDCs (Figure 4.15 C1-C2), respectively. These DC subsets were designated as CD86+mDCs, 
CD62L+mDCs and CD62L+pDCs. The CD86 staining profile of pDCs (Figure 4.15 B1-B2) as well as that of 
CD80 (Figure 4.3 B1-B2, C1-C2), CD83 (Figure 4.7 B1-B2, C1-C2)) on both DC subsets was similar to that 
of the relevant FMO stain/internal controls. Accordingly, this confirmed negative expression of these markers 
on blood DCs. 
 
HIV-1 infection induced a significantly higher distribution of CD86+mDCs which normalises during ARV 
therapy 
The median percentage CD86+mDCs was significantly higher in the ARV-HIV-1 study group (p  0.05) 
compared to the control study group. These may resemble mDCs that have responded to the HHF milieu 
and initiate export from blood to secondary lymphoid tissue.  In a similar comparison, a higher median 
percentage of CD86+mDCs was observed in the ARV-HIV-1/TB study group, although the change was not 
significant. Notably, normalization of the CD86+mDCs subset distribution was observed during ARV therapy. 
The median percentage CD86+mDCs was significantly declined in the ARV+HIV-1 study group (p = 0.01) 
compared to the ARV-HIV-1 study group. However, a similar decline was not observed in the ARV+HIV-1/TB 
study group. The normalization effect observed with the ARV+HIV-1 study group and lack thereof observed in 
the ARV+HIV-1/TB study group could be due to the  significant difference in time on therapy between these 
study groups which was 18 months in the former and 5.5 months in the latter study group (Table 4.3, Figure 
4.22 C)  
 
No significant change in the distribution of CD62L+pDCs and CD62L+mDCs or expression profile of the 
negatively expressed CD80 and CD83 markers during HIV-1 infection 
No significant change in the median percentage CD62L+pDCs was observed in the HIV-1 and HIV-1 related 
study groups when compared to that of the healthy controls (Table 4.3, Figure 4.22 A). Although a higher 
median percentage of CD62L+mDCs was observed in the ARV-HIV-1 and ARV+HIV-1 study groups the 
change was not significant. Nonetheless, an interesting trend was observed with the CD62L+mDC subsets. 
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Compared to the higher distribution of CD62L+mDCs in both the ARV-HIV-1 and ARV+HIV-1 study groups a 
decline in the median percentage CD62L+mDCs was observed in the corresponding ARV-HIV-1/TB and 
ARV+HIV-1/TB study groups. It was proposed this finding may be related to the anti-TB treatment. 
Furthermore, no significant change in the staining pattern was observed when the expression profile of the 
negatively expressed activation (CD80) and maturation markers (CD83) on both DCs of the healthy control 
study group was compared to that of the HIV-1 and HIV-1 related study groups (data not shown).  
 
Our findings was in agreement with the reports of Sehgal M, et al. (2014) and Benlahrech A, et al. (2012) in 
which similar 1) distribution frequency of CD62L+pDCs and CD62L+mDCs and 2) expression profile of CD80 
and CD83 on blood DCs between healthy controls and HIV-1 infected individuals was observed, Notably, 
other studies have reported differently on the level of CD83 and CD86 expression on DCs during HIV-1 
infection. Dillon SM, et al. (2008), in contrast to Yonkers NL, et al. (2011), did not observe statistical 
significant difference in levels of CD83 and CD86 expression by DCs between the healthy controls and HIV-
1 infected patients. However, Yonkers NL, et al. (2011) reported on significantly higher expression of these 
markers in HIV infected patients with regard to mDCs, while observing tendency of higher expression by 
pDCs. It was proposed these contrasting findings might be related to viral load variability; however, the viral 
load of the HIV infected participants of Dillon’s study was much higher than that of Yonkers’s. These 
conflicting reports might be due to the diversity of the subjects investigated (stages of disease, donor 
specificity) and factors regarding experimental design. 
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Table 4.3:  Summary of the CD4 and CD8 T lymphocyte percentage; CD4:CD8 ratio, viral load (as 
applicable) as well as the percentage distribution of DC subsets positively expressing 
markers of apoptosis, migration and activation of the control, HIV-1 and HIV-1-related 
study groups. 
 
Data indicated as 
Mea = Median cells/µl,  
Ra= Range cells/µl,  
Meb= Median % of CD45+CD3+ events,  
Rb =Range % of CD45+CD3+ events, 
Mec= Median ratio of CD4 Lymphocyte absolute number to CD8 T lymphocyte absolute number 
Rc=Range of the CD4:CD8 ratio values  
Med = Median % of positive marker expressing DCs, 
Rd= Range % of positive marker expressing DCs, 
Mee = Median RNA copies/ml,  
Re = Range RNA copies/ml 
 
 
 
 
  Study groups 
  Control ARV-HIV-1 ARV-HIV-1/TB ARV+HIV-1 ARV
+ 
HIV-1/TB 
CD4 T cells 
Mea  
Ra 
881 
412 - 1694 
354 
14 - 1175 
207 
51 - 598 
339 
137 - 1072 
319 
52 - 1274 
Meb  
Rb 
44 
22 - 62 
23 
4 - 39 
14.5 
7 - 30 
19.5 
7 - 31 
20 
4 - 47 
CD8 T cells 
Mea  
Ra 
601 
161 - 2545 
863 
187 - 2940 
1067 
229 - 3106 
1147 
346 - 2962 
805 
306 - 2988 
Meb  
Rb 
30 
14 - 52 
51 
23 - 77 
60.5 
45 - 85 
56.5 
33 - 82 
60 
34 - 85 
CD4:CD8 
Ratio 
Mec  
Rc 
1.47 
0.43-3.54 
0.45 
0.07-1.45 
0.24 
0.08-0.6 
0.37 
0.1-0.95 
0.34 
0.08-1.39 
CD86+mDC Me
d
  
Rd 
86.45 
60.70 – 98.2 
92.5 
61.5 - 100 
92.95 
66.7 - 100 
87.6 
58.5 - 100 
91.2 
62.6 - 100 
FAS+mDC Me
d
  
Rd 
92 
71.4 – 99.8 
92.7 
69 - 100 
95.2 
63.7 - 100 
89.70 
73.3 – 100 
91.40 
71.4 - 100 
TNF-R2+ mDC Me
d
  
Rd 
90.65 
29.4 - 99.10 
89.95 
37.9 – 99.6 
93.6 
59.5 - 100 
91.7 
48.9 – 99.5 
91 
62.1 – 98.5 
TNFR2+ pDC Me
d
  
Rd 
49.5 
3.7 – 96.7 
84.4 
6.1 - 99.10 
81.5 
20.4 - 100 
80.3 
4 - 100 
46.9 
10.8 -88.7 
CCR5+pDC Me
d
  
Rd 
83.89 
22.63-100 
81.98 
15.07-99.4 N/A 
68.39 
13.53-91.65 
58.62 
32.47-91.33 
CD62L+pDC Me
d
  
Rd 
91.86 
26.67 -100 
91.99 
52.60 - 100 
93.8 
60 - 100 
93.79 
66.12 - 100 
90.76 
63.84 - 98.40 
CD62L+mDC Me
d
  
Rd 
60.97 
37.88 – 92.18 
70.89 
17.8 - 94.84 
59.7 
37.04 - 81 
75.63 
30.10 – 91.6 
66.05 
36.3 – 92.6 
Viral load  Me
e 
Re N/A 
8.9 x103 
LOD - 3.5 x106 
7.3 x104 
340 - 3.3 x106 
LOD 
LOD - 1.8x105 
LOD 
LOD - 7,1x105 
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Figure 4.22: CD62L+pDCs, CD62L+mDCs and CD86+mDCs subset distribution of the control, HIV-1 and HIV-1 related study groups 
Peripheral whole blood was stained with mAbs to detect the percentage pDCs and mDCs expressing CD62L or CD86 using multi-parameter flow cytometry. The box 
and whiskers plot graphically represents the frequency distribution of the percentage CD62L+pDCs (A), CD62L+mDCs (B) and CD86+mDCs (C) of the control, HIV-1 
and HIV-1-related study groups. Each boxplot shows the 10-90 percentile range of data (whiskers) and horizontal line the median value. Outliers are represented by 
black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group comparison of interest and an asterisk(s) the significance. Refer to 
Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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4.4.1.2  Expression profile of the apoptotic markers: TNF-R2, FAS, TRAIL receptors (R1-R4) and 
FASL on blood DCs of the control, HIV-1 and HIV-1-related study groups. 
 
TNF-R2 was found positively and constitutively expressed by pDCs and mDCs, respectively. FAS expression 
was absent on pDCs and constitutively expressed by mDCs. The four TRAIL receptors as well as FASL were 
found negatively expressed by both DC subsets. 
Assessing the expression of markers related to apoptosis on blood DCs in healthy individuals showed a 
distinct shift in MFI between TNF-R2 and related FMO/internal control stain for both DC subsets (Figure 
4.13) as well as FAS staining on mDCs. The staining pattern revealed constitutive expression of FAS and 
TNF-R2 by mDCs and positive expression of the latter marker on pDCs. These blood DC subsets were 
designated as FAS+mDCs, TNF-R2+mDCs, TNF-R2+pDCs, respectively. In contrast, a similar staining profile 
between marker and related FMO/internal control stain with no change in MFI was observed with TRAIL-R1 
(Figure 4.9), TRAIL-R2 (Figure 4.10), TRAIL-R3 (Figure 4.11), TRAIL-R4 (Figure 4.12) and FASL (Figure 
4.14) on both DC subsets as well as FAS (Figure 4.16) on pDCs. This staining pattern for these markers 
confirmed negative expression of these markers on DCs from fresh whole blood. 
 
HIV-1 and HIV-1/TB co-infection associated changes on TNF-R2 expression 
The median percentage TNF-R2+pDCs was higher in the ARV-HIV-1 and ARV-HIV-1/TB study groups 
compared to the control study group, however, the change was not significant. Notably, a significantly 
reduced median percentage of TNF-R2+pDCs was observed in the ARV+HIV-1/TB study group compared to 
the ARV-HIV-1/TB study group. The reason for this change is not clear as the median time on ARV therapy 
for the ARV+HIV-1/TB study group was 5.5 months which was much shorter than the 18 months of the 
ARV+HIV-1 study group showing only slightly reduced median percentage levels of TNF-R2+pDCs. The 
significant change in median percentage TNF-R2+pDCs can possibly be attributed to anti-TB therapy as the 
median time on anti-TB therapy for the ARV+HIV-1/TB study group was 3 months compared to that of the 
ARV-HIV-1/TB study group which was < 1 month (Figure 4.23A) 
 
No significant change was observed in the median percentage TNF-R2+mDCs between the ARV-HIV-1 study 
group and control study group, however, a significantly higher median frequency of TNF-R2+mDCs was 
observed in the ARV-HIV-1/TB study group (p  0.05). Also, the median percentage TNF-R2+mDCs was 
significantly higher in the ARV-HIV-1/TB study group compared to the ARV-HIV-1 study group (p  0.05) 
which may indicate the effect of the TB co-infection. A decline in the median percentage TNF-R2+mDCs was 
observed in the ARV+HIV-1/TB study group which trended towards significance (p =0.13) (Figure 4.23B). 
The percentage FAS+mDCs of the HIV-1 and HIV-1 related study groups was comparable to the control 
study group. Hence, neither an HIV-1 nor HIV-1/TB co-infection induced a change in the distribution 
frequency of the FAS+mDCs subsets. However, a slightly lower median percentage of FAS+mDCs was 
observed in the ARV+HIV-1 study group compared to the ARV-HIV-1 study group which trended towards 
significance (p = 0.08) (Figure 4.23C).  
 
The negative staining profile of TRAIL R1-R4 and FASL on both DC subsets as well as FAS on pDCs as 
observed in healthy controls was also observed in the HIV-1 and HIV-1 related study groups (data not 
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shown). Collectively, the data indicated that HIV-1 infection and HIV-1/TB co-infection had no impact on the 
expression of these markers on blood DCs. It is suggested that future studies also focus on MFI data to 
evaluate marker density changes. 
 
The expression profile of TRAILs cognate receptors has not been widely documented, however putative 
negative expression by blood DCs in healthy individuals was considered due to the absence of significant 
TRAIL-R1 and TRAIL-R2 expression on DCs from cord blood (Peng P, et al. 2011). However, assays 
investigating the expression of the four TRAIL receptors using mo-DCs (significant of tissue resident DCs, 
namely, immature DC and mature DCs) showed positive expression of TRAIL-R2 and TRAIL-R3 (notably, 
lacking expression of TRAIL-R1 and TRAIL-R4) (Leverkus M, et al. 2000). These findings may be indicative 
of TRAIL receptor up-regulation at different stages of DC development. The FAS and FASL molecules have 
also been reported by Dillon SM and colleagues (2011) as markers negatively expressed by blood pDCs and 
mDCs in healthy individuals. In line with the current study’s findings, Dillon SM et al. (2011) also did not 
observe a significant change in FAS and FASL expression on blood mDCs and pDCs between healthy 
individuals and HIV-1 infected patients.  
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Figure 4. 23: TNF-R2+pDC, TNF-R2+mDC and FAS+mDC subsets distribution of the control, HIV-1 and HIV-1 related study groups 
Peripheral whole blood was stained with mAbs to detect the percentage pDCs and mDCs expressing TNF-R2 or FAS using multi-parameter flow cytometry. The box 
and whiskers plot graphically represents the frequency distribution of the percentage TNF-R2+pDCs (A), TNF-R2+ mDCs (B) and FAS+mDCs (C) of the control, HIV-1 
and HIV-1-related study groups. Each boxplot shows the 10-90 percentile range of data (whiskers) and horizontal line the median value. Outliers are represented by 
an enclosed circle. Horizontal lines with diamond arrows indicate the specific study group comparison of interest and an asterisk(s) the significance. Refer to Table 
3.4 for a description of the method used to indicate the level of statistical significance.  
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4.4.1.3  Expression profile of the chemokine markers: CCR5, CCR7, CCR9 and CXCR6 on blood DCs 
of the control, HIV-1 and HIV-1-related study groups. 
 
CCR5 was found positively expressed by pDCs and negatively by mDCs. The expression of CCR7, CCR9 
and CXCR6 was found negative on both DC subsets. 
Assessing chemokine marker expression in healthy controls found a significant change in the staining profile 
and MFI in the marker stain compared to the FMO control stain of CCR5 on pDCs confirming positive 
expression of CCR5 by pDCs (Figure 4.5 B1-B2). The expression profile of CCR5 on mDCs (Figure 4.5 C1-
2) as well as CCR7 (Figure 4.4), CCR9 (Figure 4.6) and CXCR6 (Figure 4.8) on both DC subsets matched 
the profile of corresponding FMO stain/internal control and indicated negative expression of these markers.  
 
ARV therapy reduced the frequency of CCR5+pDC subsets 
HIV-1 infection did not induce a change in the distribution of CCR5+pDCs as the median percentage 
CCR5+pDCs was similar between the control and ARV-HIV-1 study group. Notably, comparing the median 
percentage CCR5+pDCs of both these study groups to the ARV+HIV-1 study group a significantly lower 
median percentage of CCR5+pDCs was observed (Figure 4.24). The decline in CCR5+pDC distribution to 
levels below that of the control study group may indicate an inhibitory role induced by ARV therapy. This may 
lead to suboptimal responses to the CCR5 ligands and reduced migration to secondary lymphoid tissue and 
subsequent activation of the adaptive immune responses. Notably, the number of flow cytometry acquired 
events was extremely low in the HIV-1/TB study group and adequately analyses could not be performed, 
hence, this data point was removed from CCR5 statistical analyses. 
 
HIV-1 infection incurred no change in the expression profile of the negatively expressed chemokine markers 
HIV-1 and HIV-1/TB infection did not influence CCR9 and CXCR6 marker expression on blood DCs as the 
expression profile between the control, HIV-1 and HIV-1-related study groups was similar (data not shown). 
In regard to these findings, the study could not provide conclusive evidence that declining DC numbers are 
the result of enhanced export from blood in response to inflammatory signaling generated at 
infected/inflamed sites in the GIT and/or lungs. Possibly, the choice of markers was not sufficient for the 
purpose intended, hence, the study proposed to investigate a broader range of chemokine markers involved 
in directing migration to these sites during the relevant infection. However, in view of observing no changes 
in expression of these migratory marker expression on blood DCs when examined in conditions known for 
intestinal and pulmonary infection, it was proposed that phenotypic changes during localised infection is 
maybe restricted to tissue-specific DCs. Furthermore, it was theorised that the blood DCs that have left 
circulation to perform a homeostatic function in tissue are more prone to anticipated phenotypic changes 
upon exposure to the milieu of the specific tissue compartment. This theory was based on findings from a 
study conducted by Mann ER, et al. (2012) who showed the differentiation of blood DCs into a gut-specific 
phenotype with homeostatic function upon in vitro exposure to supernatant collected from colonic biopsies.  
 
Analysis of CCR7 (lymphoid homing marker) expression on DCs was complex due to inconsistent marker 
expression. The staining profile observed during analyses was in certain cases different to but in majority of 
cases similar to that of the FMO stain/internal control (Data not shown).  Possibly, this may be related to 
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donor specificity, however, the majority of cases showed no expression of CCR7. Notably, a study by 
Patterson S, et al. (2005) showed no expression of CCR7 in freshly isolated blood DCs while observing 
upregulated expression only in pDCs after a 2 day culture with GM-CSF and IL-4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 24: CCR5+pDC subset distribution of the control, HIV-1 and HIV-1 related study groups 
Peripheral whole blood was stained with mAbs to detect the percentage pDCs and mDCs expressing CCR5 
using multi-parameter flow cytometry. The box and whiskers plot graphically represents the frequency 
distribution of the percentage CCR5+pDCs of the control, HIV-1 and HIV-1-related study groups. Each 
boxplot shows the 10-90 percentile range of data (whiskers) and horizontal line the median value. Outliers 
are represented by an enclosed circle. Horizontal lines with diamond arrows indicate the specific study group 
comparison of interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method 
used to indicate the level of statistical significance. *Note: an insufficient number of events were obtained 
from samples of the HIV-1/TB study group, hence, adequate statistical analysis could not be performed and 
a graph excluding the boxplot for this study group was generated. 
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4.5  Conclusion 
In this study, it was proposed that declining numbers of pDCs and mDCs might be the net result of persistent 
exposure and/or response to the milieu of harmful viral elements, excessive host inflammatory agents and/or 
gut “leaking” elements in circulation during HIV-1 infection. In view of this, escalating frequencies in cellular 
mechanisms such as apoptosis, activation and cell mobilisation (either due to increased antigen capture for 
presentation in the lymph nodes and/or chemotactic movement in response to inflammatory signals 
generated at sites of infection) were proposed as three possible scenarios that could explain the decline of 
pDCs and mDCs from peripheral blood during HIV-1 infection. Accordingly, the present study examined the 
residual pool of blood pDCs and mDCs of chronically HIV-1 and HIV-1/TB co-infected as well as ARV treated 
patients for ex vivo surface expressed markers related to apoptosis, migration and activation. It was 
proposed that the effect of chronic exposure to the HIV-1 induced milieu in circulation would be mirrored by a 
change in the expression of these markers and possibly indicates their role in DC number loss. In summary 
the following was found 
1) Negative marker expression in the control study group with no significant change when compared to HIV-
1 and HIV-1-related study groups, these included 
a) the migratory markers CCR5 on mDCs, CCR9 and CXCR6 on both DC subsets,  
b) the apoptotic markers TRAIL R1 – R4 and FASL on both DC subsets and FAS on pDCs 
c) the activation markers CD80 and CD83 on both DC subsets, and CD86 on pDCs 
 
2) Positive expression of markers in the control study group with no significant change when compared to 
the HIV-1 and HIV-1 related study groups, these included 
  a) the activation marker CD62L on both DC subsets 
  b) the apoptotic marker FAS on mDCs 
 It was suggested that future studies also investigate MFI data of positively expressed marker to evaluate 
marker density changes during HIV-1 infection. 
   
3) Positive expression of markers in the control study group showing a significant change when compared to 
the HIV-1 and HIV-1 related study groups. 
  a) the activation marker CD86 on mDCs 
 b) the migratory marker CCR5 on pDCs 
c) the apoptotic marker, TNF-R2 on pDCs and mDCs.  
 
In view of the substantiated reports on viral elements and upregulated host factors in circulation during HIV-1 
infection, the stable CD62L and FAS expression was interesting. Possibly, this signifies that DCs are 
conditioned not to respond to antigen while in peripheral circulation (possibly an inherent preventative 
process of precursor DCs in blood). It was proposed that DC phenotype change or differentiation may be 1) 
significant of antigen encountered DCs in lymphatic circulation or 2) restricted to tissue-resident DCs. 
Furthermore, the study contemplated the significance of positive FAS and CD62L marker expression. It was 
proposed this to 1) imply the marker as phenotypically positive but on a functional level, temporarily 
“dormant” and 2) defined as a preset “time saving” mode that, in the event of cellular activation, not much 
time is wasted on pre-events such as gene regulation when prompt response to antigen is required.   
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It was further proposed that persistent exposure to the HIV-1 induced milieu in circulation, in addition to 
playing a part in the decline of DCs from peripheral blood, may induce exhaustion of DCs and in turn affect 
their function. Hence, the third part of the study aimed at investigating the functional abilities of the current 
blood DC pool in circulation of HIV-1 infected patients upon pathogenic in vitro stimulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 114 
 
4.6 References 
 
Books 
 
Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunoloy. 7th ed. USA: Elsevier Saunders. 2012. 
p158. 
 
Journals 
Agostini, C., Cabrelle, A., Calabrese, F., Bortoli, M., Scquizzato, E., Carraro, S., Miorin, M., Beghè, B., 
Trentin, L., Zambello, R., et al. (2005). Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell 
alveolitis in sarcoidosis. Am. J. Respir. Crit. Care Med. 172, 1290–1298. 
Ajuebor, M.N., Hogaboam, C.M., Kunkel, S.L., Proudfoot, A. E. and Wallace, J.L. (2001). The chemokine 
RANTES is a crucial mediator of the progression from acute to chronic colitis in the Rat. J. Immunol. 166, 
552–558. 
Arican, O., Aral, M., Sasmaz, S., and Ciragil, P. (2005). Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, 
IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators 
Inflamm. 5, 273–279. 
Arrieta, M.C., Madsen, K., Doyle, J., and Meddings, J. (2009). Reducing small intestinal permeability 
attenuates colitis in the IL10 gene-deficient mouse. Gut 58, 41–48. 
Baumgarth, N., and Roederer, M. (2000). A practical approach to multicolor flow cytometry for 
immunophenotyping. J. Immunol. Methods 243, 77–97. 
Benlahrech, A., Yasmin, A., Westrop, S.J., Coleman, A., Herasimtschuk, A., Page, E., Kelleher, P., Gotch, 
F., Imami, N., and Patterson, S. (2012). Dysregulated immunophenotypic attributes of plasmacytoid but not 
myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy. 
Clin. Exp. Imunol. 170, 212–221. 
Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., 
Cavalli, A., Missale, G., et al. (2007). Characterization of Hepatitis B virus (HBV)-specific T-cell dysfunction in 
chronic HBV infection. J. Virol. 81, 4215–4225. 
Breen, E.C. (2002). Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and 
acquired immunodeficiency syndrome. Pharmacol. Ther. 95, 295–304. 
Brenchley, J.M., Price, D.A., and Douek, D.C. (2006a). HIV disease: fallout from a mucosal catastrophe? 
Nat. Immunol. 7, 235–239. 
Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., 
Lambotte, O., Altmann, D., et al. (2006b). Microbial translocation is a cause of systemic immune activation in 
chronic HIV infection. Nat. Med. 12, 1365–1371. 
Brockman, M. a, Kwon, D.S., Tighe, D.P., Pavlik, D.F., Rosato, P.C., Sela, J., Porichis, F., Le Gall, S., 
Waring, M.T., Moss, K., et al. (2009). IL-10 is up-regulated in multiple cell types during viremic HIV infection 
and reversibly inhibits virus-specific T cells. Blood 114, 346–356. 
Brown, K.N., Trichel, A., and Barratt-Boyes, S.M. (2007). Parallel loss of myeloid and plasmacytoid dendritic 
cells from blood and lymphoid tissue in simian AIDS. J. Immunol. 6958–6967. 
Cantin, R., Méthot, S., and Tremblay, M.J. (2005). Plunder and Stowaways: Incorporation of cellular proteins 
by enveloped viruses. J. Virol. 79, 6577–6587. 
Stellenbosch University  https://scholar.sun.ac.za
 115 
 
Chang, W.L.W., Baumgarth, N., Meghan, K., Lee, C.Y.D., Baron, C.A., Gregg, J.P., and Barry, P.A. (2007). 
Exposure of myeloid dendritic cells to exogenous or endogenous IL-10 during maturation determines their 
longevity. J. Immunol. 178, 7794–7804. 
Chen, Y., Hwang, S., Chan, V., Chung, N., Wang, S., Li, Z., Ma, J., CW, L., Hsieh, Y., Chang, K., et al. 
(2013). Binding of HIV-1 gp120 to DC-SIGN promotes ASK-1-dependent activation-induced apoptosis of 
human dendritic cells. PLoS Pathog. 9, 1–17. 
Damås, J.K., Landrø, L., Fevang, B., Heggelund, L., Frølanda, S., and Aukrusta, P. (2009). Enhanced levels 
of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and 
response to highly active antiretroviral therapy. AIDS 23, 135–138. 
Das, S.N., Khare, P., Singh, M.K., and Sharma, S.C. (2011). Fas receptor (CD95) & Fas ligand (CD 178) 
expression in patients with tobacco-related intraoral squamous cell carcinoma. Indian J. Med. Res. 134, 54–
60. 
Davalos-Misslitz, A.C.M., Rieckenberg, J., Willenzon, S., Worbs, T., Kremmer, E., Bernhardt, G., and 
Förster, R. (2007). Generalized multi-organ autoimmunity in CCR7-deficient mice. Eur. J. Immunol. 37, 613–
622. 
De, S.K., Devadas, K., and Notkins, A.L. (2002). Elevated levels of Tumor Necrosis Factor Alpha (TNF- 
alpha) in Human Immunodeficiency Virus type 1-transgenic mice: prevention of death by antibody to TNF-
alpha. J. Virol. 76, 11710–11714. 
Degli-Esposti, M.A., Smolak, P.J., Walczak, H., Waugh, J., Huang, C.-P., Dubose, R.F., Goodwin, R.G., and 
Smith, C.A. (1997a). Cloning and characterization of TRAIL-R3, a Novel Member of the emerging TRAIL 
Receptor family. J. Exp. Med. 186, 1165–1170. 
Degli-Esposti, M.A., Dougall, W.C., Smolak, P.J., Waugh, J.Y., Smith, C.A., and Goodwin, R.G. (1997b). The 
novel receptor TRAIL-R4 induces NF-kappa B and protects against TRAIL-mediated apoptosis, yet retains 
an incomplete death domain. Immunity 7, 813–820. 
de Milito, A., Hejdeman, B.O., Albert, J., Aleman, S.O.O., Sönnerborg, A., Zazzi, M., and Chiodi, F. (2000). 
High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalised during highly active 
antiretroviral therapy. AIDS Res. Hum. Retroviruses 16, 1379–1384. 
de Vries, E.G.E., Gietema, J.A., and de Jong, S. (2006). Tumor necrosis factor-related apoptosis-inducing 
ligand pathway and its therapeutic implications. Clin. Cancer Res. 12, 2390–2393. 
Dickie, P., Felser, J., Eckhaus, M., Bryant, J., Silver, J., Marinos, N., and Notkins, A.L. (1991). HIV-
associated nephropathy intransgenic mice expressing HIV-1 genes. Virology 185, 109–119. 
Dillon, S.M., Robertson, K.B., Pan, S.C., Mawhinney, S., Meditz, A.L., Folkvord, J.M., Connick, E., McCarter, 
M.D., and Wilson, C.C. (2008). Plasmacytoid and myeloid dendritic cells with a partial activation phenotype 
accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J. Acquir. Immune Defic. Syndr. 
48, 1–12. 
Dillon, S.M., Friedlander, L.J., Rogers, L.M., Meditz, A.L., Folkvord, J.M., Connick, E., McCarter, M.D., and 
Wilson, C.C. (2011). Blood myeloid dendritic cells from HIV-1-infected individuals display a proapoptotic 
profile characterized by decreased Bcl-2 levels and by caspase-3+ frequencies that are associated with 
levels of plasma viremia and T cell activation in an exploratory st. J. Virol. 85, 397–409. 
Dunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P.T., Lampertico, P., Das, A., Lopes, A.R., 
Borrow, P., Williams, K., et al. (2007). Cytokines induced during chronic hepatitis B virus infection promote a 
pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667–680. 
Eppert, B.L., Motz, G.T., Wortham, B.W., Flury, J.L., and Borchers, M.T. (2010). CCR7 deficiency leads to 
leukocyte activation and increased clearance in response to pulmonary Pseudomonas aeruginosa infection. 
Infect. Immun. 78, 2099–2107. 
Stellenbosch University  https://scholar.sun.ac.za
 116 
 
Falschlehner, C., Emmerich, C.H., Gerlach, B., and Walczak, H. (2007). TRAIL signalling: Decisions 
between life and death. Int. J. Biochem. Cell Biol. 39, 1462–1475. 
Fang, L., Sun, L., Hu, F., and Chen, Q. (2013). Effects of FasL Expression in oral squamous cell cancer. 
Asian Pacific J. Cancer Prev. 14, 281–285. 
Faustman, D.L., and Davis, M. (2013). TNF Receptor 2 and disease: autoimmunity and regenerative 
medicine. Front. Immunol. 4, 1–8. 
Ferguson, T.A., and Griffith, T.S. (2006). A vision of cell death: Fas ligand and immune privilege 10 years 
later. Immunol. Rev. 213, 228–238. 
Forman, M.A., and Gupta, R.K. (2007). Tandem dyes for flow cytometry: can we overcome quality concerns? 
MLO. Med. Lab. Obs. 24, 26. 
Gasper-Smith, N., Crossman, D.M., Whitesides, J.F., Mensali, N., Ottinger, J.S., Plonk, S.G., Moody, M.A., 
Ferrari, G., Weinhold, K.J., Miller, S.E., et al. (2008). Induction of plasma (TRAIL), TNFR-2, Fas ligand, and 
plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-
1 vaccine design. J. Virol. 82, 7700–7710. 
Gelderblom HR, Reupke, H., and Pauli, G. (1985). Loss of envelope antigens if HTLV-III/LAV, a factor in 
AIDS pathogenesis. The Lancet. 1016–1017. 
Gimsa, U., Mitchison, N.A., and Brunner-weinzierl, M.C. (2013). Immune privilege as an intrinsic CNS 
property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm. 2013, 
1–11. 
Gomes-Santos, A.C., Moreira, T.G., Castro-Junior, A.B., Horta, B.C., Lemos, L., Cruz, D.N., Guimarães, 
M.A.F., Cara, D.C., McCafferty, D.-M., and Faria, A.M.C. (2011). New insights into the immunological 
changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin. Dev. 
Immunol. 2012, 1–13. 
Green, D.S., Center, D., and Cruikshank, W.W. (2009). Human immunodeficiency virus type 1 gp120 
reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy. J. Virol. 83, 5765–
5772. 
Gregory, M.S., Repp, A.C., Holhbaum, A.M., Saff, R.R., Marshak-Rothstein, A., and Ksander, B.R. (2002). 
Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 169, 
2727–2735. 
Gregory, M.S., Hackett, C.G., Abernathy, E.F., Lee, K.S., Saff, R.R., Hohlbaum, A.M., Moody, K.-S.L., 
Hobson, M.W., Jones, A., Kolovou, P., et al. (2011). Opposing roles for membrane bound and soluble Fas 
ligand in glaucoma-associated retinal ganglion cell death. PLoS One 6, 1–13. 
Guadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., Mcneil, A., and Dandekar, S. (2003). 
Severe CD4 + T-cell depletion in gut lymphoid tissue during primary Human Immunodeficiency Virus type 1 
infection and substantial delay in restoration following Highly Active Antiretroviral Therapy. J. Virol. 77, 
11708–11717. 
Hartigan, A.J., Westwick, J., Jarai, G., and Hogaboam, C.M. (2009). CCR7 deficiency on dendritic cells 
enhances fungal clearance in a murine model of pulmonary invasive aspergillosis. J. Immunol. 183, 5171–
5179. 
Herbeuval, J.-P., Boasso, A., Grivel, J.-C., Hardy, A.W., Anderson, S.A., Dolan, M.J., Chougnet, C., Lifson, 
J.D., and Shearer, G.M. (2005). TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients 
and its in vitro production by antigen-presenting cells. Blood 105, 2458–2464. 
Stellenbosch University  https://scholar.sun.ac.za
 117 
 
Herzenberg, L.A., Tung, J., Moore, W.A., Herzenberg, L.A., and Parks, D.R. (2006). Interpreting flow 
cytometry data: a guide for the perplexed. Nat. Immunol. 7, 681–685. 
Holland, P.M. (2014). Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine 
Growth Factor Rev. 25, 185–193. 
Hosaka, N., Oyaizu, N., Kaplan, M.H., Yagita, H., and Pahwa, S. (1998). Membrane and soluble forms of 
Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from Human 
Immunodeficiency Virus – infected persons. J. Infect. Dis. 178, 1030–1039. 
Huang, K.-J., Su, I.-J., Theron, M., Wu, Y.-C., Lai, S.-K., Liu, C.-C., and Lei, H.-Y. (2005). An interferon-
gamma-related cytokine storm in SARS patients. J. Med. Virol. 75, 185–194. 
Hulspas, R., O’Gorman, M.R.G., Wood, B.L., Gratama, J.W., and Sutherland, D.R. (2009). Considerations 
for the control of background fluorescence in clinical flow cytometry. Cytom. Part B Clin. Cytom. 76B, 355–
364. 
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., 
Kücherer, C., Blau, O., et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell 
transplantaion. N. Engl. J. Med. 360, 692–698. 
Ikomey, G.M., Okomo-Assoumou, M.-C., Atashili, J., Mesembe, M.T., Mukwele, B., Lyonga, E., Eyoh, A., 
and Ndumbe, P.M. (2012). Plasma concentrations of soluble Fas receptors (Fas) and Fas ligands (FasL) in 
relation to CD4+ cell counts in HIV-1 positive and negative patients in Yaounde, Cameroon. BMC Res. Notes 
5, 322. 
Ivetic, A., and Ridley, A.J. (2004). The telling tail of L-selectin. Biochem. Soc. Trans. 32, 1118–1121. 
Jackson, L.A., Drevets, D.A., Dong, Z., Greenfield, R.A., and Murphy, J.W. (2005). Levels of L-selectin ( 
CD62L) on human leukocytes in disseminated Cryptococcosis with and without associated HIV-1 infection. J. 
Infect. Dis. 191, 1361–1367. 
Junt, T., Scandella, E., Förster, R., Krautwald, S., Lipp, M., Hengartner, H., Ludewig, B., Fo, R., and Krebs, 
P. (2004). Impact of CCR7 on priming and distribution of antiviral effector and memory CTL. J. Immunol. 173, 
6684–6693. 
Kahnert, A., Höpken, U.E., Stein, M., Bandermann, S., Lipp, M., and Kaufmann, S.H.E. (2007). 
Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J. Infect. Dis. 195, 46–
54. 
Kaur, S., White, S., and Bartold, P.M. (2013). Periodontal disease and rheumatoid arthritis: a systematic 
review. J. Dent. Res. 92, 399–408. 
Keating, S.M., Golub, E.T., Nowicki, M., Young, M., Anastos, K., Crystal, H., Cohen, M.H., Zhang, J., 
Greenblatt, R.M., Desai, S., et al. (2011). The effect of HIV infection and HAART on inflammatory biomarkers 
in a population-based cohort of women. AIDS 25, 1823–1832. 
Kennedy, R.J., Hoper, M., Deodhar, K., Erwin, P.J., Kirk, S.J., and Gardiner, K.R. (2000). Interleukin 10-
deficient colitis: new similarities to human inflammatory bowel disease. Br. J. Surg. 87, 1346–1351. 
Klinger, A., Gebert, A., Bieber, K., Kalies, K., Ager, A., Bell, E.B., and Westermann, J. (2009). Cyclical 
expression of L-selectin (CD62L) by recirculating T cells. Int. Immunol. 21, 443–455. 
Kocks, J.R., Adler, H., Danzer, H., K, H., Jonigk, D., Lehmann, U., and Förster, F. (2009). Chemokine 
receptor CCR7 contributes to a rapid and efficient clearance of lytic murine -herpes virus 68 from the lung, 
whereas bronchus-associated lymphoid tissue harbors virus during latency. J. Immunol. 182, 6861–6869. 
Stellenbosch University  https://scholar.sun.ac.za
 118 
 
Kopp, J.B., Rooney, J.F., Wohlenberg, C., Dorfman, N., Marinos, N.J., Bryant, J.L., Katz, S.I., Notkins, A.L., 
and Klotman, P.E. (1993). Cutaneous disorders and viral gene expression in HIV-1 transgenic mice. AIDS 
Res. Hum. Retroviruses 9, 267–275. 
Kourtis, A.P., Nesheim, S.R., Thea, D., Ibegbu, C., Nahmias, A.J., and Lee, F.K. (2000). Correlation of virus 
load and soluble L-selectin , a marker of immune activation , in pediatric HIV-1 infection. AIDS 14, 2429–
2436. 
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., and Müller, W. (1993). Interleukin-10-deficient mice develop 
chronic enterocolitis. Cell 75, 263–274. 
Leverkus, M., Walczak, H., Mclellan, A., Fries, H.-W., Terbeck, G., Bröcker, E.-B., and Kämpgen, E. (2000). 
Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-
regulation of death ligand – mediated apoptosis. Am. Soc. Hematol. 96, 2628–2632. 
Liu, J.H., Wei, S., Lamy, T., Li, Y., PK, E.-B., Djeu, J.Y., Thomas, P., and Loughran, J. (2002). Blockade of 
Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 100, 1449–1453. 
Liu, P., Overman, R.G., Yates, N.L., Alam, S.M., Vandergrift, N., Chen, Y., Graw, F., Freel, S.A., Kappes, 
J.C., Ochsenbauer, C., et al. (2011). Dynamic antibody specificities and virion concentrations in circulating 
immune complexes in acute to chronic HIV-1 infection. J. Virol. 85, 11196–11207. 
Liu, Z., Zhang, P., Ma, Y., Chen, H., Zhou, Y., Zhang, M., Chu, Z., and Qin, H. (2011). Lactobacillus 
plantarum prevents prevents the development of colitis in IL-10-deficient mouse by reducing the intestinal 
permeability. Mol. Biol. Rep. 38, 1353–1361. 
Ludewig, B., Graf, D., Gelderblom, H.R., Becker, Y., Kroczek, R.A., and Pauli, G. (1995). Spontaneous 
apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-, but strongly enhanced 
by interleukin-10.pdf. Eur. J. Immunol. 25, 1943–1950. 
Madsen, K.L., Malfair, D., Gray, D., Doyle, J.S., Jewell, L.D., and Fedorak, R.N. (1999). Interleukin - 10 
gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. 
Inflamm. Bowel Dis. 5, 262–270. 
Maecker, H.T., Frey, T., Nomura, L.E., and Trotter, J. (2004). Selecting fluorochrome conjugates for 
maximum sensitivity. Cytom. Part A 62A, 169–173. 
Malaponte, G., Bevelacqua, V., Li Volti, G., Petrina, M., Nicotra, G., Sapuppo, V., Li Volti, S., Travali, S., and 
Mazzarino, M.C. (2004). Soluble adhesion molecules and cytokines in children affected by recurrent 
infections of the upper respiratory tract. Pediatr. Res. 55, 666–673. 
Mandl, J.N., Barry, A.P., Vanderford, T.H., Kozyr, N., Chavan, R., Klucking, S., Barrat, F.J., Coffman, R.L., 
Staprans, S.I., and Feinberg, M.B. (2008). Divergent TLR7 and TLR9 signaling and type I interferon 
production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14, 1077–1087. 
Mann, E.R., Bernardo, D., Al-Hassi, H.O., English, N.R., Clark, S.K., McCarthy, N.E., Milestone, A.N., 
Cochrane, S.A., Hart, A.L., Stagg, A.J., et al. (2012). Human gut-specific homeostatic dendritic cells are 
generated from blood precursors by the gut microenvironment. Inflamm. Bowel Dis. 18, 1275–1286. 
Matloubian, M., Lo, C.G., Cinamon, G., Lesneski, M., Xu, Y., Brinkmann, V., Allende, M., Proia, R., and JG, 
C. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. 
Nature 427, 355–360. 
Mavigner, M., Cazabat, M., Dubois, M., L’Faqihi, F., Requena, M., Pasquier, C., Klopp, P., Amar, J., Alric, L., 
Barange, K., et al. (2012). Altered CD4 + T cell homing to the gut impairs mucosal immune reconstitution in 
treated HIV-infected individuals. J. Clin. Invest. 122, 62–69. 
Stellenbosch University  https://scholar.sun.ac.za
 119 
 
Monsalvo, A.C., Batalle, J.P., Lopez, M.F., Krause, J.C., Klemenc, J., Hernandez, J.Z., Maskin, B., Bugna, 
J., Rubinstein, C., Aguilar, L., et al. (2011). Severe pandemic 2009 H1N1 influenza disease due to 
pathogenic immune complexes. Nat. Med. 17, 195–199. 
Montes de Oca Arjona, M., Pérez Cano, R., Orozco, M.J., Martín Aspas, A., Guerrero, F., Fernández 
Gutiérrez Del Álamo, C., and Girón-González, J.A. (2005). Absence of favourable changes in circulating 
levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption 
treatment of chronic human immunodeficiency virus infection. Clin Microbiol Infect 11, 57–62. 
Morgan, A.J., Guillen, C., Symon, F.A., Huynh, T.T., Berry, M.A., Entwisle, J.J., Briskinz, M., Pavord, I.D., 
and Wardlaw, A.J. (2005). Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. 
Clin. Exp. Allergy 35, 1572–1580. 
Muller, W.A. (2013). Getting Leucocytes to the sites of inflammation. Vet. Pathol. 50, 7–22. 
Nishimura, M., Kuboi, Y., Muramoto, K., Kawano, T., and Imai, T. (2009). Chemokines as novel therapeutic 
targets for inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1173, 350–356. 
O’ Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, 
Smyth MJ, Bouillet P, Robb L, S.A. (2009). Membrane-bound Fas ligand only is essential for Fas-induced 
apoptosis. J. Exp. Med. 461, 659–665. 
Orsilles, M.A., Pieri, E., Cooke, P., and Caula, C. (2006). IL-2 and IL-10 serum levels in HIV-1-infected 
patients with or without active antiretroviral therapy. Acta Pathol. Microbiol. Immunol. Scand. 114, 55–60. 
Ozbalkan, Z., Efe, C., Cesur, M., Ertek, S., Nasiroglu, N., Berneis, K., and Rizzo, M. (2010). An update on 
the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 212, 377–382. 
Pan, G., O’ Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R., Ni, J., and Dixit, V.M. (1997). The receptor 
for the cytotoxic ligand TRAIL. Science 276, 111–113. 
Papadakis, K.A., Prehn, J., Nelson, V., Cheng, L., Binder, S.W., Ponath, P.D., Andrew, D.P., and Targan, 
S.R. (2000). The role of Thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the 
regional specialization of the mucosal immune system. J. Immunol. 165, 5069–5076. 
Patterson, S., Donaghy, H., Amjadi, P., Gazzard, B., Gotch, F., and Kelleher, P. (2005). Human BDCA-1-
positive blood Dendritic Cells differentiate into phenotypically distinct immature and mature populations in the 
absence of exogenous maturational stimuli: differentiation failure in HIV infection. J. Immunol. 174, 8200–
8209. 
Pelsers, M.M.A.L., Hermens, W.T., and Glatz, J.F.C. (2005). Fatty acid-binding proteins as plasma markers 
of tissue injury. Clin. Chim. Acta 352, 15–35. 
Peng, P., Yan, Y., and Keng, S. (2011). Exosomes in the ascites of ovarian cancer patients: origin and 
effects on anti-tumor immunity. Oncol. Rep. 25, 749–762. 
Peppa, D., Gill, U.S., Reynolds, G., Easom, N.J.W., Pallett, L.J., Schurich, A., Micco, L., Nebbia, G., Singh, 
H.D., Adams, D.H., et al. (2013). Up-regulation of a death receptor renders antiviral T cells susceptible to NK 
cell-mediated deletion. J. Exp. Med. Med. 210, 99–114. 
Perfetto, S.P., Chattopadhyay, P.K., and Roederer, M. (2004). Seventeen-colour flow cytometry: unravelling 
the immune system. Nat. Rev. Immunol. 4, 648–655. 
Pfeffer, K. (2003). Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine 
Growth Factor Rev. 14, 185–191. 
Pham, T.H.M., Okada, T., Matloubian, M., Lo, C.G., and Jason G, C. (2008). S1P1 receptor signaling 
overrides retention mediated by Gi - coupled receptors to promote T cell egress. Immunity 28, 122–133. 
Stellenbosch University  https://scholar.sun.ac.za
 120 
 
Piddubna, A.I., and Chemych, M.D. (2013). IL-4, IL-10, TNF- profile and immunological changes in North-
Eastern Ukrainian HIV-infected individuals. HIV AIDS Rev. 12, 68–72. 
Raffler, N.A., Rivera-Nieves, J., and Ley, K. (2005). L-selectin in inflammation, infection and immunity. Drug 
Discov. Today Ther. Strateg. 2, 213–220. 
Raport, C.J., Gosling, J., Schweickart, V.L., Gray, P.W., and Charo, I.F. (1996). Molecular cloning and 
functional characterization of a novel human CC chemokine receptor ( CCR5 ) for RANTES , MIP-1  , and 
MIP-1. J. Biol. Chem. 271, 17161–17166. 
Rehermann, B. (2009). Hepatitis C virus versus innate and adaptive immune responses: a tale of 
coevolution and coexistence. J. Clin. Invest. 119, 1745–1754. 
Reimold, A.M. (2003). New indications for treatment of chronic inflammation by TNF-alpha blockade. Am. J. 
Med. Sci. 325, 75–92. 
Rosen, S.D. (2004). Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 22, 
129–156. 
Rychert, J., Strick, D., Bazner, S., Robinson, J., and Rosenberg, E. (2010). Detection of HIV gp120 in 
plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory 
cytokines. AIDS Res. Hum. Retroviruses 26, 1139–1145. 
Sehgal, M., Zeremski, M., Talal, A.H., Khan, Z.K., Capocasale, R., Philip, R., and Jain, P. (2014). Host 
genetic factors and dendritic cell responses associated with the outcome of interferon/ribavirin treatment in 
HIV-1/HCV co-infected individuals. Clin. Cell. Immunol. 5, 1–12. 
Sprick, M.R., Weigand, M.A., Rieser, E., Rauch, C.T., Juo, P., Blenis, J., Krammer, P.H., and Walczak, H. 
(2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for 
apoptosis mediated by TRAIL receptor 2. Immunity 12, 599–609. 
Stenqvist, A.C., Nagaeva, O., Baranov, V., and Mincheva-Nilsson, L. (2013). Exosomes secreted by human 
placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, 
suggesting exosome-mediated immune privilege of the fetus. J. Immunol. 191, 5515–5523. 
Stenstad, H., Ericsson, A., Johansson-Lindbom, B., Svensson, M., Marsal, J., Mack, M., Picarella, D., Soler, 
D., Marquez, G., Briskin, M., et al. (2006). Gut-associated lymphoid tissue – primed CD4 + T cells display 
CCR9-dependent and -independent homing to the small intestine. Blood 107, 3447–3454. 
Strober, W., Zhang, F., Kitani, A., Fuss, I., and Fichtner-Feigl, S. (2010). Pro-inflammatory cytokines 
underlying the inflammation of Crohn’s Disease. Curr. Opin. Gastroenterol. 26, 310–317. 
Su, D.-L., Lu, Z.-M., Shen, M.-N., Li, X., and Sun, L.-Y. (2012). Roles of pro- and anti-inflammatory cytokines 
in the pathogenesis of SLE. J. Biomed. Biotechnol. 2012, 1–15. 
Suda, T., Hashimoto, H., Tanaka, M., Takahiro, O., and Shigekazu, N. (1997). Membrane Fas Ligand kills 
human peripheral blood T lymphocytes, and soluble Fas Ligand blocks the killing. J. E 186, 2045–2050. 
Sun, Y., Jin, C., Zhan, F., Wang, X., Liang, M., Zhang, Q., Ding, S., Guan, X., Huo, X., Li, C., et al. (2012). 
Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. J. 
Infect. Dis. 206, 1085–1094. 
Thibault, S., Tardif, M.R., Gilbert, C., and Tremblay, M.J. (2007). Virus-associated host CD62L increases 
attachment of human immunodeficiency virus type 1 to endothelial cells and enhances trans infection of 
CD4+ T lymphocytes. J. Gen. Vrology 88, 2568–2573. 
Stellenbosch University  https://scholar.sun.ac.za
 121 
 
Walczak, H., Degli-Esposti, M.A., Johnson, R.S., Smolak, P.J., Waugh, J.Y., Boiani, N., Timour, M.S., 
Gerhart, M.J., Schooley, K.A., Smith, C.A., et al. (1997). TRAIL-R2: a novel apoptosis-mediating receptor for 
TRAIL. EMBO J. 16, 5386–5397. 
Walker, N.F., Meintjes, G., and Wilkinson, R.J. (2013). HIV-1 and the immune response to TB. 8, 57–80. 
Wauquier, N., Becquart, P., Padilla, C., Baize, S., and Leroy, E.M. (2010). Human fatal Zaire Ebola virus 
infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. 
Trop. Dis. 4, 1–10. 
Wendland, M., Czeloth, N., Mach, N., Malissen, B., Kremmer, E., Pabst, O., and Forster, R. (2007). CCR9 is 
a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc. Natl. Acad. Sci. U. S. A. 104, 
6347–6352. 
Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., 
Rauch, C., Smith, C.A., et al. (1995). Identification and characterization of a new member of the TNF family 
that induces apoptosis. Immunity 3, 673–682. 
Winter, S., Rehm, A., Wichner, K., Scheel, T., Batra, A., Siegmund, B., Berek, C., Lipp, M., and Höpken, U.E. 
(2011). Manifestation of spontaneous and early autoimmune gastritis in CCR7-deficient mice. Am. J. Pathol. 
179, 754–765. 
Yang, S., Liu, F., Wang, Q.J., Rosenberg, S.A., and Morgan, R.A. (2011). The shedding of CD62L (L-
selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 6, 1–10. 
Ye, P., Kazanjian, P., Kunkel, S.L., and Kirschner, D.E. (2004). Lack of good correlation of serum CC-
chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J. Lab. 
Clin. Med. 143, 310–319. 
Yonkers, N.L., Rodriguez, B., Asaad, R., Lederman, M.M., and Anthony, D.D. (2011). Systemic immune 
activation in HIV infection is associated with decreased MDC responsiveness to TLR ligand and inability to 
activate naive CD4 T-cells. PLoS One 6, 1–10. 
Zhang, X.D., Nguyen, T., Thomas, W.D., Sanders, J.E., and Hersey, P. (2000). Mechanisms of resistance of 
normal cells to TRAIL induced apoptosis vary between different cell types. Fed. Eur. Biochem. Soc. Lett. 
482, 193–199. 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 122 
 
Chapter 5 
 
Response of peripheral blood pDCs and mDCs of HIV-1 infected individuals to Toll-like receptors 
(TLR) stimulation and immunemodulation. 
 
5.1 Introduction 
HIV infection is associated with an increased risk for the development of opportunistic infections which may 
be indicative of reduced level of protection upon exposure to other viral or bacterial pathogens. Several study 
groups have reported on the altered function of DCs from HIV-1 infected individuals (as reviewed by Miller E 
and Bhardwaj N, 2013). In particular, Donaghy H and colleagues (2003) observed reduced proliferation of T 
lymphocytes from uninfected individuals when stimulated with allogeneic DCs from HIV-1 infected compared 
to DCs from uninfected individuals in a MLR assay. Also, altered cytokine production has been described, in 
particular, modification of IFN- production has been extensively recorded. Notably, the changes associated 
with this cytokine during HIV-1 infection are perplexing. In parallel to the observed elevation in serum IFN- 
during HIV-1 infection are reports on the significant reduction (from the blood) in the numbers of the cells that 
primarily produces this cytokine, namely pDCs. In better understanding this paradox, Lehman et al. (2008) 
investigated the relationship between pDC numbers and IFN- mRNA levels in lymphoid tissue. The study 
proposed that a high serum IFN- level may be the result of elevated IFN- mRNA expression in lymphoid 
tissues, which in turn may be related to an influx of pDCs in the lymph nodes as a response to HIV-1 
infection. However, the authors found the lymphoid compartment to house unchanged pDC numbers during 
HIV-1 infection in various stages of HIV-1 disease progression. Also, unaltered expression of IFN- mRNA 
levels in various lymphoid tissues (cervical, axillary and inguinal lymph nodes and tonsils) was observed. 
Notably, the authors showed that pDCs in peripheral blood of HIV-1 infected individuals exhibited a 100 fold 
higher expression of IFN- mRNA as well as increased intracellular expression of IFN- compared to 
controls. They referred to this finding as an overproduction of IFN-. Accordingly, the current study proposed 
this phenomenon to ultimately result in cellular exhaustion and reduced response when challenged with 
other invading viral/bacterial stimuli. Accordingly, Martinson JA, et al. (2007) observed significantly reduced 
levels of IFN- upon in vitro TLR7 priming of pDCs and peripheral blood mononuclear cells (PBMCs) from 
HIV-1 infected patients. Donhauser N, et al. (2012) also reported on reduced IFN- production upon in vitro 
TLR 9 stimulation of pDCs which seem to directly correlate with CD4 T lymphocyte counts.  
 
Vital to the initiation of normal inflammation in response to invading pathogens is down-regulation of immune 
responses post-infection. However, in HIV-1 infection the immune system is not able to clear the virus (in 
absence of ARV) and with a persistent pool of viral and gut leakage antigens, inflammatory conditions persist 
(one of the driving forces of the disease), which is detrimental to the host. To date research has not been 
able to find a way to fully clear the HIV and available treatment is limited to the chronic use of ARVs to 
control viral replication. Conversely, this form of treatment is associated with various harmful long-term side 
effects and increasing reports of drug resistance. Nonetheless, it remains the only available intervention to 
control HIV-1 replication and provides general alleviation of damage/pressure of HIV-1-associated immune 
activation. Hence, while various strategies to cure HIV-1/AIDS disease are being investigated, in the interim, 
improved ARV treatments and/or development of new interventions are also priority. Accordingly, a sub-
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project to this study focused on investigating the impact of a natural agent (neuropeptide) with reported anti-
inflammatory properties, namely, VIP, on activated mDCs(Delgado M, et al. 2004a). This is also a sub-project 
to a bigger study aiming at investigating alternative or cognate anti-HIV-1 treatment strategies, in particular, 
targeting HIV-1 associated chronic immune activation and inflammatory responses using VIP.  
 
Briefly, VIP is a neuropeptide consisting of 28 amino acids and as reviewed by Harmar AJ, et al. (2012), it 
has been identified to play a role in various diverse compartments of the body e.g. central nervous system, 
immune system and the GIT. Upon engagement with its cognate G-protein coupled receptors, VPAC1 and 
VPAC2, adenylate cyclase is stimulated resulting in the subsequent production of cyclic adenosine 
monophosphate (cAMP) (as reviewed by Dickson L and Finlayson K (2009)). Notably, raised intracellular 
cAMP levels have been linked to suppression of innate immune functions, in particular modulation of 1) 
phagocytic and microbiocidal activity and 2) various inflammatory cytokine expressions (down-regulating 
TNF- and IL-12, while up-regulating IL-10)(Delgado M, et al. 2004b). Also, the inhibitory effect of VIP on 
immune related molecules such as prostaglandin E2 (PGE2), an autocoid hormone (autocrine or paracrine 
but not endocrine acting) that plays a role in inflammation, has been described. Under normal inflammatory 
conditions PGE2 and cyclooxygenase-2 (COX-2) (an isoenzyme which is in involved in the conversion of 
arachidonic acid into precursor PGE2, namely prostaglandin H) are up-regulated. However, Gonzalez-Rey E 
and Delgado M (2008)  showed decreased production of both PGE2 in culture supernatants and COX-2 in 
cell lysates of LPS or LPS/IFN- stimulated microglia, bone-marrow derived DCs and peritoneal 
macrophages (cells isolated from experimental mice) when incubated with VIP. The authors also determined 
that the inhibitory effect is exerted via the interaction of VIP with the cognate VPAC1 receptor. On a 
molecular level the authors were able to link VIP inhibition to the down-regulation of NF-B induced trans-
activation of the COX-2 promoter via decreased binding of p65, a major component of the NF-B 
transcription factor, to the promoter.  
 
Another study demonstrated that VIP regulation of the NF-B transcription factor inhibited the function of 
Langerhans cells (DCs of the epidermis) (Ding W, et al.2007). The study explained that inactive NF-B 
consists of mainly a p50/p65 heterodimer and are bound to the IB inhibitory protein in the cytoplasm of 
unstimulated cells. Upon activation, i.e. cellular response to various stimuli (LPS, pro-inflammatory cytokines, 
etc.), the inhibitory protein is phosphorylated and degraded by IB kinases (IKK). This results in the release 
of the p50/p65 NF-B heterodimers and subsequent translocation to the nucleus where it acts upon binding 
sites on DNA, activating the transcription of various genes. Accordingly, the cytosol of unstimulated cells 
contains a higher ratio of IB to IKK protein with an inverted ratio upon stimulation. However, the authors 
showed that dual incubation of LPS and VIP induced cytosolic IB to IKK ratios similar to that of unstimulated 
Langerhans cells. Also, it was found that VIP plays a role in preventing degradation of the IB protein. 
Moreover, Ding W, et al. (2007), interested in determining the outcome of VIP induced inhibition of NF-B 
function on cytokine production, showed a significant decline in supernatant TNF- of LPS stimulated 
Langerhans cell cultures treated with VIP.  
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Only a few studies have investigated VIP during HIV-1 infection, even less have reported on VIP and blood 
DCs. Fabricius D,et al. (2006) used confocal microscopy to show cell surface expression of both VPAC1 and 
VPAC2 receptors and associated mRNA transcripts in blood pDCs. A crucial observation of this study was 
the significant decline in production of IFN- upon in vitro stimulation of pDCs with cytosine-phosphodiester-
guanine oligodeoxynucleotides (CpG ODN) and treatment with VIP. It was also reported that the level of IFN-
 in the culture supernatant indirectly correlated with increasing dosages of VIP. Furthermore, an increase in 
the expression of CD86 and MHC class II, whilst a down-regulation of the MHC class I was observed in VIP 
treated vs. untreated CpG ODN stimulated pDCs. On a functional level, the authors observed suppressed 
CD4 T lymphocyte proliferation in MLR experiments when incubated with VIP pre-treated pDCs. 
 
In the current study evaluation of DC function and immunemodulation was performed after in vitro TLR 
stimulation of these cells. The responses were evaluated via similar markers related to apoptosis and 
migration that were used in Chapter 4 to profile the phenotype of DC that constitute the residual DC pool 
during HIV-1 infection. Similar to the contemplated readout of the previous chapter the current study 
proposed that aberrant function may reflect as modified marker expression with regard to 1) ex vivo markers 
related to apoptosis and chemotaxis and 2) in vivo cytokine expression when compared to the marker profile 
obtained from an uninfected system. A sub-project of the study aimed to ascertain whether these 
modifications could be dampened or reversed via treatment with the immunemodulatory VIP agent. A brief 
description on the ex vivo and in vivo markers used in the current study to evaluate activated DCs are 
discussed in sections 5.1.1 - 5.1.2. 
 
5.1.1  Investigating ex vivo apoptotic and migration marker expression on whole blood TLR 
stimulated mDCs and pDCs 
This part of the study focused on the ex vivo profiling of TLR activated blood DCs, targeting markers 
associated with apoptosis (TNF-R2, TRAIL-R1 and TRAIL-R2) and migration (CCR5, CCR7, CCR9). These 
markers were also used to profile the DC phenotype in fresh whole blood as described in Chapter 4. Refer to 
the latter chapter for a description on these cell surface markers.  
 
5.1.2 Investigating in vivo cytokine expression in whole blood TLR stimulated mDCs and pDCs 
This part of the study focused on the in vivo profiling of TLR stimulated blood DCs to assess the production 
of IFN- (pDC specific), IL12p40 (mDC specific) and TNF- (produced by both pDCs and mDCs). These 
cytokines are members of the proinflammatory cytokine family. IFN- (type 1 Interferon) is an important 
effector molecule of the immune system and as described by the cofounders, Isaacs A and Lindenmann J 
(1957), is an “abortive product of virus multiplication”. Also, these cells are referred to as professional IFN- 
producing cells due to their superior ability to produce high amounts of IFN- in response to viral infections 
(as reviewed byFitzgerald-Bocarsly P, et al. 2008). In particular, the per cell production of IFN- in pDCs are 
10 times higher compared to monocytes (as reviewed by McKenna K et al. 2005; Fitzgerald-Bocarsly P, 
2002;Cella M, et al. 1999).Molecular analyses have shown that upon TLR7 stimulation of highly purified 
pDCs, IFN--associated genes constitute the majority of genes transcribed and include several subsets of 
this cytokine (IFN-2, -5, -6, -8, -1/13, -10, -14, -16, -17 and -21) as well as IFN- (Birmachu W, 
et al. 2007). TNF- has potent endocrine function and works synergistically with interferons. It is also a 
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multifunctional molecule that plays a role in the induction of cell death and activation and/or co-stimulation. 
As reviewed by Sedger LM and McDermott MF (2014), TNF is a multifunctional molecule that 1) acts 
together with IL-1 in induction of inflammation 2) is a potent inducer of IL-6 and 3) promotes  the 
differentiation of monocytes/macrophages. ILp40 and ILp35 constitute the IL-12 70-kDA heterodimeric 
protein. Specifically, the ILp40 subunit is expressed by DCs, macrophages and microglia. It functions as a 
chemoattractant to macrophages and plays a role in the migration of DCs stimulated by bacterial antigen 
(Cooper AM and Khadar SA, et al. 2006) 
 
Main research focus 
The waning of DCs from peripheral blood during HIV-1 infection most probably adds pressure to the 
remaining DC pool in circulation to provide adequate immune support in the face of other antigen 
encounters. Also, as HIV-1 infection is associated with the development of opportunistic infection, 
invading pathogens may add further tension on the DC compartment. It was proposed that these 
cells have suboptimal functionality which may reflect via changes in signature cytokine production 
and modification of cell surface markers upon activation. If so, and in view of the lack of DC number 
recovery during therapy, it was of further interest to determine the possible role of ARV in function 
recovery.  
 
Main study aim: 
The aim of the current study was to assess the functional capacity of the current pool of blood pDCs 
and mDCs of chronically HIV-1 mono, HIV-1/TB dual infected as well as ARV treated individuals  
 
Study objectives 
- to stimulate DCs in vitro using specific agonists to TLR 4 (expressed on mDCs), TLR 7/8 (expressed 
on both pDCs and mDCs) and TLR 9 (expressed on pDCs)  
- to phenotypically characterise TLR activated DCs via the expression of cell surface markers (similar 
to those used in chapter 4) related to apoptosis (TNF-R2, TRAIL R1 and R2) and homing (CCR5, 
CCR7 and CCR9)  
- to evaluate intracellular production of TNF-, IL12p40 (mDC-specific) and IFN-(2b) (pDC-specific) 
 
Sub-project aim: 
The sub-aim of the study was to examine the impact of the immunemodulatory peptide VIP on in vitro 
activated DCs  
 
Sub project objectives 
- to evaluate the expression of the immunemodulatory receptors VPAC1 and VPAC2 in fresh whole 
blood (cell surface, assayed in Chapter 4) and TLR stimulated whole blood (cell surface and intra-
vesicular) 
- to evaluate the expression of cell surface and intracellular markers in VIP treated vs. untreated TLR 
stimulated DCs.  
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5.2  Outline of the study 
Refer to sections 5.3.1 - 5.3.11 for a detailed description on sample collection and processing 
 SAMPLE COLLECTION  
Patient recruitment, blood collection by venesection at various clinics in the Western Cape, South Africa 
3 Study groups: Control, ARV-HIV-1 and ARV+HIV-1 
 
 
 
                                     WHOLE BLOOD PLASMA 
50µl 48 x ±200µl 1ml 
   
 TLR STIMULATION  
 
6 x neat, 
6 x neat + VIP 
6 x LPS (TLR4 ligand), 
6 x LPS + VIP 
6 x R848 (TLR7/8 ligand), 
6 x R848 + VIP 
6 x CpG ODN (TLR9 ligand), 
6 x CpG ODN + VIP  
   
4-COLOUR FLOW 
CYTOMETRIC 
QUANTIFICATION 
8-COLOUR FLOW CYTOMETRIC PROFILING REAL TIME PCR QUANTIFICATION 
CD4 and CD8  T cells 
 
ASSAY: 
Staining with  BD 
MultiTEST™ mAbs:         
CD3 FITC, CD8 PE, 
CD45 PerCP, CD4 APC 
in BD TruCOUNTTM tube 
TLR stimulated pDCs and mDCs 
 
ASSAY: Staining with DCID and marker specific m Abs as set out in the panels below: 
Viral load 
 
ASSAY:  
ABBOTT Real Time HIV-1 
PCR assay (ABBOTT 
m2000rt)/ 
bioMérieuxNucliSensEasy
Q® HIV-1, v1.2 test 
Cell surface markers Intracellular markers 
Panel 1 Panel 2 Panel 3 Panel 4 Panel 5 
TRAIL-R2,  
TNF-R2 
TRAIL-R1,   
VPAC 1,  
VPAC 2 
CCR 5,   
CCR 7,  
CCR 9,   
TNF-,  
VPAC 1,  
VPAC 2 
IL12p40,  
IFN-(2b)  
 
 
 
 DATA COLLECTED  
CD4 and 8 T cells 
 - count (cells/µl) 
TLR stimulated pDCs and mDCs 
- % pDC/mDCs positively expressing cell surface  and intracellular markers 
Viral load  
- RNA copies/ml 
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5.3 Material and Methods 
 
5.3.1 Study groups and clinical data 
A subset of recruits of the Control (n=17), ARV-HIV-1 (n=22) and ARV+HIV-1 (n=24) study groups of 
chapter 4 were simultaneously also employed in this third part of the study. Enlistees to these study 
groups were enrolled (Aug 2011- Mar 2012) according to the criteria defined in Table 3.1. The ARV 
regimen TDF, Lamivudine, EFV was used by 60%; the Stavudine, Lamivudine, EFV regimen used by 
20%; the Stavudine, Lamivudine, NVP regimen used by 15% and the TDF, Lamivudine, NVP regimen 
used by 5% of total recruits of the ARV+HIV-1 study group. Participants were recruited from state clinics 
in a peri-urban area of Cape Town, South Africa, which included Idasvalley (14% of total recruits), 
Durbanville (41%), Kuilsriver (5%), Tygerberg (5%) and the Desmond Tutu Emavundleni Clinic Site in 
Khayelitsha (35%). The participants from Khayelitsha were enlistees of primarily the control and ARV-
HIV-1 study group. Demographic and clinical data of the participants in each study group are shown in 
Table 5.1. 
 
Informed consent was obtained from all the study participants. The study was reviewed and approved by 
the HREC of the Faculty of Medicine and Health Sciences of Stellenbosch University (Ethics reference 
number N08/02/057). Ethical approval for the collection and analysis of blood samples from participants 
recruited at the Desmond Tutu Emavundleni Clinic Site in Khayelitsha was initially obtained from the REC 
of the Health Sciences Faculty of UCT (Ethics reference number 417/2006) with subsequent 
amendments to the project approved by the HREC of US. 
 
Table 5.1: Demographic and clinical data of the participants in the study groups analysed to 
investigate TLR responses of blood pDCs and mDCs 
 Study groups 
  Control  ARV-HIV-1 ARV+HIV-1 
Total (n) 17 22 24 
Male: Female 
nr 
% 
9:8 
53:47 
3:19 
14:86 
11:13 
46:54 
Agea 
Median 
Range 
28 
19 - 58 
32 
22 - 50 
42 
19 - 55 
Time on ARV therapyb 
Median 
Range 
N/A N/A 13.5 
<1 - 75 
aAge median and range expressed in years 
bTime on treatment median and range expressed in months 
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5.3.2 Whole blood TLR stimulation 
 
5.3.2.1  Determining optimal TLR ligand concentration 
Whole blood TLR stimulated in vitro cultures were prepared using TLR ligands (TLR-L) purchased from 
InvivoGen (San Diego, CA). Table 5.2 lists the initial TLRs targeted to activate DCs, provides the name 
and a brief description on their corresponding ligand as well as their expression properties on pDCs 
and/or mDCs. TLR-Ls were provided as a lyophilised pellet and were reconstituted in supplied endotoxin 
free physiological water (NaCl 0.9%) according to the specifications of the manufacturer (InvivoGen, San 
Diego, CA). Aliquots, sufficient for the execution of 3 consecutive cultures, were prepared and stored at    
-20°C. This was performed to prevent multiple freeze/thaw cycles that could affect the stability of the 
ligand. InvivoGen also provided the recommended TLR-L concentration range for in vitro culturing of cells 
and the current study used these as peripheral boundary titers for the dilution series intended to 
determine the optimum ligand concentration. Accordingly, dilutions performed for the 1) FSL, Poly I: C, 
R848 and LPS ligands entailed a ten–fold titration series and 2) Pam3CSK4, FLA-ST and CpG 2395 
ligands entailed preparing one midpoint titer between the set boundary titers. Ligands were serially diluted 
in 1x PBS pH 7.4 (Gibco® Carlsbad, CA, USA). Table 5.3 summarises the reconstituted stock 
concentrations, manufacturer’s recommended concentration range and the titers of the dilution series 
prepared for each of the seven ligands investigated.  
 
The prepared titers were incubated with whole blood from an HIV-1uninfected donor for 18h. 
Subsequently, DC activation was evaluated via the expression of the activation markers CD86 and CD80 
(refer to Table 4.2 for details on the conjugated fluorochrome, clone, isotype and manufacturer regarding 
the latter two mAbs) and maturation marker CD83 (conjugated to APC, clone: HB15e, isotype: Mouse 
IgG1, obtained from BD Biosciences, San Jose, CA). Whole blood stimulation and post-stimulation cell 
surface marker staining were performed following the procedure outlined in section 5.3.4. The percentage 
DCs positively expressing the activation and maturation markers as well as the MFI of these were 
recorded for each of the different titration points of the seven ligands and plotted on a line graph. 
Accordingly, the single titration point showing the highest level of functional responses were identified and 
used as the optimal ligand concentration for subsequent TLR stimulation experiments. Optimal 
concentrations for the ligands Pam 3CSK4, FSL-1, Poly I:C, LPS,  FLA-ST, R848 and CpG ODN 2395 
type C were 0.55 µg/ml, 0.1 µg/ml, 10 µg/ml, 0.1 µg/ml, 0.1 µg/ml, 0.5 µg/ml and 5 µM, respectively. This 
procedure was repeated using whole blood from an unrelated HIV-1 uninfected donor to examine the 
reproducibility of results and to eliminate any possible donor bias. 
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Table 5.2:  Description of the TLR ligands 
TLR Name of synthetic or 
natural TLR-ligand 
Description of the component recognised 
by  TLRa 
Expression by  
blood  
DC subsetb 
1 and 2 Pam3CSK4  
Acylated amino terminus of bacterial 
lipoproteins found in the cell wall of both Gram 
Positive and Gram Negative bacteria. 
Pam3CSK4 is a synthetic analog.  
mDCs:TLR 1 & 2 
pDCs: TLR 1 
2 and 6 FSL-1  
Lipoylated N-terminal diacylated cysteine 
residue of the LP44 of Mycoplasma 
salivarium. FSL-1 is the synthetic analog. 
mDCs: TLR 2 & 6 
pDCs: TLR 6 
3 
Polyinosinic-
polycytidylic acid  
(Poly I:C)  
Poly I:C, a synthetic analog, represents a 
molecular pattern associated with dsRNA of 
viruses. The high molecular weight type was 
used. 
mDCs 
4 Lipopolysaccharide (LPS) 
LPS is the structural component of the outer 
wall of Gram Negative bacteria, with the 
shape of Lipid A driving the stimulatory 
response. An ultrapure preparation from the 
Escherichia colistrain 0111:B4 was used.  
mDCs 
5 FLA-ST 
FLA-ST is an ultrapure preparation of 
bacterial flagellin, the component associated 
with motility. The preparation was purified 
from Salmonella Typhimurium.  
mDCs 
7 and 8 R848  
Resiquimod 848 (R848) is an 
imidazoquinoline compound, used clinically as 
an asynthethic immunemodulatory drugs 
against viral infections. It mimics the TLR7/8’s 
natural ligand, ssRNA from viruses. 
mDCs: TLR 8 
pDCs: TLR 7 
9 
CpG Oligo-
deoxynucleotides 
(ODN) 2395, Type C 
CpG ODNs are synthetic short single 
stranded unmethylated DNA containing a 
series of only Cytosine (C) and Guanine (G) 
nucleotides on a phosphodiester backbone. 
CpG ODN’s are predominantly present in 
bacterial DNA 
pDCs 
aInformation supplied by the manufacturer InvivoGen (San Diego, CA)  
bLiu K-J, 2006;Iwasaki A and Medzhitov R, 2004;  
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Table 5.3:  Summary of ligand reconstituted stock concentration, manufacturer’s recommended 
concentration range and the titers of the dilution series prepared for each of the 
seven ligands investigated. 
Ligand 
Reconstituted 
stock 
concentration 
Recommended 
concentration 
range 
Dilution series 
(optimal concentration are 
underlined) 
Pam3CSK4 1 mg/ml 1 - 0.1 µg/ml 1, 0.55 and 0.1 µg/ml  
FSL 100 µg/ml 1 – 0.001 µg/ml 1, 0.1, 0.01 and 0.001 µg/ml 
Poly I:C 1 mg/ml 10 – 0.03 µg/ml 10, 1, 0.1 and 0.01 µg/ml 
LPS 5 mg/ml 10 – 0.01 µg/ml 10, 1, 0.1 and 0.01 µg/ml 
FLA-ST 100 µg/ml 0.1 – 0.01 µg/ml 0.1, 0.055 and 0.01 µg/ml 
R848 1 mg/ml 5 - 0.05  µg/ml 5, 0.5 and 0.05 µg/ml 
CpG ODN 2395, Type C  500 µM 5 - 1 µM 5, 3 and 1 µM 
The underlined titre was found optimal and used in subsequent TLR stimulation experiments  
 
5.3.2.2  Selection of markers to phenotypically characterise activated DCs from TLR stimulated 
cultures 
Upon determining the optimal TLR-L concentrations for DC activation in whole blood in vitro cultures, the 
study next evaluated the expression of the cell surface markers employed in Chapter 4 (Table 4.2) on 
activated DCs. For this purpose, whole blood of an HIV-1 uninfected donor was incubated with optimal 
concentrations of the 7 ligands (Table 5.3) investigated. Whole blood stimulation and post-stimulation cell 
surface marker staining were performed according to the assay described in section 5.3.4 using the same 
mAbs volumes as specified in section 4.3.5. This experiment was repeated using whole blood from an 
unrelated HIV-1 uninfected donor to confirm reproducibility of results. The expression profile of these cell 
surface markers on TLR activated pDCs and mDCs were compared to that of the DC subsets in fresh 
whole blood (refer to Chapter 4). Markers that showed a clear change in expression (either an up-
regulation or down modulation that signifies activation) were identified and selected for the analyses of 
DC responses in subsequent TLR experiments. In addition, some markers that showed minimal to no 
change in expression were also selected as their expression on pDCs and mDCs upon TLR stimulation in 
an HIV-1 setting was of interest. Accordingly, the final set of phenotypic markers included TRAIL-R1 and -
R2, TNF-R2, CCR5, CCR7, CCR9, VPAC1 and VPAC2. These were regrouped into four new panels, 
labeled as Panel 1-3 (refer to Table 5.4). The markers previously used in phenotypic profiling of fresh 
whole blood  but excluded from the mAb staining panels for phenotypic profiling of TLR stimulated DCs 
were CXCR6, TRAIL-R3, TRAIL-R4, FAS, FASL and CD62L. Also, TLR-Ls that accordingly showed a 
significant level of marker modulation, in either one or both the DC subsets, were identified and selected 
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to use in subsequent TLR experiments. These included LPS (ligand for TLR 4 and expressed on mDCs), 
CpG ODN (ligand for TLR9 and expressed on pDCs) and R848 (ligand for TLR7/8 and expressed on both 
DC subsets).  
 
5.3.2.3  Intracellular profiling of TLR stimulated pDCs and mDCs 
In addition to the four mAb panels employed for phenotypic profiling of activated pDCs and mDCs, two 
additional panels were introduced to investigate intracellular cytokine production by DCs and were 
labeled as Panel 4 and 5, respectively. Panel 4 included the mAb TNF- Alexa Fluor®647 (used at an 
optimal volume of 0.5µl per reaction as determined by a titration assay, refer to 4.3.4) and Panel 5 the 
mAbs IL12p40 Alexa Fluor®647 (0.5µl) and IFN- (2b) PE (refer to as IFN- from this point on) (2 µl). 
These mouse anti-human mAbs were obtained from either Biolegend1 (San Diego, CA) or BD 
Biosciences2 (San Jose, CA). Panel 5 also included mAbs to investigate VPAC 1 (2 µl) and 2 (2 µl) 
expression on intracellular vesicles in activated pDCs and mDCs. Refer to Table 5.4 for clone and isotype 
information on the cell surface (Panel 1-3) and intracellular markers (Panel 4 and 5) investigated in the 
current study. 
 
Table 5.4:  mAb panels for cell surface and intracellular staining of TLR stimulated pDCs and 
mDCs 
 Panels Markers of interest Clones Isotype 
m
A
bs
 
fo
r 
D
CI
D
 
 
HLA-DR APC-Cy™7  
CD123 PE-Cy7  
CD 11c Pacific blue™  
LIN1 FITC 
Refer to Table 4.2 
m
A
bs
 
fo
r 
c
el
l s
u
rfa
c
e 
st
ai
n
in
g 
Panel 1 
+DCID 
TRAIL-R2 APC  
TNF-R2 PE  Refer to Table 4.2 
Panel 2 
+DCID 
TRAIL-R1 APC  
VPAC 2 PerCP 
VPAC 1 PE 
Refer to Table 4.2 
Panel 3 
+DCID  
CCR5 APC   
CCR7 PerCP 
CCR9 PE  
Refer to Table 4.2 
m
A
bs
 
fo
r 
In
tr
ac
el
lu
la
r 
st
ai
n
in
g 
Panel 4 
+DCID 
TNF- Alexa Fluor®647 1 
VPAC 1 PE 
VPAC 2 PerCP 
MAb11 
- 
476031 
Mouse IgG1,  
mouse IgG2a 
mouse IgG1 
Panel 5 
+DCID 
IL12p40 Alexa Fluor®647 1 
IFN-(2b) PE 2 
C11.5 
7N4-1 
Mouse IgG1,  
Mouse IgG1,  
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 132 
 
5.3.2.4  FMO staining controls and the autofluorescence factor 
FMO staining controls were also used in this part of the study to, as described in section 4.3.7.2, 
discriminate between positive and negative events and identify false positive events brought on by 
background fluorescence (fluorochrome induced) as well as autofluorescence (cell induced). 
Autofluorescence refers to the intrinsic properties of cells that can cause spontaneous fluorescence. This 
includes reduced pyridine nucleotides and flavins that can be excited, specifically by the blue laser of a 
flow cytometer, resulting in the generation of false positive events. Furthermore, changes in physiological 
conditions (such as cell culturing) may cause an increase in the level of autofluorescence. 
Autofluorescence is generally assessed visually using a FL1 (FITC) vs. FL2 (PE) density plot due to the 
excitation and emission characteristics of autofluorescence being similar to that of the FITC and PE 
fluorochromes. In the current study assessment of autofluorescence was performed as indicated, 
however, good resolution was also observed when using a PerCP (FL3) vs. PE density plot. As indicated 
in Figure 5.1 B vs. A, in comparing the mDC event profile of a PE FMO stained control of TLR stimulated 
to that of fresh whole blood autofluorescence could be identified as a characteristic “tail of positive” 
events in activated mDCs. Accordingly, marker stained samples in which the PE conjugated marker 
displayed a similar event profile as the PE FMO control stain were regarded as negatively expressing the 
marker of interest and gates were appropriately placed to exclude these events from analyses. However, 
these gates needs to be adjusted/tightened when marker expression is true positive - distinguished by an 
absence of  “tailed” events (Figure 5.1D) and displaying a mDC event profile similar to that of stained 
fresh whole blood (Figure 5.1 C) – to accurately capture these events for analyses (compare the position 
of the dashed line between Figure 5.1B and D). Notably, autofluorescence was a predominant feature of 
activated mDC population.  
 
In this part of the study FMO control staining were performed concurrent with the evaluation of the 
expression of the17 phenotypic markers of Panel A-G (Table 4.3) in TLR stimulated whole blood (Refer to 
section 5.3.2.2). Stimulated whole blood from a healthy donor was prepared according to the procedure 
described in section 4.3.7.2. TLR stimulation and post-stimulation staining was performed as outlined in 
section 5.3.4. Literature recommends performing FMO staining controls with daily experiments, but as per 
reasons defined in section 4.3.7.2, the current study performed FMO staining controls once and used the 
resulting staining profile as a guide to analyze subsequently stained samples.  
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
Figure 5.1  Description of the method used to detect autofluorescence
Detection of autofluorescence was performed by displaying events in a FL2
plot. Graph A displays a PE FMO control stain of mDCs in fresh whole blood where no autofluorescence 
was detected and graph B shows autofluorescence as a “tail of positive events” 
stain of cultured whole blood. A change (visually inspected) in the expression profile of
PE FMO control to the marker stained sample
true positive events for the marker of interest conjugated to PE. The dashed
boundary which is fixed to compare FMO control to marker stain in fresh whole blood, however, it needs 
to be adjusted between the FMO control and marker stain of cultured whole blood.
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5.3.3 General specimen processing 
Each of the participants enrolled in the study was allocated a patient number and all laboratory 
procedures were performed in reference to this number. Whole blood (2 x 10 ml) was aseptically obtained 
by venisection puncture in Sodium Heparin vacutainer tubes (BD Biosciences, San Jose, CA) (optimal for 
cell culturing as reported by Petrovsky N and Harrison LC, 1995) and used in the whole blood in vitro TLR 
stimulation assay. Whole blood was also collected in EDTA vacutainer tubes (10ml) (BD Biosciences, 
San Jose, CA) and used for determining CD4 and CD8 T lymphocytes counts (refer to section 3.3.6), 
phenotypic profiling of pDCs and mDCs (Chapter 4) as well as viral load quantification (refer to section 
3.3.7). Processing of samples was at all times performed under sterile conditions in a biosafety cabinet 
(NUAIRE biological class II safety cabinet). Barrier pipette tips were used for the sterile preparation of in 
vitro whole blood cultures. Centrifugation was performed using a Hettich Rotanta 460R benchtop 
centrifuge (Massachussets, USA). 
 
5.3.4 Whole blood TLR stimulation and mAb staining assay 
Whole blood TLR stimulated cultures were prepared in appropriately labeled (stimulant, patient nr) 12 x 
75 mm, 5 ml round bottom sterile, pyrogen-free polystyrene capped BD Falcon™ tubes (BD Biosciences, 
San Jose, CA). Section 5.2 shows the layout of sample preparation per patient for the TLR stimulation 
assay. For the profiling of cell surface marker expression on activated DCs, separate test tubes were 
prepared to which 10 µl of R848, LPS, CpG ODN and 1x PBS pH 7.4 (Gibco® Carlsbad, CA, USA) was 
added, respectively. In addition, a duplicate set of reactions were simultaneously prepared to which VIP 
(5ul, [final] = 1x10-8M, (Delgado M, et al. 2004a) was added. Similar reactions were prepared to examine 
intracellular cytokine production of activated DCs. Additionally, and concurrent with the addition of 
stimulus/PBS, the protein transport inhibitor Brefeldin A (5µl, [final] = 1:1000) was added to each of these 
reactions. This was performed to prevent cellular release of cytokines from both DC subsets as well as 
other responding cells so to a) allow for measuring the level of expression of the cytokines of interest 
produced by DCs specifically and b) prevent the release of other cytokines that may influence IFN- 
production of DCs upon in vitro challenge. The total test volume, with the addition of whole blood, was 
200 µl. These samples were gently vortexed and incubated at a 5º slant in a humidified 37C, 5% CO2 
incubator (NuAire Autoflow NU-5510). The incubation period for optimum cell surface and intracellular 
cytokine analysis was performed at 18 and 4.5 hours, respectively.  
 
Immediately after the incubation period, samples destined for the profiling of cell surface marker 
expression on activated DCs were stained with applicable mAbs. The relevant mAb cocktail (Panel 1-3, 
Table 5.4) was freshly prepared in staining buffer (0.4% heat-inactivated foetal calf serum in 1 x PBS pH 
7.4 (Gibco® Carlsbad, CA, USA)) and a volume of 50µl added to the TLR stimulated samples, the 
samples were gently vortexed and incubated for 30 min at room temperature. Red blood cell lysing was 
performed with 1.8 ml 1 x BD FACS lysing solution (BD Biosciences, San Jose, CA), the samples were 
gently vortexed and incubated for 10 min in the dark at room temperature. The cells were centrifuged for 
5 min at 400 x g and after discarding the supernatant staining buffer (2 ml) was added. Washing with 
staining buffer was performed twice. Discarding of the supernatant entailed inverting the tube to dispose 
the fluid in biological hazard container and blotting the inverted tube dry on absorbent paper to remove 
excess fluid. The samples prepared for examining cell surface expression were resuspended in 350 µl 
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staining buffer and immediately acquired on a BD FACSCanto II™ flow cytometer (BD Biosciences, San 
Jose, CA). A threshold was set on 30 000 for the FSC and 200 for the FITC (LIN1) detector.  A maximum 
of 750 000 total events were acquired. Data on the height (H), area (A) and width (W) of the fluorescence 
pulse generated in the different channels was collected. 
 
The TLR stimulated samples prepared for the examination of intracellular cytokine production were firstly 
stained with the DCID cell surface markers, lysed and washed following the procedure as described 
above. The cell pellet was then either stored in 1ml staining buffer at 4ºC for processing the next day or 
immediately subjected to fixation and permeabilisation. This entailed adding 100µl of the BD 
Cytofix/Cytoperm™ reagent (BD Biosciences, San Jose, CA) to the cell pellet and incubating the sample 
for 20 min at 4°C in the dark. Following this, 500 µl Permwash buffer (BD Biosciences, San Jose, CA) 
was added to the sample and centrifuged at 400 x g at 4°C for 5 min. The supernatant was discarded and 
a cocktail of the mAbs of Panel 4 and 5 (refer to Table 5.4) were freshly prepared in permwash buffer. A 
volume of 50µl was then added to the samples and incubated for 30 min at 4°C in the dark.  Two wash 
steps followed, the first was performed with Permwash buffer (500 µl) and the second in staining buffer (2 
ml) at 400 x g and 4°C for 5 min. The sample was resuspended in 250 µl staining buffer and immediately 
acquired on a BD FACSCanto II™ flow cytometer (BD Biosciences, San Jose, CA). A threshold was set 
at 30 000 for the FSC detector and maximum of 450 000 total events were acquired. Data on the height 
(H), area (A) and width (W) of the fluorescence pulse generated in the different channels was collected.  
 
5.3.5  Flow cytometric detection of nonviable DCs in TLR stimulated whole blood cultures 
The 7-AAD nucleic acid dye was used to detect nonviable DCs. Two additional control samples per 
patient were prepared to detect nonviable pDCs and mDCs from the 4.5h and 18 h stimulations 
(incubation periods for the in vitro detection of intracellular cytokine production and cell surface receptor 
expression, respectively). These samples were prepared by stimulating (4.5h and 18h incubation periods) 
whole blood (190 µl) from each of the patients,followed by staining with DCID markers and 7–AAD dye 
(according to the specification of the manufacturer, BD Biosciences, San Jose, CA), to detect non-viable 
pDCs and mDCs. Note that 7-AAD fluorescence is detected in the PerCP detector. The pDC and mDC 
population was defined from the total acquired events following the gating strategy as previously 
described (Figure 4.20). The boundary of negatively stained 7-AAD events was determined by staining 
unstimulated whole blood cultures with only the DCID surface markers. Hence, events from TLR 
stimulated samples were classified as positive for 7-AAD when detected outside of the negative staining 
boundary. Literature recommends the inclusion of the 7-AAD dye within each of the panels designed in a 
multi-colour experiment so to identify and exclude nonviable cells during analyses of acquired events. 
However, as the current study was limited with regard to availability of detectors (only able to employ 7 of 
the 8 accessible channels of the BD FACSCanto™ II 8-colour flow cytometer (BD Biosciences, San Jose, 
CA) due to the fact that most markers used in the study, at the time of panel design, was not available 
conjugated to either the fluorochromes AmCyan or V500 that emit light within the 8th channel (510/50 BP 
filter of the Violet laser) the PerCP detector could not be used as a dedicated channel for the detection of 
non-viable 7-AAD fluorescing cells. Nonetheless, 7-AAD staining was performed separately and used to 
monitor non-viable pDCs and mDCs during the TLR experiments. 
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5.3.6 Statistical analyses 
Comparative analyses of DC function were performed using data collected on DCs positively expressing 
cell surface markers and intracellular cytokines of interest in TLR–L stimulated and unstimulated cultures 
(alternatively also refer to as TLR-L- cultures). Assessment of the data collected was performed as 
follows: 
 
- to assess the general TLR activation profile each of the TLR-L+ cultures were compared to TLR-L- 
culture of the control study group. The non-parametric two tailed Mann-Whitney t test was applied; 
- to assess the activation abilities of DCs during HIV-1 infection TLR-L+/TLR-L- cultures of the ARV-
HIV-1 and ARV+HIV-1 study groups were separately compared to the control study group. Spontaneous 
levels of marker change in the TLR-L+ cultures were similarly investigated. The non-parametric two 
tailed Mann-Whitney t test was applied; 
-to assess the effect of VIP: VIP treated TLR-L- and TLR-L+ cultures were compared to corresponding 
VIP untreated TLR-L- and TLR-L+ cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups. The 
non-parametric two tailed Mann-Whitney t test was applied. 
 
Statistical analysis was performed using the Graphpad Prism version 5.00 software (San Diego, 
California, USA).  Refer to Table 3.4 for the summary of the method used to report significant and non-
significant data as well as the corresponding P value range. 
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5.4 Results and Discussion 
 
5.4.1   Defining marker expression related to apoptosis, migration/homing and 
immunemodulation on both DC subsets upon in vitro TLR activation during HIV-1 
infection. 
 
5.4.1.1 Profiling apoptotic markers TNF-R2, TRAIL–R1 and TRAIL-R2 expression on TLR 
activated DCs 
 
Whole blood TLR-L+ cultures (LPS and R848) of HIV-1 infected individuals show significantly higher 
frequencies of TNF-R2+pDCs, while reduced levels were observed in TLR-L+ cultures of ARV treated 
individuals 
Compared to the TNF-R2 pDC profile obtained from fresh whole blood (Figure 4.23), a reduced frequency 
of TNF-R2+pDCs were observed in the TLR-L- culture of the control, ARV-HIV-1 and ARV+HIV-1 study 
groups. This may be due to signal deprivation considering that these cells were removed from the host 
and/or cultured in suboptimal ex vivo conditions in the synthetic environment. The TLR-L- culture of the 
ARV-HIV-1 study group showed a significantly higher median percentage of TNF-R2+pDCs when 
compared to that of the control study group (p  0.0001). This may be an indication of the activation 
status of these cells in response to the HIV/host induced milieu of pathogenic/inflammatory molecules. 
The median percentage TNF-R2+pDC of the ARV+HIV-1 study group was significantly reduced when 
compared to theARV-HIV-1 study group (p = 0.005) and similar to the control study group. ARV seems to 
have a recovery effect on the TNF-R2+pDCs subsets. Assessment of the TNF-R2+pDC profile in TLR-L+ 
cultures via the control study group, the study found a significantly higher frequency of TNF-R2+pDCs in 
the LPS (p < 0.0001), CpG ODN (p < 0.0001) and R848 (p < 0.0001) cultures when compared to the 
unstimulated culture. Clearly, pDCs responded to the TLR-L signal by upregulating TNF-R2 expression. 
In the LPS (p = 0.002) and R848 (p = 0.01) culture the median percentage of TNF-R2+pDCs was 
significantly higher in the ARV-HIV-1 study group compared to the control study group. In the CpG ODN 
culture the median percentage of TNF-R2+pDCs was similar between these study groups. ARV therapy 
seemed to reduce the frequency of the TNF-R2+pDC subset as significantly lower median percentage of 
TNF-R2+pDCs was observed in the ARV+HIV-1 study group compared to ARV-HIV-1 study group of the 
LPS culture (p = 0.05). This adjusted frequency distribution of TNF-R2+pDCs in the ARV+HIV-1 study 
group was comparable to that of the control study group. Notably, reduced median percentage of TNF-
R2+pDCs was also observed in the ARV+HIV-1 study group of the CpG ODN culture (p < 0.0001) and 
R848 culture (p < 0.0001) when compared to the ARV-HIV-1 study group. These immune recovery levels 
were even significantly lower than the median percentageTNF-R2+pDCs of the control study group (CpG 
ODN culture: p < 0.0001), trending towards significance in the R848 culture (p = 0.1). These findings 
suggested that ARV therapy has an inhibitory effect on the expression of TNF-R2 when DCs are 
activated by related signals (Figure 5.2, Table 5.6).The degree of decline below that of the healthy 
controls is unexpected and concerning as it may indicate ARV therapy negatively affecting immune 
responses. 
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The frequency distribution of TNF-R2+mDCs of the control, ARV-HIV-1 and ARV+HIV-1 study group of the 
TLR-L- cultures were mostly similar to that of fresh whole blood. Also, the study found no significant 
difference in TNF-R2+mDCs frequency distribution between the control, ARV-HIV-1 and ARV+HIV-1 study 
groups of the TLR-L- culture. Assessing the activation profile via responses by the control study group, no 
significant difference between unstimulated and the LPS and R848 cultures was found. However, 
comparison with the CpG ODN culture showed a tendency (p = 0.05) towards a lower TNF-R2+mDCs 
frequency distribution. Compared to the control, the ARV-HIV-1 study group of the CpG ODN culture 
showed a significant higher median percentage of TNF-R2+mDCs (p = 0.046) while in the LPS and R848 
culture we observed a tendency toward higher TNF-R2+mDCs frequency (p = 0.14, p = 0.14, respectively) 
in the ARV-HIV-1 study group. Notably, the TLR-L+ cultures of the ARV+HIV-1 study group compared to 
that of the ARV-HIV-1 study group showed a significantly lower median percentage of TNF-R2+mDCs 
(LPS: p = 0.009, CpG ODN: p < 0.0001; R848: p = 0.0007). This decline of TNF-R2+mDCs as observed 
with the ARV+HIV-1 study group when compared to the control study grouped was significant for the CpG 
ODN culture (p = 0.0034) and tended towards significance for the R848 culture (p = 0.11). Similar to TNF-
R2+pDCs, ARV therapy also has an immune-inhibitory effect on TNF-R2+mDCsto a degree lower than the 
healthy control study group. No significant change in the frequency distribution of TNF-R2+pDCs or TNF-
R2+mDCs was observed between VIP treated and untreated TLR-L+ cultures of all three the study groups 
investigated (Figure 5.3, Table 5.7). 
 
The markers TRAIL-R1 and TRAIL-R2, like in fresh whole blood, were found to be unexpressed by both 
DC subsets of all the study groups in the TLR-L- cultures. Also, no change in expression was observed 
upon ex vivo stimulation with the R848, LPS or CpG ODN ligands (data not shown). 
 
In contrast to the decline in the frequency of TNF-R2+pDCs and TNF-R2+mDCs of the ARV+HIV-1 study 
group when compared to the ARV-HIV-1 study group for all the TLR-L+ cultures (Figure 5.2 and Figure 
5.3), the immune status parameters (CD4 and CD8 T lymphocyte absolute count and CD4:CD8 ratio, 
Table 5.5) were similar between these study groups. Although ARV therapy did not incur a change in 
parameters related to immune status after an approximate 1 year of ARV therapy, it seemed that it did 
affect the function of DCs. 
 
Table 5.5 Summary of the CD4 T and CD8 T lymphocytes absolute numbers; CD4:CD8 ratio 
and viral load (as applicable) of the control, HIV-1 and HIV-1-related study groups. 
 
Data indicated as 
Mea = Median cells/µl, Ra = Range cells/µl, Meb = Median % of CD45+CD3+ events,  
Rb = Range % of CD45+CD3+ events, Mec = Median ratio of CD4 Lymphocyte absolute number to CD8 T 
lymphocyte absolute number, Rc = Range of the CD4:CD8 ratio values, Me = Median RNA copies/ml, 
Re = Range RNA copies/ml
  Study groups 
  Control ARV-HIV-1 ARV+HIV-1 
CD4 T cells Me
a
, Ra 799, 412 - 1694 331, 14 - 909 323, 143 - 1072 
Meb, Rb 42, 26-54 21.5, 4-39 19.5, 8-31 
CD8 T cells 
Mea, Ra 602, 205 - 1048 828, 187 - 2940 1093, 346 - 2962 
Meb, Rb 29, 15-40 50.5, 41-77 51.5, 34-82 
CD4:CD8 Ratio Mec, Rc 1.34, 0.5-2.9 0.42, 0.07-0.89 0.41, 0.11-0.72 
Viral load Mee, Re N/A 1.5x104, LOD - 3.5x106 LOD, LOD - 310 
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Figure 5.2: Frequency distribution of TNF-R2+pDCs in R848, LPS and CpG ODN stimulated whole blood cultures of the control, ARV-HIV-1 and 
ARV+HIV-1study groups 
TLR-L- and TLR-L+ (R848, LPS, CpG ODN) whole blood cultures, set up to assess cell surface expression, were incubated for 18h and afterwards stained with mAbs 
to examine the expression of TNF-R2 on pDCs using multi-parameter flow cytometry. The box and whiskers plot represents the percentage TNF-R2+pDC of the 
control, ARV-HIV-1 and ARV+HIV-1 study groups per whole blood culture. Each boxplot shows the 10-90 percentile range of data (whiskers) and horizontal line the 
median value. Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group comparison of interest and 
an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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Table 5.6 Summary of TNF-R2+pDCs frequency in TLR-L- and TLR-L+ whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups 
Study groups 
TNF-R2+pDCs Control ARV
-HIV-1 ARV+HIV-1 
 
TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP 
Minimum % 0.92 3.12 8.82 1.38 2.17 3.46 
Median % 5.65 12.00 18.56 15.71 10.12 8.97 
Maximum % 10.05 19.80 39.75 41.03 16.79 21.69 
 
R848 R848 + VIP R848 R848 + VIP R848 R848 + VIP 
Minimum % 38.51 43.70 65.31 70.00 15.73 17.44 
Median % 63.30 76.77 81.46 83.18 48.97 51.72 
Maximum % 92.18 92.52 92.45 93.59 80.88 83.64 
 LPS LPS + VIP LPS LPS + VIP LPS LPS + VIP 
Minimum % 15.36 8.530 19.39 15.54 9.300 9.520 
Median % 30.11 21.95 54.86 57.56 28.90 35.56 
Maximum % 41.58 37.30 91.47 88.55 72.16 67.74 
 CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP 
Minimum % 38.45 41.94 30.77 26.32 8.860 8.890 
Median % 52.91 59.65 59.23 55.54 27.92 29.64 
Maximum % 64.29 67.82 83.43 82.61 39.52 56.96 
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Figure 5.3 Frequency distribution of TNF-R2+mDCs in R848, LPS and CpG ODN stimulated whole blood cultures of the control, ARV-HIV-1 and 
ARV+HIV-1study groups 
TLR-L- and TLR-L+ (R848, LPS, CpG ODN) whole blood cultures, set up to assess cell surface expression, were incubated for 18h and afterwards stained with mAbs 
to examine the expression of TNF-R2 on mDCs using multi-parameter flow cytometry. The box and whiskers plot represents the percentage TNF-R2+mDC of the 
control, ARV-HIV-1 and ARV+HIV-1 study groups per whole blood culture. Each boxplot shows the 10-90 percentile range of data (whiskers) and horizontal line the 
median value. Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group comparison of interest and 
an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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Table 5.7: Summary of TNF-R2+mDCs frequency in TLR-L- and TLR-L+ whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups 
 
Study groups 
TNF-R2+mDCs Control ARV-HIV-1 ARV+HIV-1 
 
TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP 
Minimum % 78.41 77.40 75.32 71.88 35.88 41.00 
Median % 90.51 90.00 87.68 89.01 85.80 84.48 
Maximum %  94.68 93.45 97.24 96.61 95.18 94.62 
  
R848 R848 + VIP R848 R848 + VIP R848 R848 + VIP 
Minimum % 66.39 66.38 77.24 86.29 31.10 33.50 
Median % 94.51 94.80 97.13 98.13 88.97 81.80 
Maximum % 98.78 97.96 100.0 100.0 98.92 98.77 
 LPS LPS + VIP LPS LPS + VIP LPS LPS + VIP 
Minimum % 62.37 55.20 73.92 85.00 44.86 43.36 
Median % 95.24 91.74 96.77 94.95 78.54 85.37 
Maximum % 98.63 98.44 99.29 100.0 98.84 97.79 
 CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP 
Minimum % 64.42 61.61 57.57 57.58 39.84 35.92 
Median % 84.38 87.99 90.45 88.22 67.89 66.13 
Maximum % 90.21 90.66 96.73 98.36 89.19 88.24 
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5.4.1.2 Profiling chemotactic markers CCR5, CCR7 and CCR9 expression on TLR activated DCs 
Compared to the positive CCR5 staining of pDCs in fresh whole blood, complete down-regulation of this 
marker in the TLR-L cultures was observed. Lack of expression of CCR5 by mDCs as observed in fresh 
whole blood was also observed in TLR-L cultures. Also the negative staining profile of CCR7 and CCR9 
for both DC subsets in TLR-L cultures was similar to that of fresh whole blood (data not shown). 
 
5.4.1.3 Profiling immunemodulatory markers VPAC1 and VPAC2 on fresh and TLR activated 
whole blood 
The staining profile of the FMO control and marker stain samples of VPAC1 and VPAC2for both DC 
subsets was similar in fresh and TLR stimulated whole blood cultures. This was indicative of DC subsets 
negatively expressing the immunemodulatory markers evaluated for both cell surface and intra-vesicular 
expression. 
 
5.4.1.4 Profiling intracellular expression of IFN-, TNF- and IL12p40 on TLR activated DCs 
The whole bloodR848 culture of HIV-1 infected individuals showed significantly higher frequencies of  
IFN-+pDCs whilst normalisation of responses were observed in ARV treated individuals 
IFN- is a cytokine characteristically produced by pDCs. In assessing the TLR activation profile of IFN- 
via the control study group, as expected, no spontaneous expression of IFN- by pDCs in the 
unstimulated culture was observed. However, staining for this marker detected a high degree of IFN- 
production by pDCs of the R848 stimulated whole blood culture. Both the CpG ODN and LPS cultures 
showed no to minimal IFN- production by pDCs. Specifically, the R848 culture of the control study group 
showed a significantly higher median percentage of IFN-+pDCs when compared to TLR-L- culture of this 
study group (p  0.0001). R848 stimulated whole blood cultures of the ARV-HIV-1 study group showed a 
significantly higher frequency of IFN-+pDCs compared to the control study group (p = 0.04).  A similar 
observation was reported in a study that investigated IFN- supernatant levels of purified pDC stimulated 
with R848. The report also showed that cytokines IL-6, MIP-1, MIP-1 and RANTES were also produced 
in higher levels in HIV infected individuals compared to controls (Sabado RL, et al. 2010). This is in 
contrast to the findings of Martinson JA, et al. (2007) who reported on the significantly lower percentage 
of IFN-+pDCs observed upon R848 stimulation of HIV-1 infected compared to uninfected individuals. 
Normalisation was observed with ARV therapy. The median percentage of IFN-+pDCs was significantly 
lower in the ARV+HIV-1 study group compare to the ARV-HIV-1 study group (p = 0.004). In addition, ARV 
therapyshowed to induce immune reconstitution with the levels of IFN-+pDCs observed in the ARV+HIV-
1 study groups being similar to the control study group.  
 
In assessing the impact of VIP therapy, the study did not find the distribution of IFN-+pDCs to be 
significantly different between the VIP treated and untreated R848 whole blood cultures of the ARV-HIV-1 
and ARV+HIV-1 study groups. Notably, in the ARV-HIV-1 study group VIP treatment showed a tendency 
towards immunemodulation (p = 0.15) (Figure 5.4, Table 5.8).  
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Lower frequency of IL12p40+mDC in R848 stimulated cultures of HIV-1 infected individuals whilst 
recovery was observed in ARV treated individuals  
No IFN- expression was observed by mDCs in neither of the TLR-L stimulated whole blood culture (data 
not shown). This was an expected outcome as IFN- is not inherently produced by activated mDCs. In a 
similar way IL12p40 is a cytokine not characteristically produced by pDCs (IFN- and IL12p40 also 
served as DC specific culture controls in the study). Accordingly, the study showed no production 
ofIL12p40 by pDCs in the LPS, CpG ODN and R848 whole blood cultures (data not shown). Notably, 
IL12p40 (a signature cytokine of mDCs) was detected at increased levels in mDCs upon R848 stimulation 
of the control study group (p < 0.0001) compared to the TLR-L- culture.IL12p40 production by mDCs was 
not detected in the LPS and CpG ODN cultures. Notably, the study observed a significantly reduced 
median percentage of IL12p40+mDCs in the ARV-HIV-1 study group compared to the control study group 
(p = 0.02). This may indicate that HIV-1 infection plays an inhibitory role in the production of IL12p40. In 
contrast Martinson JA, et al. (2007) found a higher percentage of IL12p40/p70+mDCs in the HIV-infected 
compared to the uninfected cohort upon R848 stimulation. Also Sabado RL et al. (2010) showed higher 
supernatant levels of IL12p40 produced by purified mDCs. Note that in both these studies the R848 
incubation period was between 16 and 24h which may produce different results to the current study in 
which stimulation was performed for 4.5h. Notably, a study that pre-exposed moDCs of healthy controls 
to the plasma of HIV infected individuals followed by Poly I: C (TLR 3 stimulation) showed reduced levels 
of IL12p70 (a heterodimer consisting of p35 and p40) in culture compared to the control sample. 
Exposure of moDCs to the plasma of HIV infected individuals on cART showed recovery in IL12p70 
levels (Miller EA, et al. 2012).In the current study, ARV therapy seemed to normalise the frequency 
ofIL12p40+mDCs as an increase in IL12p40+mDCs was observed when the median percentage of 
IL12p40+mDCs of the ARV+HIV-1 study group was compared to that of the ARV-HIV-1 study group. The 
change trended towards significance (p = 0.12). 
 
The current study showed that all three study groups of the R848 culture arm had lower median 
frequencies of IL12p40+mDCs in the VIP treated compared to the untreated sample. A significant 
immunemodulatory effect was observed in the ARV-HIV-1 study group.VIP treatment showed a 
significantly lower IL12p40+mDCs frequency compared to the untreated R848 sample (p = 0.04). Notably, 
VIP treatment in the ARV-HIV-1 study group showed a median percentage of IL12p40+mDCs significantly 
lower than the control study group (p<0.0001). It was suggested that VIP treatment may result in the 
reduction of IL12p40 production to levels significant of inefficient immune responses, which would be 
detrimental to the host (Figure 5.5, Table 5.9). 
 
The TNF-+pDC frequency was unaltered between R848 cultures of healthy, HIV-1 infected and ARV 
treated individuals 
As with IFN- and IL12p40, spontaneous production of TNF- was not detected by both DC subsets in 
the unstimulated cultures. The TNF- activation profile showed TNF- production by mDCs in the LPS 
and R848 cultures, while pDCs stained positive for TNF- only in the R848 culture. CpG ODN stimulation 
showed minimal TNF- production by the DC subsets in the different study groups. pDC TNF- 
production in the R848 culture (p <  0.0001) and mDC TNF- production in the LPS (p <  0.0001) and 
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R848 (p <  0.0001) were significantly higher when compared to the unstimulated culture of the control 
study group. HIV-1 infection seem not to influence TNF- production as similar median percentages of 
TNF-+pDCs was observed in the control, ARV-HIV-1 and ARV+HIV-1 study groups of the R848 culture. 
This finding is in contrast with a study by Martinson et al. (2007) who observed suppression in the 
production of TNF- when pDCs of HIV infected individuals were stimulated with R848. Possibly the type 
of cell suspension stimulated may affect these contrasting findings. The author used PBMCs which is a 
processed cell suspension and exposed to manipulation vs. whole blood in the current study which 
resembles a more natural cell suspension (but also includes many other cell types than PBMC fractions). 
 
The median percentage of TNF-+mDCs was not different between the ARV-HIV-1 study group and 
control study group of the R848 culture. ARV therapy induced a significantly lower median TNF-+mDCs 
distribution in the ARV+HIV-1 study group compared to the ARV-HIV-1 study group of the R848 culture (p 
= 0.01). The decline was comparable to that of the control study group indicating the role of ARV therapy 
in immune function recovery. A similar phenomenon was also observed with the LPS culture. Whereas a 
higher frequency of TNF-+mDCs was observed in the ARV-HIV-1 study group (p = 0.003) compared to 
the control study group, ARV treatment seemed to induce a significant change in the frequency of TNF-

+mDCs. The median percentage of this subset was significantly lower in the ARV+HIV-1 study group (p = 
0.004) compared to the ARV-HIV-1 study group.  
 
VIP immunemodulation was apparent with TNF- production by pDCs. A significantly lower median 
percentage TNF-+pDCs was found upon comparing the R848+VIP culture of the control study group (p = 
0.006), ARV-HIV-1 study group (p = 0.03) and ARV+HIV-1 study group (p= 0.02) to corresponding 
untreated study groups (TNF-+pDCs: Figure 5.6, Table 5.10). Immunemodulation was not as profound 
with the TNF-+mDCs subset. A tendency to reduce the TNF-+mDCs subset frequency was observed 
when the R848+VIP culture of the control study group (p = 0.19) and ARV-HIV-1 study group (p = 0.1) 
was compared to untreated R848 cultures. Similarly, a tendency to reduce immune activation was 
observed when the LPS+VIP culture of the ARV+HIV-1 study group (p =0.06) and ARV-HIV-1 study group 
(p = 0.19) was compared to corresponding untreated LPS culture (TNF-+mDCs: Figure 5.7, Table 5.11). 
Further investigation is needed to determine the efficacy of VIP treatment. 
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Figure 5.4: Frequency distribution of IFN-+pDCs in R848, LPS and CpG ODN stimulated whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-
1study groups 
TLR-L- and TLR-L+ (R848, LPS, CpG ODN) whole blood cultures, set up to assess intracellular cytokine production, were incubated for 4.5 hours and afterwards 
stained with mAbs to examine IFN- expression by pDCs using multi-parameter flow cytometry. The box and whiskers plot represents the percentage +pDCs of the 
Control, ARV-HIV-1 and ARV+HIV-1 study groups per whole blood culture. Each boxplot shows the 10-90 percentile range of data (whiskers) and IFN- horizontal 
line the median value. Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group comparison of 
interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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Table 5.8:  Summary of IFN-+pDCs frequency in TLR-L- and TLR-L+ whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups 
 
 
 Study groups 
IFN-+pDCs Control ARV-HIV-1 ARV+HIV-1 
 TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP 
Minimum % 0 0 0 0 0 0 
Median % 0 0 0 0 0 0 
Maximum % 0.20 0.40 0.90 0.50 0.30 0 
 LPS LPS + VIP LPS LPS + VIP LPS LPS + VIP 
Minimum % 0 0 0 0 0 0 
Median % 0 0 0 0 0 0 
Maximum % 0.40 1.40 0.0 1.30 1.40 1.10 
 CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP 
Minimum % 0 0 0 0 0 0 
Median % 0.40 0.30 0.90 0.15 0 0 
Maximum % 2.10 2.10 4.90 2.90 1.90 1.30 
 R848 R848 + VIP R848 R848 + VIP R848 R848 + VIP 
Minimum % 16.90 12.20 52.60 35.90 11.20 10.50 
Median % 53.00 46.40 62.70 59.00 36.00 33.10 
Maximum % 80.10 79.80 79.20 80.00 68.80 68.90 
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Figure 5.5 Frequency distribution of IL12p40+mDCs in R848, LPS and CpG ODN stimulated whole blood cultures of the control, ARV-HIV-1 and 
ARV+HIV-1study groups 
TLR-L- and TLR-L+ (R848, LPS, CpG ODN) whole blood cultures, set up to assess intracellular cytokine production, were incubated for 4.5 hours and afterwards 
stained with mAbs to examine IL12p40 expression by mDCs using multi-parameter flow cytometry. The box and whiskers plot represents the percentage IL12p40 
+mDCs of the Control, ARV-HIV-1 and ARV+HIV-1 study groups per whole blood culture. Each boxplot shows the 10-90 percentile range of data (whiskers) and 
horizontal line the median value. Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group 
comparison of interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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Table 5.9: Summary of IL12p40+mDCs frequency in TLR-L- and TLR-L+ whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups 
 
 
 
 
 
 Study groups 
IL12p40+mDCs Control ARV-HIV-1 ARV+HIV-1 
 TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP 
Minimum % 0.0 0.0 0.0 0.0 0.0 0.0 
Median % 0.30 0.60 0.60 0.70 0.45 0.30 
Maximum % 1.40 1.10 2.10 1.90 1.60 1.60 
 LPS LPS + VIP LPS LPS + VIP LPS LPS + VIP 
Minimum % 0.0 0.0 0.0 0.1000 0.0 0.0 
Median % 2.550 2.550 2.050 1.300 1.600 0.4000 
Maximum % 4.800 4.800 3.900 13.70 3.900 2.000 
 CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP 
Minimum % 0.0 0.0 0.0 0.1000 0.0 0.0 
Median % 0.4000 0.8500 0.7000 1.000 0.4000 0.6000 
Maximum % 1.200 2.200 2.300 1.800 2.000 1.800 
 R848 R848 + VIP R848 R848 + VIP R848 R848 + VIP 
Minimum % 7.20 12.50 4.20 1.40 1.50 2.00 
Median % 32.90 23.40 18.50 13.75 32.45 23.50 
Maximum % 65.30 56.00 42.40 28.50 46.90 52.70 
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Figure 5.6:  Frequency distribution of TNF-+pDCs in R848, LPS and CpG ODN stimulated whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-
1study groups 
TLR-L- and TLR-L+ (R848, LPS, CpG ODN) whole blood cultures, set up to assess intracellular cytokine production, were incubated for 4.5 hours and afterwards 
stained with mAbs to examine TNF- expression by pDCs using multi-parameter flow cytometry. The box and whiskers plot represents the percentage TNF-+pDCs 
of the Control, ARV-HIV-1 and ARV+HIV-1 study groups per whole blood culture. Each boxplot shows the 10-90 percentile range of data (whiskers) and horizontal 
line the median value. Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group comparison of 
interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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Table 5.10: Summary of TNF+pDCs frequency in TLR-L- and TLR-L+ whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups 
 
 
 Study groups 
 
 
Control ARV-HIV-1 ARV+HIV-1 
 TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP 
Minimum % 0.0 0.0 0.0 0.0 0.0 0.0 
Median % 0.0 0.0 0.0 0.0 0.0 0.0 
Maximum % 0.4000 1.000 1.100 1.500 1.400 0.8000 
 LPS LPS + VIP LPS LPS + VIP LPS LPS + VIP 
Minimum % 0.0 0.0 0.0 0.0 0.0 0.0 
Median % 0.3500 0.6000 0.8000 0.9000 0.7000 0.7000 
Maximum % 5.800 8.000 8.900 6.000 7.100 5.900 
 CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP 
Minimum % 0.1000 0.0 0.0 0.0 0.0 0.0 
Median % 3.900 2.000 2.050 1.700 2.250 2.750 
Maximum % 6.600 3.400 9.100 7.200 10.10 10.50 
 R848 R848 + VIP R848 R848 + VIP R848 R848 + VIP 
Minimum % 57.10 29.00 51.70 33.00 52.90 6.200 
Median % 73.90 57.45 67.30 61.70 64.50 53.70 
Maximum % 92.90 75.00 100.0 75.10 88.60 75.20 
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Figure 5.7: Frequency distribution of TNF-+mDCs in R848, LPS and CpG ODN stimulated whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-
1study groups 
TLR-L- and TLR-L+ (R848, LPS, CpG ODN) whole blood cultures, set up to assess intracellular cytokine production, were incubated for 4.5 hours and afterwards 
stained with mAbs to examine TNF- expression by mDCs using multi-parameter flow cytometry. The box and whiskers plot represents the percentage TNF-

+mDCs of the Control, ARV-HIV-1 and ARV+HIV-1 study groups per whole blood culture. Each boxplot shows the 10-90 percentile range of data (whiskers) and 
horizontal line the median value. Outliers are represented by black enclosed circles. Horizontal lines with diamond arrows indicate the specific study group 
comparison of interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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Table 5.11: Summary of TNF+mDC frequency in TLR-L- and TLR-L+ whole blood cultures of the control, ARV-HIV-1 and ARV+HIV-1 study groups  
 Study groups 
TNF+mDC Control ARV-HIV-1 ARV+HIV-1 
 TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP TLR-L- TLR-L- + VIP 
Minimum % 0 0 0 0 0 00 
Median % 0.75 0.70 1.15 0.60 1.55 0.90 
Maximum % 1.60 2.40 2.40 3.40 3.00 5.60 
 LPS LPS + VIP LPS LPS + VIP LPS LPS + VIP 
Minimum % 11.80 0 12.40 6.60 8.40 7.50 
Median % 18.05 16.25 35.90 28.10 21.10 15.25 
Maximum % 45.40 50.00 63.30 60.30 41.10 31.30 
 CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP CpG ODN CpG ODN + VIP 
Minimum % 0.40 0 0.20 0 0.20 0.50 
Median % 1.70 1.35 1.00 0.60 1.50 1.50 
Maximum % 9.50 2.40 3.10 2.20 5.60 5.00 
 R848 R848 + VIP R848 R848 + VIP R848 R848 + VIP 
Minimum % 49.40 41.60 55.40 50.40 14.30 23.50 
Median % 70.80 61.00 74.30 66.90 62.50 60.30 
Maximum % 92.10 85.10 88.20 84.00 84.90 77.70 
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5.5 Conclusion 
In view of the reduced DC numbers during HIV-1 infection and complete lack of number correction during 
ARV therapy, it is believed that the remaining DC pool in circulation is under immense strain. In lower 
number capacity the cells are required to respond to persistent levels of 1) HIV antigen (in untreated 
infection) in circulation and 2) HIV-1 induced inflammatory signals whilst being bombarded by higher degree 
of invading pathogens due to the immunocompromised status of an HIV-infected system. The current study 
aimed to evaluate how effective DCs from an HIV-1 infected system respond to the third proposed stimulus 
and were activated in vitro by triggering TLR receptors that activate DCs to respond to signals of bacterial 
and viral origin. The responses were evaluated via markers associated with apoptosis and chemotaxis. In 
addition, cytokine responses were also assessed. In this part of the study whole blood TLR-L- (unstimulated) 
and TLR-L+ (LPS, R848, CpG ODN) cultures were prepared for each of the study groups to evaluate the 
level of spontaneous and activated cellular marker expression, respectively. The results were then grouped 
so to evaluated the responses from the control, ARV-HIV-1 and ARV+HIV-1 study group per culture. In the 
current study the following was found 
 
1) DCs from HIV infected individuals effectively respond to TLR stimulation and the measured response was 
either greater (TNF-R2+pDCs:LPS and R848,TNF-R2+mDCs:CpG ODN, IFN-+pDCs: R848, TNF-
+mDCs: LPS), lesser (IL12p40+mDCs: R848)or similar (TNF-R2+pDCs:CpG ODN, TNF-R2+mDCs: LPS 
and R848,  TNF-+pDCs a R848) to the healthy control study group. 
2) ARV therapy (approx. 1 year of treatment) had a restorative effect with reduction of responses 
comparable to the healthy control study group (TNF-R2+pDCs: LPS and R848, IFN-+pDCs: R848, IFN-
+pDCs: R848, TNF-+mDCs: LPS,  
3) immune-inhibitory effect of ARV therapy with reduction of responses significantly lower than the control 
study group (TNF-R2+pDCs: CpG ODN, TNF-R2+mDCs:CpG ODN) 
4) spontaneous responses in unstimulated cultures: TNF-R2+pDCs 
 
DCs from a HIV-1 exposed environment showed heightened responses compared to unexposed DCs in 
most of the parameters investigated upon TLR stimulation. This may indicate the role that these cells play in 
driving inflammation during HIV infection. Nevertheless, the study showed that DCs are not functionally 
deprived during HIV-1 infection. Interestingly, as ARV therapy had seemingly no effect on the established 
parameters of immune status (no significant difference in CD4 and CD8 T lymphocyte counts as well as the 
CD4:CD8 ratio between the treated and untreated study groups) the results obtained from the TLR cultures 
were somewhat different. ARV therapy mostly corrected the changes induced by an HIV-1 infection to a 
degree that was comparable to the control study group. In some cases, ARV induced changes to levels 
lower than baseline (control study group). This may have adverse effects resulting in insufficient immune 
responses and would need to be investigated further. The reported discordancy has also been observed in 
Chapter 6 where ARV therapy fully recovered parameters of activation and exhaustion whilst having no 
effect on the signature parameters of immune status.VIP induced immune modulation of DC was limited and 
a more in-depth investigation is required into the use of VIP as an immunemodulatory agent for treating HIV-
1 infection. In essence DC function is not impaired in chronic HIV-1 infection, rather these cells appear to 
respond more strongly to innate stimulation. ARV therapy appeared to normalize the hyper-responsive, but 
in certain instances may actually impair DC function. 
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Chapter 6 
 
Distribution of CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets and relationship 
to apoptosis and activation markers expressing DCs during HIV-1 infection 
 
6.1 Introduction 
In addition to the gradual depletion of CD4 T lymphocytes, untreated HIV-1 infection is also characterised by 
aberrant immune activation. The latter phenomenon, however, is currently not assessed together with the 
standard HIV-1 clinical tests that quantify viral load and CD4 T lymphocyte numbers. Immune activation 
during HIV-1 infection has been assessed via expression of CD38 (T lymphocyte activation associated 
antigen) on CD8 T lymphocytes. Related studies strongly suggest the inclusion of this assay in ongoing 
clinical assessment of the disease. It was shown to have the potential in predicting disease progression to 
AIDS (Mahnke YD, et al. 2013; Liu Z, et al. 1997) as well as ARV therapy failure in vertically HIV-1 infected 
children (Resino S, et al. 2004). It might also prove to be an imperative test during HIV-1/TB co-infection 
where disease progression is more rapid.  
 
Many have investigated the distribution of CD8+CD38+ T lymphocyte subset during untreated HIV-1 infection 
and reported significantly higher frequency distribution of this subset compared to healthy individuals 
(Sharada RS, et al. 2012; Shi W, et al. 2009; Tuaillon E, et al. 2009; Hunt PW, et al. 2008; Almeida M, et al. 
2007; Hazenberg MD, et al. 2003; Sousa AE, et al. 2002). According to Chun T-W, et al. (2004), this subset 
was more prone to spontaneous and FAS mediated apoptosis and showed a distribution frequency that 
directly correlated with viral load. Others have shown the direct relationship between a related phenotype 
(CD8+CD45RO+CD38+ T lymphocyte) and plasma IFN- (Hardy GAD, et al. 2013) and that prolonged ARV 
treatment seemed to induce a decline in frequency distribution of these cells (Resino S, et al. 2004; Tilling R, 
et al. 2002). 
 
In addition to altered CD8+CD38+ T lymphocyte subset frequencies during HIV-1 infection, also higher 
numbers of CD8+ T lymphocyte subsets expressing Programmed Death 1 (PD-1/CD279) have been 
observed. Its association with disease progression has also been reported (as reviewed by Keir ME, et al. 
2008; Day CL, et al. 2006; Trautmann L, et al. 2006). PD-1 is a member of the CD28/CTLA-4 family of 
negative (inhibitory) regulators of T lymphocyte activation. Studies using a lymphocytic choriomeningitis virus 
(LCMV) infected mouse model have illuminated the role of PD-1 as a marker of immune exhaustion. Barber 
DL, et al. (2006) introduced the Armstrong and clone 13 LCMV strain into adult mice which produced an 
acute (cleared within 7 days) and chronic infection, respectively. Acute LCMV infection is characteristic of 
robust LCMV-specific CD8 T cell responses, while the functionality of these subsets wanes during chronic 
LCMV infection. Accordingly, post infection in vitro cultures showed CD8 T lymphocytes from chronically 
infected mice weakly responding to stimulation with LCMV peptide, displaying a significantly lower 
expression of CD44 (marker of proliferation) and IFN- (effector cytokine). In parallel, steady up-regulation 
(at mRNA as well as protein level) of PD-1 was observed in these mice during consecutive days of infection. 
The authors also observed an up-regulated expression of PD-1 on virus specific CD8 T lymphocyte during 
acute LCMV infection (6 days post infection), however, expression levels returned to a basal state upon 
clearance of the virus. The inhibitory effect associated with PD-1 is induced upon interaction with its natural 
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ligand, PD-1L. Notably, in employing in vivo anti-PD-L1 blocking treatment the authors observed improved 
antigen-specific CD8 T cell responses viz. higher expression of IFN- and TNF-. This was also 
accompanied by effective reduction of viral titers in serum and various organs. However, contrary to 
expectations, PD-L1 knock-out mice infected with Armstrong clone 13 LCMV strain succumbed to immune 
associated damage. This was indicative of the essential role that PD-1 plays in protecting immune responses 
from going into lethal “overdrive”. 
 
Main research interest 
Literature describes HIV-1 associated changes with regard to immune activation and exhaustion via 
the expression of CD38 and PD-1 on CD8 T lymphocyte subsets, respectively (Tuaillon E, et al. 2009; 
Zhang J-Y, et al. 2007; Day CL, et al. 2006;Petrovas C, et al. 2006; Trautmann L, et al. 2006; Hazenberg 
MD, et al. 2003; Sousa AE, et al. 2002). We wished to evaluate mono and dual CD38 and PD-1 
expression on CD8 T lymphocytes in ARV untreated and treated patients with or without TB co-
infection and relate the distribution of these CD8 T lymphocyte subsets to DCs positively expressing 
markers of apoptosis, activation and migration.  
 
Study aim: 
The present study aimed to profile CD38 and PD-1 (mono and dual) expression on CD8 T 
lymphocytes to investigate immune activation and exhaustion during HIV-1 infection and HIV-1/TB 
co-infection with or without ARV therapy. 
 
Study objectives 
- to determine the frequency distribution of the percentage CD8 T lymphocyte subsets as well as the 
CD4 and CD8 T lymphocyte count and CD4:CD8 ratio in HIV-1 and HIV-1/TB co-infected patients on 
or naïve for ARV therapy.  
- to determine the relationship of the CD8 T lymphocyte subsets to CD4 T lymphocyte counts and 
viral load  
- to determine the relationship of DC subsets positively expressing markers of apoptosis, activation 
and migration to each of the CD8 T lymphocyte subsets during untreated and ARV treated HIV-1 
and HIV-1/TB co-infection.It is believed that the current study is first to report on these 
relationships. 
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6.2  Outline of the study 
 
Refer to sections 6.3.1 - 6.3.6 for a detailed description on sample collection and processing 
SAMPLE COLLECTION 
Patient recruitment, blood collection by venesection at various clinics in the 
Western Cape, South Africa 
 
STUDY GROUPS 
5 Study groups: Control, ARV-HIV-1, ARV-HIV-1/TB, ARV+HIV-1 and ARV+HIV-1/TB 
 
WHOLE BLOOD (EDTA) PLASMA (EDTA) 
50µl 100µl 1ml 
   
4-COLOUR FLOW CYTOMETRY REAL TIME PCR 
CD4 and CD8 T cell 
quantification.  
ASSAY: Staining with BD 
MultiTEST™ mAbs: CD3 
FITC, CD8 PE, CD45 
PerCP, CD4 APC in BD 
TruCOUNTTM tube 
CD8 T lymphocyte profiling  
 
ASSAY: Staining with mAbs: CD3 FITC, 
CD8 PerCP, CD38 APC, PD-1 PE 
 
Viral load quantification  
 
ASSAY: ABBOTT Real Time 
HIV-1 PCR assay (ABBOTT 
m2000rt)/bioMérieuxNucliSensE
asyQ® HIV-1, v1.2 test 
   
DATA COLLECTED 
CD4 and CD8 T cells      
- cells/µl 
CD8 T lymphocytes 
- % CD8+CD38+T lymphocytes 
- % CD8+PD-1+ T lymphocytes  
- % CD8+CD38+PD-1+ T lymphocytes  
Viral load 
- RNA copies/ml 
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6.3  Material and methods 
 
6.3.1 Study groups and clinical data 
A subset of participants (enrolled between Sept 2011 and Mar 2012) of the 5 study groups described within 
the broader project (chapters 4 and 5) were concurrently also used in this part of the study. Table 6.1 
summarises the demographic and clinical data of the participants of the 5 study groups (Controls (n=16), 
ARV-HIV-1 (n=13), ARV-HIV-1/TB (n=12), ARV+HIV-1 (n=12) and ARV+HIV-1/TB (n=16)). Refer to Table 3.1 
for a detailed description on the criteria for participant enrolment relevant to these study groups. Recruited 
patients on ARVs were using one of the following treatment regimens: TDF, Lamivudine, EFV (57% of the 
total ARV users); Stavudine, Lamivudine, EFV (17%) and less than 7% were using different combination of 
ARV therapy. TB co-infected patients were either using Pyridoxine or Rifafour (Combination of four agents: 
Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) drugs.Participants were from state clinics in a peri-
urban area of Cape Town, South Africa, which included Tygerberg (1% of the total recruits), Idasvalley 
(12%), Durbanville (66%), Kuilsriver (5%) as well as the Desmond Tutu Emavundleni Clinic Site in 
Khayelitsha (16%). Participants from the latter site were predominantly enlistees of the ARV-HIV-1 study 
groups.Note that this assay was initiated on a later stage during the study due to an emerging interest to 
examine the relationship of HIV-1 associated immune activation and exhaustion to DCs positively expressing 
markers of apoptosis, activation and migration. Accordingly, this part of the study comprised of a smaller 
sample size per study group. 
 
Table 6.1:  Demographic and clinical data of participants in the study groups analysed to examine 
CD38 and PD-1 (mono and dual) expression by CD8 T lymphocytes 
aAge median and range expressed in years 
bTime on treatment median and range expressed in months 
 Study Groups 
 Control 
ARV- ARV+ 
HIV-1 HIV-1/TB HIV-1 HIV-1/TB 
Total (n)  16 13 12 12 16 
Male: Female 
nr 
% 
5:7 
42:58 
2:10 
17:83 
6:6 
50:50 
5:7 
42:58 
10:6 
63:38 
Agea 
Median  
Range  
29 
21-58 
30 
22-50 
34 
23-69 
42 
23-55 
38 
26-50 
Time on ARV therapyb 
Median  
Range  
N/A N/A N/A 16 
<1 - 49 
5 
2 - 69 
Time on anti-TB therapyb 
Median  
Range 
N/A N/A 0 
0-8 
N/A 3 
0-8 
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6.3.2 General specimen processing 
Specimens were processed as described in section 4.3.2. Briefly, the blood sample that was collected in 
EDTA vacutainer tubes (BD Biosciences, San Jose, CA) for CD4 and CD8 T lymphocyte absolute number 
(refer to section 3.3.6) and HIV viral load (refer to section 3.3.7)  quantification was also used for whole blood 
staining with markers to examine immune activation and exhaustion.  
 
6.3.3 mAbs used to investigate signature markers of immune activation and exhaustion on CD8 T 
lymphocytes in peripheral whole blood 
Mouse anti-human mAbs used in this part of the study included CD3 FITC (expressed on T lymphocytes); 
CD8 PerCP (expressed on cytotoxic T lymphocytes); CD38 APC (expressed on activated T lymphocytes) 
and PD-1 PE (expressed on activated T and B lymphocytes). These mAbs were purchased from either 
Biolegend1 (San Diego, CA), BD Biosciences2 (San Jose, CA) or e-Bioscience3 (San Diego, CA).  Refer to 
Table 6.2 for mAb clone and isotype information. 
 
Table 6.2: Clone , isotype and reactivity information on the mAbs used to detect immune 
activation and exhaustion 
mAb Clone Isotype Reactivity 
CD3 FITC1 OKT3 Mouse IgG2a,   Human 
CD8 PerCP2 SK1 Mouse IgG1,  Human 
CD38 APC2 HB7 mouse IgG1,  Human 
PD-1 PE 3 MIH4 Mouse IgG1,  Human 
 
6.3.4 Whole blood staining procedure to detect CD38 and PD-1 expressing CD8 T lymphocytes 
Staining of EDTA whole blood (100 µl) was performed as outlined in section 4.3.5. Briefly, the mAb cocktail 
used consisted of 5µl of each of the CD8 PerCP, CD38 APC,CD3 FITC and PD-1 PE mAbs as well as 50µl 
staining buffer (titration was not required as a standardised in-house assay was followed). After lysing and 
washing, the sample was resuspended in 500
l staining buffer and immediately acquired on a BD 
FACSCaliburTM 4-colour flow cytometer utilizing the BD CellQuestTM Pro software (BD Biosciences, San 
Jose, CA). The BD FACSDiva™ software v6.1.3 (BD Biosciences, San Jose, CA) was used to analyze the 
acquired events. The gating strategy is displayed in Figure 6.1. During event acquisition, the general 
lymphocyte population was identified in a SSC-A vs. FSC-A density plot and a stopping gate set to collect a 
total of a 100 000 gated lymphocyte events (Figure 6.1 B). A specific threshold was set on the FSC 
parameter to exclude debris.  
 
6.3.5 Flow cytometric analyses: Gating strategy to define the CD38 and PD-1 expressing CD8 T 
lymphocytes from total acquired events 
In analyses, total acquired events was displayed in a SSC vs. CD3 dot plot and a polygon gate, P1, used to 
select CD3 positive events with low SSC properties (Figure 6.1 A). In parallel, these events were also 
identified in a SSC vs. FSC density plot displaying total acquired events. P1 was then displayed in a CD3 vs. 
CD8 density plot (Figure 6.1 C) and a P2 polygon gate collected the dual CD3 and CD8 expressing T 
lymphocyte population. The latter was displayed in a CD38 vs. CD8 (Figure 6.1D), PD-1 vs. CD8 (Figure 6.1 
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E) and CD38 vs. PD-1 (Figure 6.1 F) density plot and events analysed using a quadrant (Q) gating. Q2, Q2-1 
and Q2-2 defines the CD8 T lymphocytes expressing CD38, PD-1 and dual CD38 PD-1, respectively. These 
populations were also referred to as CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+T lymphocyte subsets. 
The position of the polygon and quadrant gates to distinguish between positive and negative events was 
determined via the procedure of FMO controls as previously described (Section 4.3.7.2).  
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6.3.6 Statistical analyses 
Comparative statistical analyses of the percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T 
lymphocytes; CD4 and CD8 T lymphocytes absolute counts and CD4:CD8 ratio was primarily performed as 
described in section 3.3.8. Correlation analyses were performed using the test as described in section 3.3.8 
and the following was of interest: the relationships of the percentage CD8+CD38+, CD8+PD-1+ and 
CD8+CD38+PD-1+ T lymphocyte subsets to a) CD4 T lymphocyte counts of the control, HIV-1 and HIV-1-
related study groups, b) viral load of the ARV-HIV-1 and ARV-HIV-1/TB study groups and c) percentage DCs 
positively expressing markers related to apoptosis (these include TNFR-2+pDCs, TNFR-2+mDCs, 
FAS+mDCs) and activation (CD62L+pDCs, CD62L+mDCs and CD86+mDCs) of the control, HIV-1 and HIV-1-
related study groups.  Statistical analysis was performed using the Graphpad Prism version 5.00 software 
(San Diego, California, USA). Refer to Table 3.4for the summary of the method used to report significant and 
non-significant data as well as the corresponding p value range. 
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6.4  Results and Discussion 
 
6.4.1 Frequency distribution of the percentage CD8+CD38+, CD8+PD-1+and CD8+CD38+PD-1+ T 
lymphocytes of the control and HIV-1-related study groups 
Significantly higher levels of CD8+CD38+, CD8+PD-1+and dual expressing CD8+CD38+PD-1+ T lymphocytes 
circulate during ARV-HIV-1 infection. 
The current study observed marked changes in the distribution of CD8+CD38+, CD8+PD-1+ and, in particular, 
CD8+CD38+PD-1+T lymphocytes during ARV untreated HIV-1 infection and HIV-1/TB co-infection. Compared 
to the control study group, the frequency distribution of the median percentage CD8+CD38+PD-1+T 
lymphocytes showed a significant increase of 3.85 fold and 4.62 fold in the ARV-HIV-1 study group (p  
0.001)  andARV-HIV-1/TB study group (p  0.001), respectively(Table 6.3; Figure 6.2C). These study groups 
also showed significantly higher frequencies of the CD38and PD-1 mono expressing CD8 T lymphocytes 
subsets, however, to a lesser degree of intensity when compared to the dual expressing subset.In relation to 
the control study group, the median percentageCD8+CD38+and CD8+PD-1+T lymphocyte subsets was 
significantly higher in the ARV-HIV-1 study group at a degree of 82% (p  0.05) and 81% (p   0.01), 
respectively, as well as in the ARV-HIV-1/TB study group at a degree of 112% (p   0.001) and 73% (p   
0.01), respectively (Table 6.3; Figure 6.2: A and B). These changes observed clearly show the impact of an 
HIV-1 infection on immune activation and exhaustion. However, not much has been reported on the specific 
process that triggers these changes. A report by Hunt PW, et al. (2008) proposed microbial leakage to play a 
role as the authors were able to correlate plasma LPS levels with enhanced CD38+HLA-DR+CD8+ T 
lymphocyte frequency during HIV infection. In view of a report by Peretz Y, et al. (2012), it was proposed that 
studies on T cell exhaustion should also investigate the frequency distribution of CD8 T lymphocyte subsets 
expressing CD160 (a negative regulator of T lymphocyte activation) together with PD-1 and CD38 as this 
may represent a phenotype with suboptimal functional abilities. The authors showed that CD160+CD8+PD-
1+T lymphocytes were indicative of a functionally exhausted phenotype compared to subsets of T 
lymphocytes mono expressing CD160/PD-1. 
 
Similar distribution of CD8 T lymphocytes with mono and dual expressing CD38 and PD-1 markers observed 
during ARV-HIV-1 infection and ARV-HIV-1/TB co-infection 
Contrary to expectations, a significant change in the frequency distribution of the median percentage  
CD8+CD38+, CD8 +PD-1+ and CD8+CD38+PD-1+T lymphocytes between the ARV-HIV-1 and  ARV-HIV-1/TB 
study groups was not observed (Table 6.3; Figure 6.2: A, B and C, respectively). This finding indicated that a 
TB co-infection does not alter the distribution of these subsets more significantly than an HIV-1 infection. 
Similar findings were reported by Sunder SR, et al. (2012) with regard to the CD8+CD38+and CD8+PD-1+ T 
lymphocyte subsets. In contrast to our findings, however, the authors did observe a significantly higher 
distribution of CD8+CD38+PD-1+T lymphocytes during HIV-1/TB co-infection compared to HIV-1 infection. As 
little information was available on the study cohort investigated we proposed several factors for the 
discrepancy between the studies, namely, difference in sample size as well as cohort specific factors such as  
stage of HIV and TB disease, viral load, CD4 T lymphocyte count and immunological status (CD4:CD8 ratio) 
at the time of data collection. 
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Reduced frequency ofCD8+CD38+, CD8+PD-1+ and dual expressing CD8+CD38+PD-1+ T lymphocytes 
circulate during ARV treatment > 12 months. 
Untreated HIV-1 infection allows unrestrained replication of the HIV-1and drastically impacts on various 
aspects of the immune system. However, ARV treatment (in most cases) has proven effective in controlling 
HIV-1 replication and reducing viral load to undetectable plasma levels (Almeida M, et al. 2006). Similarly, 
ARV therapy seemed to have a strong restorative impact on  circulating  CD8+CD38+, CD8 +PD-1+ and 
CD8+CD38+PD-1+T lymphocyte subsets during HIV-1 infection as a clear trend towards normalisation was 
observed. In comparing the percentage CD8 T lymphocyte subsets of the ARV+HIV-1 study group to the  
ARV-HIV-1 study group, the  CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets seemed 
to circulate at a reduced median frequency of 37% (p = 0.087), 27% (p = 0.054) and 60% (p =0.054), 
respectively. Notably, the indicated p values strongly curved towards significance (Table 6.3; Figure 6.2: A, B 
and C). However, the propensity of ARV therapy to reduce immune activation and exhaustion was not 
observed in the ARV+HIV-1/TB study group. In comparing the CD8 T lymphocyte subsets of the latter study 
group to the corresponding ARV-HIV-1/TB study group the study observed a minor decline of 11%, 10%  and 
33%in the median percentage  CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+T lymphocytes, respectively. 
Notably, comparative statistics for the latter CD8 T lymphocyte subset trended towards significance (p=0.1). 
The insignificant reduction in these subsets was, as expected, mirrored by the lack of immune recovery. 
Compared to the control study group, the ARV+HIV-1/TB study group showed a significantly higher median 
distribution to a degree of 87% (p  0.01), 56% (p  0.05) and 274% (p  0.001) in the CD8+CD38+, CD8+PD-
1+ and CD8+CD38+PD-1+T lymphocyte subsets, respectively (Table 6.3; Figure 6.2: A, B and C). It was 
proposed that the lack of decline in frequency distribution of the CD8 T lymphocyte subsets of the ARV+HIV-
1/TB study group was most probably due to an insufficient time on ARV therapy. The median time on ARV 
therapy for the ARV+HIV-1/TB study group was 5 months, vastly different to the 16 months of the ARV+HIV-1 
study group, which, as reported previously, showed a significant decline in the distribution of the CD8 T 
lymphocyte subsets. Hence, these findings suggest that prolonged treatment (> 12 months) is required to 
reduce the CD8 T lymphocyte subset levels. A longitudinal study conducted by Tilling R, et al. (2002), 
following the  CD8+CD38+T lymphocytes over a 7 month period of HAART treatment, also showed  the 
frequency of these cells to decline during treatment. Noteworthy is the fact that the besides ARV therapy (> 
12 month) influencing immunological recovery (to a certain degree) with 1) immune activation and 
exhaustion levels normalizing and 2) CD4 T lymphocyte numbers and CD4:CD8 ratio improving (partially) 
(chapter 3) it does not induce DC number recovery (chapter 3).   
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Table 6.3: Summary of the CD4 and CD8 T lymphocyte absolute number and percentage; 
CD4:CD8 ratio; viral load (as applicable) as well as the percentage distribution of the 
CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte of the control, HIV-1 and 
HIV-1-related study groups. 
Data indicated as: 
Mea = Median cells/µl,  
Ra= Range cells/µl,  
Meb = Median % of CD8 T lymphocytes,  
Rb= Range % of CD8 T lymphoctes,  
Mec = Median ratio of CD4 Lymphocyte absolute number to CD8 T lymphocyte absolute number 
Rc= Range of CD4:CD8 ratio 
Med = Median RNA copies/ml,  
Rd = Range RNA copies/ml 
 
 
 
 
 
 
 
 
 
 
Study groups 
 Control ARV-HIV-1 ARV
-HIV-1 
/TB ARV
+HIV-1 ARV
+HIV-1  
/TB 
CD4  
T cells 
Mea 
Ra 
960 
412-1694 
369 
14-909 
200 
51-598 
388 
143-1072 
243 
52-840 
Meb 
Rb 
44 
31-67 
22 
4-31 
15 
11-30 
20.5 
11-31 
14 
4-47 
CD8  
T cells 
Mea 
Ra 
582 
205 - 1132 
1045 
187 - 1667 
816 
229 - 3106 
1058 
477 - 1789 
818 
306 - 2738 
Meb 
Rb 
28.5 
15 - 40 
51 
38 - 77 
56.5 
45 - 76 
48 
34 - 73 
61.5 
34 - 85 
CD4:CD8 
ratio 
Mec 
Rc 
1.44 
0.81 - 2.8 
0.43*** 
0.07 - 0.66 
0.26*** 
0.16 - 0.6 
0.49** 
0.15 - 0.72 
0.25*** 
0.08 - 0.39 
CD38+ 
CD8+T 
cells 
Meb 
Rb 
31.35 
11.86 - 67.27 
56.95 
8.98 - 97.54 
66.33 
33.98 - 89.74 
36.05 
4.46 - 70.05 
58.75 
13.16 - 92.59 
PD-1+ 
CD8+T 
cells 
Meb 
Rb 
28.84 
6.8 - 48.44 
52.17 
19.10 - 80.85 
50 
29.11 - 76.09 
37.83 
14.04 - 61.72 
44.91 
15.98 - 80.94 
CD38+ 
PD-1+ 
CD8+ 
T cells 
Meb 
Rb 
6.19 
1.14 - 24.89 
30.02 
4.37 - 76.12 
34.81 
21.37 - 57.52 
12 
1.42 - 32.05 
23.17 
9.01 - 77.09 
Viral load  Me
d
 
Rd N/A 
2.7x103 
LOD - 3.5x106 
7.2x104 
340-3.3x106 
LOD 
LOD-310 
LOD 
LOD–1.3x103 
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Figure 6.2: Changes in percentage CD8+CD38+, CD8+PD-1+ and dual expressing CD8+CD38+PD-1+T lymphocytes during ARV untreated and treated HIV-
1 mono and HIV-1/TB co-infection 
Peripheral whole blood was appropriately stained to examine the expression (mono and dual) of CD38 and PD-1 on CD8 T lymphocytes using 4- colour flow 
cytometry. The box and whiskers plot graph represent the percentage CD8+CD38+ T lymphocytes(A), CD8+PD-1+ T lymphocytes (B) and CD8+CD38+PD-1+ T 
lymphocytes (C) of the control, untreated and ARV treatedHIV-1 and HIV-1/TB study groups. Each boxplot shows the 10-90 percentile range of data (whiskers) and 
horizontal line the median value. Outliers are represented by a black enclosed circle. Horizontal lines with diamond arrows indicate the specific study group 
comparison of interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to indicate the level of statistical significance.  
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6.4.2  Absolute numbers of CD4 and CD8 T lymphocyte counts and CD4:CD8 ratio in the control 
and HIV-1-related study groups 
Additionally, the CD4 and CD8 T lymphocyte counts of the participants enrolled were also determined.  
Compared to the control study group, the decline in the median CD4 T lymphocyte count of the HIV-1 and 
HIV-1-related study groups was significant and, notably, similar between the ARV untreated and treated 
study groups. Also, the same profile was observed upon evaluation of the CD4:CD8 ratio across the different 
study groups. The median CD4 T lymphocytes counts in both the ARV-HIV-1 and ARV+HIV-1 study groups 
were observed at a 60% lower frequency (ARV-HIV-1: p  0.01; ARV+HIV-1: p  0.05) while in  the ARV-HIV-
1/TB and ARV+HIV-1/TB study group a 79% (p  0.001) and 75% (p  0.001) lower frequency was observed 
compared to the control study group, respectively (Table 6.3, Figure 6.3 A and B). As the median CD4 T 
lymphocyte absolute number as well as CD4:CD8 ratio distribution of the untreated study groups was 
analogous to the ARV treated study groups, we were unable to show in this part of the study the ARV-
associated (partial) recovery as reported in chapter 3. This contrasting finding was attributed to various 
factors such as the small sample size of the study groups as well as enrolment of individuals regardless of 
their CD4 T lymphocyte count. Hence, it is most likely that the study groups included participants at various 
stages of HIV-1 disease progression which may influence the statistical outcome. The median CD8 T 
lymphocyte counts were higher in both the ARV treated and untreated study groups, however the change 
when compared to the control study group was only significant in the ARV+HIV-1 study group (p  0.05). 
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Figure 6.3:  Changes in CD4 T lymphocyte and CD8 T lymphocyte absolute number as well as 
CD4:CD8 ratio during ARV untreated and treated HIV-1 mono and HIV-1/TB co-
infection 
Peripheral whole blood was stained with the BD MultiTEST™ reagent (CD3, CD8, CD45, CD4 mAb cocktail) 
using the BD TruCOUNT™ assay and analysed using 4 - colour flow cytometry to determine the absolute 
count (cells/µl) of CD4 and CD8 T lymphocytes and CD4:CD8 ratio. The box and whiskers graph represents 
the absolute number of CD4 T lymphocytes (A), CD8 T lymphocytes (B) and CD4:CD8 ratio (C) of the 
control, untreated and ARV treated HIV-1 and HIV-1/TB study groups. Each boxplot shows the 10-90 
percentile range of data (whiskers) and horizontal line the median value. Outliers are represented by black 
enclosed circles. Horizontal lines with diamond arrows indicate the specific study group comparison of 
interest and an asterisk(s) the significance. Refer to Table 3.4 for a description of the method used to 
indicate the level of statistical significance.  
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6.4.3  Correlating CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes frequency to CD4 T 
lymphocyte count and viral load 
Immune activation and exhaustion levels indirectly correlate with CD4 T lymphocyte count and directly with 
viral load during HIV-1 infection 
Distinctively different profiles were obtained in the control and ARV-HIV-1 study group when correlating the 
percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes with median CD4 T lymphocyte 
counts. In the control study group no correlation was found, hence, constant frequencies of the CD8 T 
lymphocyte subsets was observed across the CD4 T lymphocyte count range (CD8+CD38+ T lymphocytes (r 
= 0.04, p = 0.74), CD8+PD-1+ T lymphocytes (r = -0.02, p = 0.96), CD8+CD38+PD-1+ lymphocytes (r = 0.009, 
p = 0.86) (Figure 6.4). However, this profile was mostly altered in the ARV-HIV-1 study group. A strong 
indirect correlation was observed between median CD4 T lymphocyte counts and the percentage 
CD8+CD38+ (r = -0.85, p = 0.0002) as well as the percentage CD8+CD38+PD-1+ (r = -0.8, p = 0.004) T 
lymphocytes. The percentage CD8+PD-1+ T lymphocytes (r = -0.44, p = 0.15) showed a weak indirect 
correlation (Figure 6.5 A). Clearly, this finding suggests that concurrent to the higher frequencies of CD8 T 
lymphocyte subsets associated with immune activation and/or exhaustion, lower CD4 T lymphocyte numbers 
circulate during untreated HIV-1 infection. In addition, raised activation levels were also associated with 
increasing viral load. In the ARV-HIV-1 study group we observed a significant direct association between viral 
load and the percentage CD8+CD38+ T lymphocytes (r = 0.54, p = 0.01), a weak direct association with the 
percentage CD8+CD38+PD-1+ T lymphocytes (r = 0.32, p = 0.1) and no correlation with the percentage 
CD8+PD-1+ lymphocytes (r = -0.07, p = 0.73) (Figure 6.6 A). Clearly, CD38 expression, but less to that of 
PD-1 is influenced by viral load. 
 
In assessment of the percentage CD8 T lymphocyte subsets vs. CD4 T lymphocyte count of the ARV-HIV-
1/TB study group, we observed a correlation profile different to the ARV-HIV-1 study group (Figure 6.5 B). 
One would have expected the correlation profile of the two study groups to be similar as these groups 
manifested with similar 1) frequencies of circulating CD8 T lymphocyte subsets (Table 6.3) and 2) CD8 T 
lymphocyte subsets vs. viral load correlation profiles. As with the ARV-HIV-1 study group, the viral load of the 
ARV-HIV-1/TB study group showed a strong direct correlation with the percentage CD38+8+ T lymphocytes (r 
= 0.78, p = 0.003), weak direct correlation with percentage CD8+CD38+PD-1+ lymphocytes (r = 0.43, p = 
0.13) and no correlation with the percentage CD8+PD-1+ T lymphocytes (r = - 0.22, p = 0.79) (Figure 6.6 B). 
However, a pertinent difference between the two study groups was the median CD4 T lymphocyte counts. 
The ARV-HIV-1 and ARV-HIV-1/TB study group had a median CD4 T lymphocyte count of 369 cells/µl, 
ranging from 14 – 909 cells/µl and 200 cells/µl, ranging from 51 - 598 cells/µl, respectively. Accordingly, the 
former study group included participants from early to late stage of disease progression, while the latter 
group mostly represent participants in intermediate to late state of disease progression. Hence, it was 
proposed that the dissimilar correlation pattern between the ARV-HIV-1 and ARV-HIV-1/TB study group 
might be due to the inadvertent exclusion of participants with a CD4 T lymphocyte count suggestive of early 
stage of disease. Hence, we propose that future studies aiming to define or monitor the relationship between 
the CD8 T lymphocyte subsets and CD4 T lymphocyte count during HIV-1 infection, includes participants 
with disease status ranging from early to late stage.  
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Prolonged ARV therapy contributes to reduced immune activation and exhaustion 
A clear indirect correlation profile was observed when comparing the percentage CD8+CD38+ T lymphocytes 
(r = - 0.67, p = 0.05), CD8+CD38+PD-1+ T lymphocytes (r = - 0.62, p = 0.08) and CD8+PD-1+ T lymphocytes 
(r = - 0.48, p = 0.11) to the CD4 T lymphocyte count of the ARV+HIV-1/TB study group (Figure 6.5 D). The 
former two subsets showed a mostly strong, while the latter a weak relationship. The correlation profile of 
this ARV treated HIV-1/TB study group was comparable to that of the untreated HIV-1 study group and 
attributed to the short and ineffective median ARV treatment time (5 months) associated with the former 
group. In contrast, the CD4 T lymphocyte count of the ARV+HIV-1 study group did not correlate with any of 
the CD8 T lymphocytes subsets (CD8+CD38+ T lymphocytes (r = - 0.09, p = 0.85), CD8+PD-1+ (r = - 0.42, p = 
0.26) and CD8+CD38+PD-1+ T lymphocytes (r = - 0.32, p = 0.36)) (Figure 6.5 C) and produced  a correlation 
profile closely related to the control study group (Figure 6.4). This study group had a median time on ARV 
therapy of more than 12 months and clearly showed that prolonged ARV control over HIV-1 replication 
effectively reduced immune activation and exhaustion. However, as the median CD4 T lymphocyte counts of 
the ARV+HIV-1 study group (median: 369 cells/µl, range: 14-949 cells/µl) after 16 months of ARV therapy 
was similar to that of the untreated HIV-1 study group (median 388 cells/µl, range143-1072 cells/µl) it seems 
that an ARV treatment period greater than 1 year does not exert a similar remedial effect on CD4 T 
lymphocyte numbers as observed with the CD8 T lymphocyte subsets. This, however, needs to be confirmed 
upon analyses of a bigger sample cohort. 
 
Correlation between the CD8 T lymphocyte subsets and viral load was not determine for the ARV+HIV-1 and 
ARV+HIV-1/TB study group as the median viral load for both groups was LOD. 
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Figure 6.4: Correlating percentage CD8 T lymphocyte subsets and CD4 T lymphocyte counts in the 
control study group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study group and plotted together with corresponding CD4 T lymphocyte count 
on a line graph. The percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 
1) represented by the symbols ,  and , and 2) relationship to CD4 T lymphocyte count illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to CD4 T lymphocyte counts. 
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Figure 6.5: Correlating the percentage CD8T lymphocyte subsets to CD4 T lymphocyte counts 
during ARV untreated and treated HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding CD4 T lymphocyte 
count on a line graph. The percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte 
subsets were 1) represented by the symbols ,  and , and 2) relationship to CD4 T lymphocyte count 
illustrated by a green, pink and blue-coloured linear regression line, respectively. The non-parametric 
Spearman test was use to correlate the percentage CD8 T lymphocyte subsets to CD4 T lymphocyte counts. 
Statistically significant data are highlighted in bold. 
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Figure 6.6: Correlating the percentage CD8 T lymphocytes to viral load during ARV untreated HIV-1 
mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control and HIV-1-related study groups and plotted together with corresponding HIV-1 
viral load on a line graph. The percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte 
subsets were 1) represented by the symbols ,  and , and 2) relationship to viral load illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to CD4 T lymphocyte counts. Statistically 
significant data are highlighted in bold. 
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6.4.4  Correlating CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes to DC subsets 
positively expressing markers of apoptosis, migration and activation 
 
As described previously, TNF-R2 and FAS play a role in apoptosis, CD62L is a marker related to cell 
activation and CD86 is a characteristic DC activation marker. These markers were investigated in 
accordance with the current study’s hypothesis proposing cell death, migration and activation to play a role in 
the decline of DCs numbers during HIV-1 infection. As described in Chapter 4 these markers were found 
positively expressed by either both or one of the DC subsets. Furthermore, comparative analysis found no 
significant change in the frequency distribution of mDCs expressing TNF-R2, FAS, CD62L and CD86 and 
pDCs expressing CD62L. However, a significant change in distribution of TNF-R2 expressing pDCs during 
HIV-1 infection was observed. It was of great interested to determine the relationship of DCs positively 
expressing these markers of apoptosis, migration and activation to signature markers of exhaustion and 
activation during HIV-1 infection. Hence, this part of the study focused on correlating the CD8+CD38+, 
CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes subsets to TNF-R2+pDCs, TNF-R2+mDCs, FAS+mDCs, 
CD62L+pDCs,CD62L+mDCs and CD86+mDCs of the control, HIV-1 and HIV-1-related study groups. 
 
TNF-R2+pDCs did not significantly correlate with the CD8 T lymphocyte subsets during HIV-1 infection 
In evaluating the relationship of the percentage CD8+CD38+T lymphocytes (r = 0.16, p = 0.17) and CD8+PD-
1+ T lymphocytes (r = 0.18, p = 0.38) to the percentage TNF-R2+pDCs of the control study group, no 
significant correlation was observed. However, the percentage dual CD38 and PD-1 expressing CD8 T 
lymphocytes(r = 0.44, p = 0.10) showed a weak tendency to directly correlate with the percentage TNF-
R2+pDCs (Figure 6.7). Furthermore, no significant relationship was observed between the percentage TNF-
R2+pDCs and percentage CD8+CD38+ T lymphocytes, CD8+PD-1+ T lymphocytes and CD8+CD38+PD-1+ T 
lymphocytes of the ARV-HIV-1 study group (r = 0.28, p = 0.20; r = 0.22, p = 0.51; r = 0.21, p = 0.42, 
respectively, Figure 6.8A), ARV-HIV-1/TB study group (r = 0.25, p = 0.33; r = -0.13, p = 0.8; r = 0.18, p = 
0.46, respectively, Figure 6.8B) as well as the  ARV+HIV-1/TB study group (r = 0.24, p = 0.26; r = 0.23, p = 
60; r = 0.38, p = 0.20, respectively, Figure 6.8D). Notably, as the relationship between TNF-R2+pDCs and 
the CD8 T lymphocytes of the control study group steered towards a direct correlation, an inverse 
relationship was observed with the ARV+HIV-1 study group (r = -0.18, p = 0.57; r = -0.22, p = 0.25; r = -0.37, 
p = 0.42) (Figure 6.8C). However, these relationships were not significant. 
 
Prolonged ARV therapy (>1year) results in higher percentage TNF-R2+mDCs to circulate with declining 
levels of the CD8 T lymphocyte subsets 
The control study group showed a strong direct and significant relationship upon correlating the percentage 
TNF-R2+mDCs to the percentage CD8+PD-1+ T lymphocyte subsets which was accompanied by a strong 
tendency of this mDC subset to indirectly correlate with CD8+CD38+T lymphocytes (r = -0.42, p = 0.06). Also 
in this study group the CD8+CD38+PD-1+ T lymphocyte population (r = 0.42, p = 0.09) showed a weak but 
insignificant direct relationship with TNF-R2+mDCs. Hence, it seems that higher frequency of TNF-R2+mDCs 
tends to associate with increasing apoptotic and declining activation activity in HIV-1 uninfected individuals 
(Figure 6.9). However, in the ARV-HIV-1 study group the percentage CD8+CD38+T lymphocytes (r = 0.21, p 
= 0.53), CD8+PD-1+T lymphocytes (r = 0.22, p = 0.51) and CD8+CD38+PD-1+ (r = 0.51, p = 0.88) of the ARV-
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HIV-1 study group showed a positive, but insignificant, relationship with TNF-R2+mDCs (Figure 6.10A). An 
interesting observation was the significant correlation between the percentage TNF-R2+mDCs and 
percentage CD8 T lymphocyte subsets of the ARV+HIV-1 study group. Here the study observed a strong 
indirect correlation between the percentage TNF-R2+mDCs and 1) the percentage CD8+CD38+ T 
lymphocytes (r = -0.84, P = 0.06), 2) CD8+PD-1+ lymphocytes (r = -0.56, p = 0.01) and 3) CD8+CD38+PD-1+ 
T lymphocytes (r = -0.88, p = 0). It seems that ARV therapy reduces the distribution of the CD8 T phenotype 
subsets together with TNF-R2+mDCs (Figure 6.10C). In contrast to the profile observed with the ARV+HIV-1 
study group, the percentage  CD8+CD38+T lymphocytes (r = 0.51, p = 0.05), CD8+PD-1+ T lymphocyte (r = 
0.2, p = 0.48) and CD8+CD38+PD-1+ T lymphocytes (r = 0.37, p = 0.18) of the ARV+HIV-1/TB study group 
showed a direct correlation with TNF-R2+mDCs of which the former subset correlated significantly (Figure 
6.10D). It was proposed that the contrasting profile observed between the ARV+HIV-1 and ARV+HIV-1/TB 
study groupsmaybe the effect of prolonged ARV therapy as the median time on therapy of the former study 
group was 16 months and that of latter study group 5 months. Its debated, whether this association that 
develops upon the use of ARV therapy would be beneficial to the host as the relationship of CD8+PD-1+ T 
lymphocytes and CD8+CD38+PD-1+ T lymphocytes to TNF-R2+mDCs did not revert to that of the control 
study group during ARV therapy, in fact, a direct contrasting profile was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Correlating TNF-R2+pDCs to percentageCD8 T lymphocyte subsets in the control study 
group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study groups and plotted together with corresponding percentage TNF-R2 
pDCs on a line graph. The  CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 1) 
represented by the symbols ,  and , and 2) relationship to percentage TNF-R2 pDCs illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentage TNF-R2+pDCs.  
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Figure 6.8:  Correlating TNF-R2+pDCs to percentage CD8 T lymphocyte subsets in ARV untreated 
and treated HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding percentage TNF-
R2 pDCs on a line graph. The percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte 
subsets were 1) represented by the symbols ,  and , and 2) relationship to percentage TNF-
R2+pDCs illustrated by a green, pink and blue-coloured linear regression line, respectively. The non-
parametric Spearman test was use to correlate the percentage CD8 T lymphocyte subsets to percentage 
TNF-R2+pDCs.  
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Figure 6.9: Correlating TNF-R2+mDCs to percentage CD8 T lymphocyte subsets of the control 
study group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study group and plotted together with corresponding percentage TNF-
R2+mDCs on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 
1) represented by the symbols ,  and , and 2) relationship to percentage TNF-R2 mDCs illustrated by 
a green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentage TNF-R2+mDCs. Statistically 
significant data are highlighted in bold. 
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Figure 6.10: Correlating TNF-R2+mDCs to percentage CD8 T lymphocyte subsets in ARV untreated 
and treated HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding percentage TNF-
R2+mDCs on a line graph. The percentage CD8+CD38+,CD8+PD-1+and CD8+CD38+PD-1+T lymphocyte 
subsets were 1) represented by the symbols ,  and , and 2) relationship to percentage TNF-
R2+mDCs illustrated by a green, pink and blue-coloured linear regression line, respectively. The non-
parametric Spearman test was use to correlate the percentage CD8 T lymphocyte subsets to percentage 
TNF-R2+mDCs. Statistically significant data are highlighted in bold. 
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No correlation between the CD8 T lymphocyte subsets and FAS+mDCs during HIV-1 infection 
No signicant relationship was observed in relating the percentage CD8+CD38+, CD8+PD-1+, CD8+CD38+PD-
1+ T lymphocyte subsets to the percentage FAS+mDCs of the control study group (r = 0.14, p = 0.73; r = -
0.16, p = 0.49; r = -0.10, p = 0.68, respectively, Figure 6.11), ARV-HIV-1 study group (r = 0.10, p = 0.91; r = -
0.44, p = 0.26; r = -0.23, p = 0.49, respectively; Figure 6.12A), ARV-HIV-1/TB study group (r = 0.31, p = 0.52; 
r = -0.21, p = 0.68; r = 0.12, p = 0.51, respectively, Figure 6.12B), ARV+HIV-1 study group (r = -0.36, p = 
0.35; r = 0.17, p = 63; r = 0.06, p = 0.94, respectively, Figure 6.12C) and ARV+HIV-1/TB study group (r = 
0.38, p = 0.21; r = 0.09, p = 0.43; r = 0.40, p = 0.16, respectively, Figure 6.12D).. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: Correlation FAS+mDCs to percentage CD8 T lymphocyte subsets of the control study 
group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study group and plotted together with corresponding percentage FAS+mDCs 
on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 1) 
represented by the symbols ,  and , and 2) relationship to percentage FAS+mDCs illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentage FAS+mDCs.  
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Figure 6.12: Correlating FAS+mDCs to % CD8 T lymphocyte subsets in ARV untreated and treated 
HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding percentage 
FAS+mDCs on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 
1) represented by the symbols ,  and , and 2) relationship to percentage FAS+mDCs illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentage FAS+mDCs.  
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No correlation between the CD8 T lymphocyte subsets and CD62L+pDCs and mDCs during HIV-1 infection 
In correlating the percentage CD62L+pDCs to the percentage CD8+CD38+ T lymphocytes(r = 0.12, p = 0.63), 
CD8+PD-1+ T lymphocytes (r = -0.27, p = 0.76) and CD8+CD38+PD-1+ T lymphocytes subsets (r = 0.02, p= 
0.92) of the control study group (Figure 6.13) no significant correlation was found. Also, no significant 
relationship was found between the percentage CD62L+pDCs and percentage CD8+CD38+, CD8+PD-1+, 
CD8+CD38+PD-1+ T lymphocyte subsets of the ARV-HIV-1 study group (r = -0.36, p = 0.31; r = -0.45, p = 
0.22; r = -0.60, p = 0.14, respectively, Figure 6.14 A), ARV-HIV-1/TB study group (r = 0.28, p = 0.61; r = 0.25, 
p = 0.26; r = 0.39, p = 0.62, respectively; Figure 6.14 B), ARV+HIV-1 study group (r = 0.01, p = 0.18; r = 0.26, 
p = 0.86; r = 0.25, p = 0.39, respectively, Figure 6.14 C) and ARV+HIV-1/TB  study group (r = 0.33, p = 0.32; 
r = -0.06, p = 78; r = 0.13, p = 0.65, respectively, Figure 6.14 D). 
 
A similar profile, as observed with CD62L+pDCs, was found when correlating the CD8 T lymphocyte subsets 
with CD62L+mDCs. No significant relationship was detected upon correlating the percentage CD62L+mDCs 
to the percentage CD8+CD38+ T lymphocytes(r = -0.08, p = 0.45), CD8+PD-1+ T lymphocytes (r = -0.02, p = 
0.77) and CD8+CD38+PD-1+ T lymphocytes subsets (r = 0.07, p = 0.46) of the control study group (Figure 
6.15). Also no correlation was observed when relating the CD8+CD38+, CD8+PD-1+, CD8+CD38+PD-1+ T 
lymphocyte subsets of the ARV-HIV-1 (r = -0.16, p = 0.45; r = -0.34, p = 0.23; r = -0.39, p = 0.13, 
respectively, Figure 6.16A), ARV-HIV-1/TB (r = -0.08, p = 0.85; r =0.24, p = 0.47; r = 0.02, p = 0.84, 
respectively; Figure 6.16B), ARV+HIV-1 (r = 0.01, p = 0.53; r = -0.20, p = 0.35; r = 0.15, p = 0.99, 
respectively, Figure 6.16 C) and ARV+HIV-1/TB  study groups (r = 0.43, p = 0.14; r = 0, p = 0.75; r = 0.17, p 
= 0.71, respectively, Figure 6.16 D) to CD62L+mDCs. 
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Figure 6.13: Correlating CD62L+pDCs to percentageCD8 T lymphocyte subsets of the control study 
group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study group and plotted together with corresponding percentage CD62L+pDCs 
on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 1) 
represented by the symbols ,  and , and 2) relationship to percentage CD62L+pDCs illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentageCD62L+pDCs.   
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Figure 6.14:   Correlating CD62L+pDCs to percentage CD8 T lymphocyte subsets in ARV untreated 
and treated HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding 
percentageCD62L+pDCs on a line graph. The percentage CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T 
lymphocyte subsets were 1) represented by the symbols ,  and , and 2) relationship to 
percentageCD62L+pDCs illustrated by a green, pink and blue-coloured linear regression line, respectively. 
The non-parametric Spearman test was use to correlate the percentage CD8 T lymphocyte subsets to 
percentageCD62L+pDCs.  
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Figure 6.15: Correlating CD62L+mDCs to percentage CD8 T lymphocyte subsets of the control 
study group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study group and plotted together with corresponding percentage CD62L+mDCs 
on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 1) 
represented by the symbols ,  and , and 2) relationship to percentage CD62L+mDCs illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentage CD62L+mDCs.  
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Figure 6.16:  Correlation between CD62L+mDCs to percentage CD8 T lymphocyte subsets during 
ARV untreated and treated HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding 
percentageCD62L+mDCs on a line graph. The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T 
lymphocyte subsets were 1) represented by the symbols ,  and , and 2) relationship to 
percentageCD62L+mDCs illustrated by a green, pink and blue-coloured linear regression line, respectively. 
The non-parametric Spearman test was use to correlate the percentage CD8 T lymphocyte subsets to 
percentageCD62L+mDCs.  
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CD86+mDCs tend to weakly correlate with the CD8 T lymphocyte subsets during HIV-1 infection 
CD86+mDC of the control study group showed an overall low indirect correlation with the CD8 T lymphocyte 
subsets. Specifically, the relationship of CD86+mDC to 1) the percentage CD8+CD38+PD-1+ T lymphocytes 
(r = -0.51, p = 0.02) was significant, 2) the percentage CD8+CD38+T lymphocytes (r = -0.16, p = 0.10) weakly 
significant and 3) the percentage CD8+PD-1+ T lymphocytes (r = -0.36, P = 0.27) not significant (Figure 
6.17). Similar to the control study group an indirect correlation was observed in the ARV-HIV-1 study group. 
In this group the  relationship of the percentage CD8+CD38+ T lymphocytes (r = -0.68, p = 0.13), CD8+PD-1+ 
T lymphocytes (r = -0.69, p = 0.1) and CD8+CD38+PD-1+ T lymphocytes (r = -0.67, p = 0.11) to CD86+mDCs 
was weakly significant (Figure 6.18A). In clear contrast, a positive correlation was observed between 
CD86+mDCs and CD8+CD38+ T lymphocytes (r = 0.85, p = 0.01) as well as the percentage CD8+CD38+PD-
1+ T lymphocytes (r = 0.61, p =0.11) in the ARV-HIV-1/TB study of which the former was significant and the 
latter weakly significant. The percentage CD8+PD-1+ T lymphocytes (r = 0.13, p = 0.98) of this study group 
did not correlate with the CD86+mDCs (Figure 6.18B). In the ARV+HIV-1/TB study group a direct but 
insignificant relationship was observed between the CD86+mDCs and 1) CD8+CD38+ T lymphocyte subset (r 
= 0.26, p = 0.31), 2) percentage CD8+PD-1+ T lymphocytes (r = 0.29, p = 0.33) and 3) CD8+CD38+PD-1+ (r = 
0.19, p = 0.39) (Figure 6.18D). Notably, in the ARV+HIV-1 study group a significant and strong direct 
relationship was observed between CD86+mDCs and both the percentage CD8+PD-1+ T lymphocytes (r = 
0.63, p = 0.01) and the percentage CD8+CD38+PD-1+ T lymphocyte (r = 0.78, p = 0.01). In this group the 
percentage CD8+CD38+T lymphocytes showed no significant correlation with the percentage CD86+mDCs 
(Figure 6.18C). 
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Figure 6.17:  Correlating CD86+mDCs to percentage CD8 T lymphocyte subsets of the control study 
group. 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the control study group and plotted together with corresponding percentageCD86+mDCs 
on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocyte subsets were 1) 
represented by the symbols ,  and , and 2) relationship to percentageCD86+mDCs illustrated by a 
green, pink and blue-coloured linear regression line, respectively. The non-parametric Spearman test was 
use to correlate the percentage CD8 T lymphocyte subsets to percentage CD86+mDCs. Statistically 
significant data are highlighted in bold. 
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Figure 6.18: Correlating CD86+mDCs to percentage CD8 T lymphocyte subsets during ARV 
untreated and treated HIV-1 mono and HIV-1/TB co-infection 
The percentageCD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T lymphocytes was determined for each of 
the participants of the HIV-1-related study groups and plotted together with corresponding 
percentageCD86+mDCs on a line graph. The CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+T lymphocyte 
subsets were 1) represented by the symbols ,  and , and 2) relationship to percentageCD86+mDCs 
illustrated by a green, pink and blue-coloured linear regression line, respectively. The non-parametric 
Spearman test was use to correlate the percentage CD8 T lymphocyte subsets to percentage CD86+mDCs. 
Statistically significant data are highlighted in bold. 
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6.5 Conclusion 
In addition to the characteristic decline of CD4 T lymphocytes during HIV-1 infection, persistent immune 
activation with consequent exhaustion is also a well-described feature of this disease. Immune activation and 
exhaustion during HIV-1 infection is examined via the expression of CD38 and PD-1 on CD8 T lymphocytes, 
respectively. The current study was interested in evaluating the frequency distribution of these CD8 T 
lymphocyte subsets during HIV-1/TB co-infection, anticipating significantly altered frequencies in dual 
infection. Briefly, the study investigated the 1) frequency distribution of the CD8+CD38+, CD8+PD-1+, 
CD8+CD38+PD-1+ T lymphocyte subset in chronically HIV-1 infected and HIV-1/TB co-infected patients on or 
naïve for ARV therapy and 2) relationship of the percentage CD8 T lymphocyte subsets to CD4 T 
lymphocytes counts and viral load. The study found the CD8+CD38+, CD8+PD-1+ and CD8+CD38+PD-1+ T 
lymphocytes subsets to: 
1) circulate in significantly higher frequencies in peripheral blood during ARV-HIV-1 infection. 
2) have a similar distribution profile during HIV-1 and HIV-1/TB co-infection - contrary to expectations. 
3) normalise upon ARV treatment of more than 1 year, opposed to CD4 T lymphocyte number and 
CD4:CD8 ratio which showed no recovery 
4) indirectly correlate with CD4 T lymphocytes during ARV-HIV-1 infection 
5) directly correlate with viral load, although, PD-1expression did not seem affected by HIV-1 infection 
 
Additionally, the relationship of the CD8 T lymphocyte subsets to TNF-R2+pDCs, TNF-R2+mDCs, 
FAS+mDCs, CD62L+pDCs, CD62L+mDCs and CD86+mDCs was also determined. In summary the study 
found 
1) No correlation between the TNF-R2+pDCs and CD8 T lymphocyte subsets during HIV-1 infection 
2) Prolonged ARV therapy (>1year) resulted in higher percentage TNFR-2+mDCs to circulate with 
declining levels of the CD8 T lymphocyte subsets 
3) FAS+mDC, CD62L+pDCs and CD62L+mDCs did not correlate with the CD8 T lymphocyte subsets 
4)  CD86+mDCs indirectly but weakly correlated with the CD8 T lymphocyte subsets during HIV-1 infection 
while with ARV therapy a significant direct relationship was observed with the CD8+PD-1+ and 
CD8+CD38+PD-1+ T lymphocytes. 
 
Parallel to the increase in immune activation observed in untreated HIV-1 infection is the fact that the HIV-1 
virus causes a chronic infection; hence, immune activation is a persistent phenomenon in the disease. It is 
proposed to have major damaging effects (e.g. tissue damage, immune exhaustion). Importantly, ARV 
therapy has the ability to optimally manage chronic immune activation (alleviating immune pressure) whilst 
the impact on recovery of DC and CD4 T cell numbers is limited. This is indicative of other factors that need 
to be targeted so to correct waning cellular numbers during untreated HIV-1 infection. 
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Chapter 7 
 
Concluding remarks 
  
Challenges of the study: Analysis of rare cellular events and the dark art of flow cytometry 
The study encountered and overcame many technical challenges. Primarily, the naturally low number 
distribution of blood pDCs and mDCs in circulation made flow cytometric analyses of marker expression 
complex, even more so in an HIV-1 infection setting of reduced numbers. It may be beneficial that future 
blood DC studies investigate the use of a concentrated leukocyte suspension (buffy coat) as substitute to 
whole blood analyses of pDCs and mDCs. Furthermore, accurate data reporting required optimization on 
various levels viz. gating strategy for collecting pDCs and mDCs from acquired events (refer to 4.3.9), 
acquiring mDC specific events from occasional non-DC events contaminating the HLA-DR+LIN1DIM gate 
(possibly a result of cellular change due to HIV-1 infection, refer to 4.3.10), adjustment of compensation to 
remove fluorescence overlap (refer to section 4.3.7.1), identification of true positive events and false positive 
events (as a result of autofluorescence(refer to 5.3.2.4), direct and/or indirect non-specific binding and 
undercompensated data (refer to 4.3.7.1 and Figure 4.1)), identification of internal controls to determine the 
negative staining border and guide the identification of true positive events in the absence of daily 
experimental controls (refer to 4.3.8, Figure 4.3, the daily use of FMO controls was excluded from this study 
due to this technique being a prohibitory expensive routine) and general analyses of marker expression by 
rare events (refer to 4.3.8). 
 
Population cohort 
The enrollment of HIV-1 infected patients regardless of CD4 T lymphocyte count and disease status 
throughout this cross-sectional study resulted in blood analyses of participants at various 1) stages of 
disease progression and 2) periods of ARV therapy.Accordingly, the CD4 T lymphocyte count data 
summarised in chapter 3 showed number recovery during ARV therapy, whereas in Chapters 4-6 the CD4 T 
lymphocyte counts were similar between the ARV naïve and treated study groups. This raised the question 
whether the impact of ARV therapy was actually captured per the objectives of the particular chapters. 
However, Chapter 6 showed normalisation of the CD8 T subsets in parallel to no CD4 T cell number 
recovery of the HIV-1 study cohort on ARV therapy. This finding showed that recovery time while on ARV 
therapy varies between the different affected compartments of the host and that additional to incrementing 
CD4 T lymphocyte numbers, other factors should also be monitor to determine the impact of ARV therapy 
and resulting recovery. A longitudinal study is proposed for future work in this field. 
 
Proposed future of therapeutic interventions 
It remains a mystery why the relationship of the (genetically related) viruses, HIV-1 and SIV, to their 
respective (also related) hosts is so vastly different. Contrary to SIV infection of the natural host, which 
seems not to harm the natural primate host, HIV-1 infection induces a high rate of morbidity and mortality in 
the human species. In view of this it seems that the immune system of the non-human primate has the ability 
to exert a level of immune control over SIV infection. It is proposed that upon defining the exact mechanism 
underlying SIV immune control, so to manipulate the human immune system to exert a similar control over 
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HIV-1 infection, would drastically transform the life expectancy of millions of people currently living with the 
virus.  
 
Narrowing the scope 
HIV is a formidable virus as demonstrated by an extensive database on the complex viral-host interaction 
and a, yet, undefined intervention. This may indicate suboptimal strategies in the fight against HIV, 
warranting a radical paradigm change so that in the near future signs of a previous HIV-1 infection would be 
reflected by only the “footprint” of remnant antibodies in the human system. 
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